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Chapter 1 
INTRODUCTION 
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The first report of a nonsurgical technique of dilating areas of obstructive 
atherosclerotic disease in the human arterial system was reported by Dotter and Judkins 
in 1964 [1 ]. The technique described was for peripheral arteries, and involved the 
passage of tapered dilating catheters of increasing diameter over a guidewire. This 
technique had a limited following and was never widely accepted as an established mode 
of treatment. 1n 1973 the use of a balloon dilatation catheter in humans was reported. 
This consisted of the passage of a double lumen dilatation catheter with a non-elastic 
balloon through an area of stenosis in the femora-popliteal and iliac arteries. This 
balloon was then inflated to dilate the stenosis [2]. The late Andreas Griintzig adapted 
this technique for use in human coronary arteries. 1n 1977 he first presented the 
experimental results of dilating coronary artery stenosis [3]. The first percutaneous 
transluminal coronary angioplasty in a human was performed by Andreas Griintzig in 
Zurich in September 1977. This treatment modality for ischemic heart disease proved to 
be safe and effective and rapidly gained widespread acceptance. Since then the growth 
of angioplasty has been dramatic with an exponential growth pattern since its initiation 
in 1977. An estimated 900.000 procedures were performed worldwide in 1991. Increased 
experience and advances in technology have resulted in a high primary success rate (over 
90%) and a low complication rate (death, non fatal myocardial infarction; 4-5%) [4]. 
However, the luminal narrowing process after a successful procedure still hampers the 
long term outcome of the procedure in a considerable percentage of patients. 
Mechanisms of coronary balloon angioplasty 
Dotter and Judkins [1] in their original description of the angioplasty procedure 
attributed the mechanism of balloon angioplasty to redistribution and compression of 
the atherosclerotic plaque. However the vast majority of atherosclerotic plaques in 
human coronary arteries are composed of incompressible dense fibrocollageneous tissues 
with varying amounts of calcific deposits and far less amounts of intracellular and 
extracellular lipid (hard plaques). Therefore it appears unlikely that plaque compression 
plays a major role in balloon angioplasty (figure 1). 
Castaneda Zuniga suggested that angioplasty induced paralysis, by overstretching 
the vessel wall beyond its limits of elasticity, was the cause of permanent luminal 
widening after balloon angioplasty. This widening was associated with histopathological 
features of smooth muscle cell lysis and twisted nuclei [5]. These correlates of severe 
medial damage were not found in human post mortem arteries after recent dilatation 
[6,7]. In in vitro models of balloon angioplasty in rabbit iliac artery, rabbit aorta and pig 
carotid artery, only severe oversizing of the balloon produced impairment of 
vasoconstrictor responsiveness [8]. Since Roubin et al. showed that deliberate oversizing 
of the balloon leads to an increased complication rate [9] and that satisfactory initial 
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results can be obtained by conservative balloon sizing [9,10], severe oversizing of the 
angioplasty balloon is not conunon practice in angioplasty today. Therefore arterial 
paralysis must be questioned as an explanation for the luminal widening achieved by 
angioplasty in human coronary arteries. 
Ao 
"Compression''.of plaque 
Focal plaque "break". (B) 
"fracture" or "tear" 
(c~ z:~ ..... :,.i!::E 
"Stretching" of plaque-free 
wall segment in 
eccentric lesion 
~~ 
"Stretching" of artery with 
minima! plaque compression 
Focal plaque "break", 
"fracture" or "tear" 
with localized dissection {0) 
Figure 1. Diagram showing possible mechanisms of coronary artery balloon angioplasty. 
Ao ; aorta, LAD ; left anterior descending artery, LC ; left circumflex artery, LM ; left 
main coronary artery. (from Waller, JAm Call Cardio/1985;6:1100) 
In an experimental rabbit model Sanborn found that localized aneurysm formation 
in addition to intimal splitting was responsible for the luminal widening after balloon 
dilatation of the artery [11]. 
It is now widely accepted that luminal widening of balloon angioplasty is caused 
by plaque fracture or splitting with or without localized medial dissection [7,12-18]. 
Plaque fractures, breaks and dissections within the plaque eventually extending to the 
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media improve luminal patency by creating additional channels for coronary blood flow 
(figure 1). 
An additional mechanism of luminal widening as proposed by Waller et al.[19,20] 
seems to be the stretching of the plaque-free wall segment of an eccentric atherosclerotic 
lesion (figure 1). Balloon inflation in these type of lesions may result in preferential 
stretching of the non-diseased portion of the vessel wall circumference, while not 
affecting the relatively rigid remaining portions. Stretching of the plaque-free wall 
segment may result in an initial increase in coronary cross-sectional area but immediate 
or delayed elastic recoil might reduce the coronary lumen towards its predilatation state. 
The presence of immediate recoil has indeed been confirmed by in vivo studies using 
quantitative angiography and balloon ultrasound inflation catheters (BUIC) [chapter 2, 
chapter 3, chapter 4, 21-23]. 
Relatively few studies have been performed, studying the mechanism of balloon 
angioplasty in vivo. Jain et a!. [24] describe three patterns of plaque dilation by 
examining pressure volume curves created while the balloon was being inflated. The 
first pattern was stretching of the plaque. After dilation these vessels would recoil and 
required several dilatations to achieve adequate dilation. The second pattern showed 
small incremental jumps in the pressure-volume curve. This was believed to reflect 
progressive compaction of the lesion. The third pattern was sudden yielding of the 
balloon at a given pressure. This pattern was angiographically correlated with dissection 
of the artery at the angioplasty site. Hjemdahl-Monsen et al. [25] found that in eccentric 
lesions more distention of the vessel wall was achieved at the same inflation pressures 
than in concentric lesions and that the former lesions showed more elastic recoil. Finally, 
on-line analysis with an intravascular balloon ultrasound inflation catheter (BUIC) shows 
that plaque fracture is the major contributor to improved luminal patency by balloon 
angioplasty [26]. 
Thus the weight of evidence indicates that the mode of action of angioplasty is 
by "controlled injury" of the vessel wall, with intimal and sometimes medial disruption. 
Elastic recoil could explain the "stubborn" character of some lesions at angioplasty. 
Pathophysiology of luminal narrowing after coronary balloon angioplasty. 
Despite widespread acceptance and use of coronary balloon angioplasty to treat severely 
narrowed coronary arteries in patients with symptomatic coronary heart disease, 
recurrence of stenoses at the angioplasty site remains a major problem. The frequency 
of clinical restenosis ranges from 17 to 47 percent depending on variations in definition 
(angiographic, clinical, physiologic). 
It can be hypothesized that restenosis is a manifestation of the general wound 
healing process expressed specifically in vascular tissue. This process is very complex and 
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requires the interaction of an abundance of chemical substances and cells. The following 
is a speculative model of a largely unknown process and has recently been proposed by 
Forrester [27]. 
According to Forrester an analogy exists between wound repair, and the healing 
of coronary arteries after balloon damage [27]. The process begins with platelets 
aggregating at the damaged area. Aggregating platelets release substances that promote 
local vasoconstriction, further platelet aggregation and thrombus formation (e.g. 
thromboxane A2), and growth factors (e.g. Platelet Derived Growth Factor, PDGF) that 
activates mesenchymal cells in the vicinity of the injured site. Within a few hours 
monocytes appear. These monocytes also produce growth factors with chemotactic and 
mitogenic effects on local mesenchymal cells. An abundance of growth factors is now 
known and their actions and interactions are highly complex. 
The next phase consists of cell migration into the damaged area. Endothelial cells 
from the wound margin migrate and proliferate to cover the wound surface. Smooth 
muscle cells begin to migrate and proliferate from adjacent tissue to the injured area. 
Smooth muscle cells migrating into and proliferating within the intima exhibit 
ultrastructural and functional properties equivalent to synthetic phenotype cells in 
culture; such cells show increased amounts of synthetic organelles, loss of capacity to 
contract and increased capacity to divide [28,29]. In contrast, cells of the contractile 
phenotype possess the opposite properties and make up most smooth muscle cells in 
normal vessels. Control of smooth muscle cell migration and proliferation is determined 
by the action of mitogens (e.g. PDGF) and opposing effects of inhibitors (e.g. heparin 
sulfates). 
The third phase, extracellular matrix deposition and remodelling, continues for 
months. Smooth muscle cells slow their proliferation and begin to produce large amounts 
of extracellular matrix components. The injured blood vessel thus develops the histologic 
appearance of intimal hyperplasia: proliferating smooth muscle cells scattered through 
a loose extracellular matrix. By several months the return to contractile phenotype of the 
smooth muscle cells is parallelled by a change in extracellular matrix: proteoglycans are 
replaced by large bundles of type I collagen and elastin. 
In Forrester's model restenosis is thought to result from migration and replication 
of medial smooth muscle cells into a developing neointima. An alternative model has 
recently been proposed by Schwartz et al. on the basis of observations in a porcine 
coronary injury model [30,31]. In their opinion 3 cellular stages can be identified as an 
obstructive neointima develops in response to arterial injury. In the thrombotic stage 
early after injury platelets, fibrin and red blood cells accumulate at the site of injury. In 
the recruitment stage, this thrombus endothelializes and mononuclear cells infiltrate on 
the lumen side of the vessel. In the proliferative stage cells staining positive for alpha 
actin (smooth muscle cells or myofibroblasts) appear on the luminal side of the 
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degenerating thrombus. These cells form a thin cap just beneath the endothelial surface. 
This cap thickens downward towards the media as the remaining thrombus material is 
resorbed. The healing process reaches completion when all thrombus material has been 
resolved and replaced by neointima and the mononuclear infiltrate has disappeared. The 
origin of the smooth muscle cells in this model is apparantly not the media at the site 
of damaged to the artery, since they first appear at the luminal side of the 
endothelialized thrombus. This model places mural thrombus in the center of the 
restenosis process. From their observations Schwartz et aL conclude that the magnitude 
of the luminal narrowing process may derive more from the volume of local mural 
thrombus at the site of arterial injury than from uncontrolled cellular proliferation. 
Other mechanisms ofluminal narrowing at the angioplasty site involve progression 
of atherosclerotic disease and gradual elastic recoil of an overstretched disease free wall 
in an eccentric lesion or return to predilatation state of a stretched concentric lesion, as 
proposed by Waller [32]. In chapter 2,3 4 and 5 the contribution of elastic recoil to 
luminal narrowing after balloon angioplasty will be extensively discussed. 
Timing of restenosis 
In 1988 two different studies, performing follow-up angiography at different pre selected 
follow-up intervals gave remarkable similar results and showed how lesions behave after 
angioplasty [33,34]. In the study carried out at the Thoraxcenter the minimal lumen 
diameter increased slightly from 2.06 mm directly post angioplasty to 2.11 mm at 30 days 
and then decreased steadily to 1.93, 1.77, 1.69 and 1.82 mm at the subsequent follow-
up times (2,3,4,5 months) [34,35]. Nobuyoshi and colleagues restudied 229 patients at 24 
hours, 1, 3, 6 and 12 months [33]. Their findings were very similar to those from the 
Thoraxcenter (figure 2) Furthermore, lesion progression after 6 months was found to be 
unusual [33]. These findings show a remarkable resemblance with the peak of intimal 
hyperplasia after vascular injury in animals, which reaches a peak at 4 to 12 weeks 
[36,37]. 
Symptoins, function or anatomy as for the assessment of restenosis? 
The incidence of late restenosis has remained much the same since the introduction of 
coronary angioplasty 14 years ago and a preventive treatment against restenosis still has 
to be developed. Primary success and restenosis after angioplasty may be defined by 
symptomatic criteria, like severity of angina pectoris, by functional criteria, such as 
provided by various exercise tests, or may be defined by anatomic criteria using histology, 
angiography or intravascular ultrasound. These three sets of criteria may be considered 
separately or may be interrelated. 
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Figure 2. Minimal lumen diameter (MLD) and reference diameter (RD) measurements as 
reported by Nobuyoshi et a1. [33} and Serruys et a1. [34,35}. 
1) Symptomatic criteria. 
Although the subjective improvement of symptoms after coronary balloon angioplasty 
is probably the most desirable end-point, it is also the least objective evaluation [38]. 
The frequency of symptomatic improvement appears to be lower than that of 
angiographic success: only 70% of the patients with a satisfactory angiographic result 
immediately post angioplasty exhibit such an improvement, probably due to incomplete 
revascnlarization in multivessel disease [39]. Furthermore, the reappearance of angina 
as criterion of restenosis underestimates the angiographic rate of restenosis as the 
reported incidence of silent restenosis may be as high as 31% [40]. In a recent review, 
Califf et al. [41] described that in studies with a high rate of angiographic follow-up, the 
probability that patients with symptoms had restenosis (i.e. the positive predictive value) 
ranged from 48% to 92%, whereas the probability that patients without symptoms were 
free of restenosis (i.e. the negative predictive value) ranged from 70% to 98%. The low 
positive predictive value found in many of these studies may be explained by the 
presence of other mechanisms of angina, such as incomplete revascularization or 
progression of disease in other vessels. In view of the above considerations, the 
usefulness of symptomatic criteria for the detection of restenosis is at best limited. 
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2) Functional criteria 
a. ECG exercise testing 
Several studies have examined the ability of the exercise test to detect restenosis after 
coronary angioplasty. These studies have generally found that the presence of exercise 
induced ST-segment depression angina at exercise or both is not highly predictive of 
restenosis whether the test is performed early or late after angioplasty. The positive 
predictive values of early exercise testing range from 29% to 60%, and the corresponding 
values for late exercise testing range from 39% to 64% [41,42]. The low positive 
predictive value is most likely a consequence of incomplete revascularization, that is a 
significant stenosis at a site other than that dilated by angioplasty. It is, however, also 
possible that the non-invasive test is accurately demonstrating a functionally inadequate 
dilatation, despite the appearance of angiographic success. 
b. Thallium scintigraphy 
The positive predictive value of thallium scintigraphy for detection of restenosis in series 
with a variable angiograpbic follow-up ranged from 37-100% [41]. Since coronary 
angiography is "the gold standard" for detection of restenosis in these studies, the 
reported value of a non-invasive test is detemtined not only by the actual accuracy of the 
test but also by the completeness of angiographic follow-up [43]. In studies with a high 
angiographic follow-up rate, the negative predictive value of thallium scintigraphy varies 
between 42 and 100% Potentially, tomographic imaging of nuclear scintigrarns may prove 
superior to planar imaging for the detection of restenosis [44]. 
3) Anatomic criteria 
a. Intravascular ultrasound 
Intravascular ultrasound (IVUS) has been shown to yield detailed cross-sectional images 
of the arterial wall and, therefore, has the potential to offer new insights into the 
mechanisms, complications and long-term results of coronary interventions. Before IVUS 
can be accepted as an alternative to arteriography, several significant limitations need 
to be surmounted. In particular the size and relative inflexibility of the current devices 
prevent their routine use. In addition, the safety and accuracy of IVUS has yet to be 
demonstrated in clinical studies. When these technical obstacles have been overcome and 
the clinical efficacy of this exciting new imaging modality has been established, its 
contribution to our understanding of the restenosis process will be invaluable. 
b. Histology 
In vivo histological exantination, by taking biopsies from intracoronary lesions \}'ith an 
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atherectomy catheter is currently the only approach which can discriminate between 
classic atherosclerosis and fibrocellular hyperplasia. However, to what extent single 
biopsy samples represent the lesion as a whole is still undetermined. Furthermore, this 
teclmique is only applicable in a subset of patients with a lesion suitable for atherectomy 
treatment. Some authors have suggested that there may be a relationship between the 
cellnlar density of the atherectomy specimen [45] or growth rate and migratory rate of 
these cells in culture [46-49] and the later development of restenosis. 
c. Coronary angiography 
In view of the above, coronary angiography is still the most objective and reliable means 
of assessing the long term outcome of coronary interventions. The numerous studies 
already available on coronary restenosis using angiography, lack consistency in their 
methods and the defutitions of restenosis used. Figure 3 illustrates this point. On the 
vertical axis of this "non scientific" figure, we have the names of the investigators, who 
have studied the restenosis problem, on the horizontal axis we have the restenosis rates 
observed in their studies. A restenosis rate ranging between 15 and 55% seems to 
emerge. However, we have to emphasize the following facts: the angiographic follow up 
ranges between 57 and 100%, the time to follow-up ranges between I and 9 months, II 
different criteria of restenosis have been applied and finally, visual assessment of the 
coronary angiogram was used in these studies. 
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Figure 3. Restenosis rates reported in the literature, applying II different restenosis criteria, 
different angiographic follow-up periods (I-9 months), while the percentage of patients 
undergoing repeat angiography varied (57-I 00% ). In addition, different angiographic analysis 
techniques (visual or quantitative) were used. 
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The variety of restenosis criteria in current use is shown in Table 1. As stated by Beatt 
et aL [50] most are entirely arbitrary, some are based on doubtful logic and some, 
although of some relevance for visual estimation of percent diameter stenosis, are 
unrealistic (e.g NHLBI II criterion) when applied to the more accurate values obtained 
from quantitative angiography. Most of the discrepancies between these studies can be 
attributed to 3 factors [50]: 1) selection of patients, 2) method of analysis and 3) the 
definition of restenosis used. 
ad 1. In order to objectively asses the long term outcome it is necessary for all patients 
to be angiograpbically followed up at a predetermined time interval. This will avoid a 
selection bias in favor of symptomatic patients. The sample size of any clinical trial must 
be adequate to avoid type II error. 
ad 2. A well validated system of analysis with known accuracy and variability must be 
employed. The use of a visual percent diameter stenosis measurement with its inherent 
inter- and intraobserver variability precludes meaningful results, and edge tracing by 
hand or other techniques that produce values not physiologically possible, are also 
unacceptable [51-53]. Videodensitometry may eventually provide the best measurement 
because the technique estimates the cross~sectional area of the lumen independent of 
geometric assumptions, but for technical reasons this method has not (yet) proven 
practical [54]. 
ad 3. The measured variable must be chosen so as to reflect the restenosis proliferative 
process and distinguish between the acute results of angioplasty (good or poor) and this 
proliferative process. We believe that the conventional assessment of percent diameter 
stenosis is not sufficiently discriminating in doing this and that definitions based on 
percent diameter stenosis measurement fail to identify lesions undergoing significant 
deterioration [50,55]. The >50% diameter stenosis at follow-up criterion may be of 
some relevance in determining a significant stenosis in human atherosclerotic vessels [56], 
but it tells us nothing about the dynamic behavior of the lesion since the angioplasty 
procedure. Furthermore, percent diameter stenosis criteria relate the minimal lumen 
diameter to the so called "normal" diameter of the vessel in the immediate vicinity of the 
obstruction. This assnmes that there is a normal diameter, but diffuse intimal or 
subintimal thickening is frequently present in arteries with discrete stenoses (particular 
in multivessel disease). A coronary angiogram is not able to detect diffuse atherosclerotic 
disease. In addition, this "normal"' area almost certainly is affected by the barotrauma of 
the balloon and will therefore also be involved in the reactive intimal hyperplasia and 
luminal narrowing [55]. This seriously questions the use of percent diameter stenosis as 
the index of restenosis. 
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Table 1. Criteria of restenosis in current use 
1. Reduction ;:: 30% in diameter stenosis (NHLBI I) 
2. An inunediate post aogioplasty diameter stenosis < 50% that increases to ;:: 70% 
at follow up (NHLBI TI) 
3. A return to within 10% of the pre-aogioplasty diameter stenosis (NHLBI TII) 
4. Loss of at least 50% of the initial gain (NHLBI IV) 
5. As for 2 but for a diameter stenosis ;:: 50% at follow-up 
6. Reduction > 20% in diameter stenosis 
7. A diameter stenosis ;:: 50% at follow-up 
8. A diameter stenosis ;:: 70% at follow-up 
9. Area stenosis > 85% 
10. Loss > 1 mm2 in stenosis area 
11. Deterioration of ;::0.72 nun in minimal lumen diameter from post aogiopiasty to 
follow-up 
12. Deterioration of ;:: 0.5 nun in minimal lumen diameter from post aogioplasty to 
follow-up 
NHLBI ; National Heart Lung aod Blood Institute restenosis criterium 
Quantitative angiography for the assessment of luminal narrowing after successful coronary 
balloon angioplast:y 
Attempts to correlate closely the aoatomy of a coronary stenosis aod its physiologic 
significaoce by visual interpretation of cineaogiograms are hampered by several serious 
shortcomings. The large intra· and inter-observer variability [57-60], aod lack of 
correlation with pathologic [61] findings of visually interpreted coronary cineaogiograms 
are well recognized. Inter- aod intraobserver variations from 8% to 37% in judging the 
location aod severity of coronary obstructions from visual interpretations have been well 
documented in the literature. Furthermore, the reproducibility of visual lesion assessment 
is influenced by the severity aod extent of the coronary stenosis. In general, visually 
assessed lesions between 20% aod 80% diameter stenosis ("moderate lesions") have a 
wider range of inter- and intraobserver variability than stenoses less than 20% or more 
thao 80%. The limitation that visual lesion assessment is not sufficiently accurate [62] for 
measuring small luminal chaoges in moderate lesions is compounded by the fact that 
these minor chaoges have major hemodynamic consequences. While resting coronary 
blood flow is not altered until ao obstruction of at least 85% is present, maximal 
coronary flow is already diminished by obstructions as small as 30% aod marked 
impairment of coronary flow reserve occurs with progressive diameter stenosis above 
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65%. Quantitative angiographic analysis in the Carport trial (chapter 8) revealed that 
mean gain in lumen diameter achieved by angioplasty was 0.75 mm or 28% in diameter 
stenosis. Mean loss in lumen diameter at follow up was found to be -0.31 mm or 12% 
in diameter stenosis. It is clear that such small changes cannot be accurately assessed by 
visual interpretation of cineangiograms. A quantitative computer based analysis technique 
enhances objectivity, while it reduces the problem of high inter and intraobserver 
variability inherent to visual interpretation of the coronary cineangiogram [52,63]. 
Absolute change in minimal lumen diameter, as measurement of the restenosis process 
As a result of quantitative angiographic studies a new concept for measuring restenosis 
has been introduced. The changes in minimal lumen diameter from post angioplasty to 
follow-up angiography gives a reliable quantitative measurement of luminal narrowing. 
It describes the magnitude of the reactive intimal hyperplasia after balloon trauma to the 
vessel wall. The minimal lumen diameter is an unambiguous measurement of lesion 
severity (simply the lowest point on the diameter function curve (figure 5)) and has the 
lowest long term variability of all quantitative angiographic measurements of lesion 
severity [64]. 
For the purpose of clinical trials a continuous measure of luminal reobstruction 
is preferable over a binary measure (restenosis yes/no). When the main concern is 
clinical decision making, however, a binary or categorical measure of restenosis provides 
clinicians with more workable information. Keeping in mind that an angiographic 
restenosis study assesses only the anatomical component of the restenosis problem, the 
threshold above which a loss in luminal diameter would have clinically significant 
functional or symptomatic consequences is not of great importance. Why then would one 
bother to try to define a threshold above which "significant" quantitative angiographic 
restenosis occurs? The possible benefit of a treatment (pharmacological or 
interventional) can be measured with much greater precision by comparing the absolute 
change in lumen diameter for each treatment group. For example, if treatment is 
expected to reduce the loss in lumen diameter from 0.4±0.50 mm under placebo [34], to 
0.25 ± 0.50 mm under active medication with a power of 90%, it can be calculated that 
233 patients will be required per treatment group. The above treatment effect 
corresponds with restenosis rates (defined as loss in minimal lumen diameter of :::0.72 
mm) of 25% and 17.5% respectively (figure 4). When alternatively a categorical 
restenosis definition is used in order to demonstrate the same difference (with a power 
of 90%) in restenosis rates (7 .5% ), 620 patients per treatment group will be required. 
This is because a categorical end point does not take full advantage of the available 
information. In chapters 8 and 9 this continuous approach has been followed to study the 
possible beneficial effect of a thromboxane A2 receptor blocker on the restenosis process 
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and to find risk factors for the luminal narrowing process. 
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Figure 4. Gaussian model of luminal narrowing after angioplasty in the reference group 
and in the treatment group, considering a 30% reduction in change in minimal lumen 
diameter (MLD) in the latter group. Under this Gaussian model one can calculate the 
corresponding restenosis rates (applying the ?::0.72 mm loss in MLD restenosis criterium). 
This restenosis rate (25%) is very close to the actually observed restenosis rates in the study 
of Serruys et al. [34]. Under this continuous model 233 patients per treatment group are 
required to show a 30% reduction in change in MLD with a power of 90%. If however a 
categorical model is applied then 620 patients per treatment group are required to show a 
decrease in restenosis rate from 25% to 17.5% (30%) with the same power. 
Description of the quantitative angiographic analysis system 
a) Edge detection 
The quantitative angiographic analysis system we applied is the Coronary Angiographic 
Analysis System (CAAS) and has been in operation at the Thoraxcenter since 1982. 
The system has been extensively validated and described in detail elsewhere [52,64]. 
Essentially, the contours of a selected coronary segment are detected automatically from 
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optically magnified and videodigitized regions of interest (512 x 512 pixels) of an end 
diastolic cineframe. Absolute diameter values (in mm) are determined using the guiding 
catheter as a scaling device (each individual catheter tip is retained and measured by 
micrometer). A correction factor for the selective magnification of an object near the 
edges of the image intensifier (pincushion distortion) is introduced. From the detected 
vessel contours, a diameter function is determined by computing the shortest distances 
between corresponding left hand and right hand contour positions (figure 5). The 
difficulty with selection of reference or "normal" diameter is solved by using a computer 
derived or "interpolated" reference diameter, by which technique the computer 
reconstructs the original "disease-free" dimension of the segment of interest, on the basis 
of diameter measurements proximal and distal to the obstruction. The interpolated 
reference diameter is then determined at the site of the minimal lumen diameter (figure 
5). The interpolated technique allows for tapering of the vessel (figure 5). The area 
between the actual and reconstructed contours at the obstruction site is a measure for 
the amount of "atherosclerotic plaque" and is expressed in mm2• The length of the 
obstruction site is determined from the diameter function on the basis of curvature 
analysis and expressed in millimeters. Using the reconstructed borders of the vessel wall, 
the computer can calculate a symmetry coefficient for the stenosis. A symmetrical lesion 
having a value of 1 and a severe eccentric lesion having a value of 0 (figure 5). 
b) Densitometric procedure. 
Constitution of the relationship between pathlength of the X-rays through the artery and 
the brightness value requires a detailed analysis of the complete X-ray/cine/video chain, 
including the film development process [65]. For the first part of the chain from the X-
ray source to the output of the image intensifier we use Lambert Beer's law for the x-
ray absorption and apply certain models for the x-ray source and the image intensifier. 
From the output of the image intensifier upto the brightness values in the digital image 
we use a linear transfer function. Details of this technique have been described 
elsewhere [66]. The cross-sectional area of a vessel is then obtained as follows. The 
contours of a selected arterial segment are detected as described above. On each 
scanline perpendicular to the centerline a profile of brightness values is measured. This 
profile is transformed into an absorption profile by means of a logarithmic transfer 
function. The background contribution is estimated by computing the linear regression 
line through the background points directly left and right of the detected contours. 
Subtraction of this background portion yields the net cross-sectional absorption profile. 
Integration of this function gives a measure for the cross-sectional area at the particular 
scanline. By repeating this procedure for each scanline, the cross-sectional area function 
is obtained. Calibration of the densitometric area values is accomplished by comparing 
the reference area calculated from the diameter measurements (assuming a circular 
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cross-section) with the corresponding densitometric area value. 
Theoretically, densitometry seems the ultimate solution for the computation of 
a vessel's cross-sectional area from a single angiographic view [67-72]. Phantom studies 
have shown that densitometry is a very attractive, precise, and accurate technique for the 
assessment of the severity of coronary obstructions from only a single view in vitro. In 
particular if the cross-sectional shape is highly irregular as after angioplasty, densitometry 
is expected to be more reliable than edge detection methods. The in vitro measurement 
of radiographic phantoms however, cannot reproduce some of the sources of error of the 
videodensitometric approach in-vivo. Arterial branches overlapping or parallel to the 
analyzed segment impairing the measurement of the density of the lumen or of its 
background, patient structural noise inducing an inhomogeneous background, lack of 
orthogonality of the vessel with the radiographic beam, inhomogeneous filling of the 
vessel during injection are conditions which cannot be assessed in in vitro studies. 
Therefore Di Mario et al. (unpublished data) from our institution performed an animal 
study to validate and compare edge detection and videodensitometry techniques of the 
CAAS system in vivo. Phantoms with known circular lumina were implanted in the left 
coronary arteries of pigs and cineangiograrns were obtained. Twenty eight cineframes 
were analyzed. Both edge detection and videodensitometry showed a good correlation 
with true phantom dimensions (minimal lumen diameter (MLD) and cross-sectional area 
(CSA)). Correlation coefficients for MLD measurements were 0.95 with a SEE of 0.12 
for edge detection and 0.93 with a SEE of 0.19 for videodensitometry. Correlation 
coefficients for CSA measurements were 0.94 with a SEE of 0.24 for edge detection and 
0.94 with a SEE of 0.31 for videodensitometry (figure 6). The mean differences between 
edge detection and densitometric MLD and CSA measurements and corresponding true 
phantom dimensions were calculated and considered an index of the accuracy of the 
measurements, while the standard deviation of the differences was considered an index 
of precision. For MLD measurements mean differences were -0.06:!: 0.14 mm for the edge 
detection technique and -0.11:!:0.20 for the videodensitometry technique (difference not 
significant). For CSA measurements mean differences were -0.15 ± 0.30 mm2 for the edge 
detection technique and -0.12:!: 0.31 mm2 for the videodensitometry technique (difference 
not significant). These circular phantoms however, probably do not mimic true arterial 
obstructions since it is known that a large percentage of coronary lesions are non circular 
in particular immediately after balloon angioplasty [72]. Furthermore, some of the most 
important sources of non-linearity of densitometry such as scatter /veiling glare and beam 
hardening are difficult to correct for in vivo. The analyses in the Carport study showed 
that in approximately 10% of the pre-angioplasty cineframes, 2% of the post-angioplasty 
cineframes and 4% of the follow-up cineframes, videodensitometry failed to measure the 
lumen cross-sectional area because of the combined effect of low density of a severe 
stenosis, dense background and/ or presence of parallel vessels interfering with the 
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background subtraction. Medium- and long term variability studies for videodensitometric 
assessment of lesion severity have not been performed for the CAAS system and are 
certainly a prerequisite before this techniqne can be applied for large scale restenosis 
prevention studies or atherosclerosis progression regression studies. 
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Figure 5. Graphic representation of the quantitative angiographic measurements. The upper 
panel represents a stenosed arterial segments. The lower panel is the diameter function curve. 
The length of the analyzed segment is depicted on the X-axis and the vessel diameter on the 
Y-axis. MLD ; minimal lumen diameter. Extent of obstruction ; Lesion length. Lesion 
length is determined with curvature analysis of the descending and ascending limb of the 
diameter function curve at the site of the MLD. Eccentricity is determined the site of the 
MLD and calculated as ajb. The plaque area is depicted by the hatched part of the upper 
panel drawing. 
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Figure 6a. Line air regression analysis of the phantom lumen diameter (LD) vs the minimal 
lumen diameter (MLD) measured with edge detection (left) and videodensitometry (right). 
The dashed line and the continuous line correspond to the line of identity and the regression 
line respectively. 
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Figure 61>. Lineair regression analysis of the phantom cross-sectional area (CSA) vs the 
CSA measured with edge detection (left) and videodensitometry (right). The dashed line 
and the continuous line correspond to the line of identity and the regression line respectively. 
Variability of angiographic data acquisition 
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For the interpretation of the quantitative coronary angiographic results from 
intervention studies, the total variability of the angiographic data acquisition and analysis 
procedure must be known. The source of variation and the approaches towards 
standardization for the technical aspects of the CAAS system are beyond the scope of 
this chapter. These are described in detail elsewhere [73,74]. The angiographic data 
acquisition is also hampered by various sources of variation. Measures taken to minimize 
the variation in data acquisition and analysis in the studies presented in the following 
chapters are discussed below and in Table 3. 
1. On line registration of X-ray system settings 
The angular settings of the x-ray system were recorded for every projection filmed at 
angioplasty and repositioned at follow-up angiography to correspond exactly to the 
projections used during angioplasty angiography 
2. Preangiographic administration of vasodilative drugs 
One of the most important variables in the quantitative assessment of arterial dimensions 
is the vasomotor tone. If no precautions are taken, the vasomotor tone may differ even 
during immediate consecutive coronary angiographic studies. The only way to achieve 
such control is by attempting to reach the ceiling of vasodilation of the vessels by means 
of a drug that produces fast and complete vasodilation. Such results seem to be obtained 
most reliably by the intracoronary administration of nitrates [75]. Therefore the same 
dose of intracoronary nitrates, either nitroglycerin 0.1-03 mg or isosorbidedinitrate 1-3 
mg, was given before each angiographic study (pre angioplasty, post angioplasty and at 
follow-up angiography). 
3. Use of nonionic and iso~osmolar contrast media 
Adverse effects of conventional contrast media are related to single-valence cations, 
such as sodium and meglumine, to an imbalance in the ratio of sodium to calcium ions, 
to the high osmolality of the solutions and to their hyperviscosity [76]. Collective studies 
offer experimental and clinical evidence of the advantage of the low-osmolality agents 
in radiology [77,78]. Jost et a!. have clearly demonstrated that the vasodilative changes 
in vessel dimensions due to the contrast medium administration are significantly smaller 
with use of a nonionic contrastrnedium than with use of an ionic contrast medium [79]. 
Therefore, in quantitative coronary angiographic studies, nonionic contrastmedia with iso-
osmolality should be applied. Because the data presented in this thesis originate from a 
multicenter trial it was unpractical to impose the use of 1 or 2 possible contrastrnedia on 
all participating centers. Therefore it was requested to use the same type of 
contrastrnedium at baseline and follow-up angiography. 
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4. Selection of catheter material 
In the quantitative angiographic studies described in this thesis, the contrast catheters 
have been used for calibration. To determine the accuracy of such calibration 
measurements from coronary cineangiograms and the effects of catheter material, 
contrast filling of the catheter and kilovolt setting of the x-ray source on image quality 
of the irradiated catheter and thus on the accuracy of the measurements, Reiber et a!. 
analyzed 4 catheter materials filmed under different conditions [80]. On the basis of their 
evaluation data it was concluded that woven dacron is the most suitable material for 
quantitative coronary angiographic studies. The polyvinylcbloride and polyurethane 
catheters performed equally well, but slightly less than the woven dacron catheter. The 
nylon catheter should however not be used for these type of studies. Investigators in the 
studies described in this thesis were asked not to use nylon catheters. 
5. Micrometer measurement of catheters following catheterization [80] 
It has been our experience that the size of the catheter as specified by the manufacturer 
often deviates from the true size. If the manufacturers cannot guarantee narrow ranges 
for the size of the catheter, for example :!: 0.05 Fr, its actual size should be determined 
with a micrometer following the catheterization. This problem is even more significant 
for the tip of a catheter, which is often hand-made and thus poorly specified. Most often 
the tip of the catheter is used for calibration. Films from all centers involved were 
requested to send the tips of all used catheters to the central core laboratory for film 
analysis. Prior to film analysis the exact size of the catheter was determined with a 
micrometer. 
In addition, several other measures were taken to standardize the method of data 
acquisition and analysis of the preangioplasty, post angioplasty and follow-up angiograms. 
All cineframes to be analyzed were preferentially selected at end-diastole to mininrize 
any possible blurring effect of motion and to limit foreshortening often observed during 
systole. In cases where the segment to be analyzed overlapped with other vessels or 
structures, the frame was selected at end systole or as near as possible to end-diastole. 
Before the post-angioplasty angiogram, totally radiopaque guidewires had to be removed 
to avoid interference with automated edge detection. The user defined beginning and 
end points of the analyzed segments in the coronary tree were identified according to the 
definitions of the American Heart Association [81]. Hard copies of the videoimage of the 
analyzed segment with the detected contours superimposed were made to ensure that the 
follow-up analysis was performed on the same coronary segment. 
Table 3. Sources of variation in angiographic data acquisition and analysis 
Sources of Error 
Patient related 
Patient size 
Vasomotor tone 
Vessel motion (blurring) 
Cardiac 
Respiratory 
Cyclic variation in diameter 
Geometric considerations 
Vessel curvature, stenosis irregularity, relation 
to other vessels or branches 
Technique related 
Different x-ray gantry sellings between 1st and 
second film 
Foreshortening 
Insufficient mixing of contrast 
Pincushion distortion 
Methodology related 
Edge detection algorithm 
Calibration technique 
Pincushion distortion 
From de Feyter et al. Circulation 1991;84:414 
Prevention 
Standardized vasodilation 
End-diastolic frame 
Held inspiration 
End-diastolic frame 
Many projeclions 
On-line annotation of x-ray gantry settings 
Objecl of interest parallel to image intensifier 
At least 7F catheter, big bolus injection, with injection pump, 
isoviscous, isoosmolar contrast medium 
Lesion or segment of interest centrally located 
1st derivative: overestimation 
2nd derivative: underestimation 
weighted sum 1st and 2nd derivative: precise 
Catheter tip caliper measurement 
Correelion for each particular image intensifier 
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Overview of the thesis 
The central topic of this thesis is early (immediate and up to 24 hours) and late 
(6 months) luminal narrowing after percutaneous transluminal coronary balloon 
angioplasty as assessed by quantitative angiography. 
In chapter 2 to 4 the role of elastic recoil as a cause of early luminal narrowing 
after balloon angioplasty is studied (up to 24 hours after angioplasty). In the studies 
described in chapter 2 and 4 videodensitometry was used to assess lesion severity before 
and after angioplasty because the balloon could ouly be filmed in 1 projection and 
videodensitometry offers the opportunity to accurately measure the cross-sectional area 
of a stenosis site in only 1 projection. It was assumed that edge measurements of 
performed in ouly 1 projection might be less accurate than the usual average value of 
MLD and cross-sectional area obtained from multiple projections. Therefore it seemed 
methodologically more correct to compare balloon measurements with lesion 
measurements in the same single projection using videodensitometry. 
The 136 patients described in chapter 2 represent the first 136 consecutive patients in 
the Carport study in whom the balloon was filmed and in whom videodensitometry was 
possible in the same projection as the balloon was filmed in. In chapter 4 the same 
applied for the first 526 consecutive patients enrolled in the Carport trial. The patients 
described in chapter 3 were enrolled in a trial comparing the efficacy of recombinant 
hirudin to heparin with respect to 24 hour patency after balloon angioplasty. Only 
patients in whom a balloon was filmed in a non-foreshortened projection were analyzed 
and described in this preliminary report. 
In chapter 5 angiographic risk factors, including stretch and recoil, for long term 
luminal narrowing ( 6 months) after a successful angioplasty procedure were investigated. 
To obtain independent predictors of a significant loss in MLD (loss ::: 0.72 mrn), a 
multivariate logistic regression analysis was applied to 595 lesions with balloon 
measurements. Patients described in this chapter were enrolled in the Carport trial. 
One risk factor for restenosis that has been the subject of controversy in the 
literature is the site of dilatation, with according to some, a higher risk of restenosis in 
the proximal left anterior descending (LAD) coronary artery as compared to lesion in 
the right coronary artery and circumflex artery. In chapter 6 this was investigated in 
1234 patients (follow-up rate 91% ). For this study quantitative angiographic data of the 
Carport and Mercator trial were combined. The latter is a restenosis prevention trial 
comparing an ACE inhibitor ( cilazapril) to placebo. In the Mercator trial neither 
angiographic nor clinical benefit of cilazapril could be demonstrated so both treatment 
groups ( clazapril, placebo) could be pooled. 
In chapter 7 it was investigated whether luminal narrowing or restenosis after 
balloon angioplasty occurs ouly in a subset of patients/lesions or that it occurs to a 
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certain extent in all dilated patients/lesions. For this study quantitative angiographic data 
of the Carport and Mercator trial were again combined. 
In chapter 8 the results of the Carport trial are presented. In this restenosis 
prevention trial a thromboxane A2 receptor antagonist (GR32191B) was compared to 
placebo with respect to the amount of luminal narrowing at 6 months follow-up. Most 
of the data described in the thesis originate from this trial. 
In chapter 9, we investigated which quantitative angiographic parameter best 
predicts the functional status of patients 6 months after successful coronary balloon 
angioplasty. Only patients with single vessel disease and a single site dilatation with 
quantitative angiographic follow-up were studied. Patients described in this study were 
enrolled in the Carport trial. 
Finally in chapter 10, an attempt was made to predict the absolute change in 
lumen diameter at follow-up angiography with simple, independent, clinical, lesion 
related and procedure related variables collected in the Carport trial. Therefore a 
multiple lioear regression analysis was applied to 666 lesions with the change in minimal 
lumen diameter from post angioplasty angiogram to follow-up angiogram as dependent 
variable. 
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Quantitative Angiographic Assessment of Elastic 
Recoil After Percutaneous Transluminal 
Coronary Angioplasty 
Benne J. Rensing, MD, Walter R.M. Hermans, MD, Kevin J. Beatt, MD, Gert Jan Laarman, MD, 
Harry Suryapranata, MD, Marcel van den Brand, MD, Pim J. de Feyter, MD, 
and Patrick W. Serruys, MD, PhD 
Little is known about the elastic behavior of the 
coronary vessel wall directly after percutaneous 
transluminal coronary angioplasty (PTCA). Minimal 
Iwninal cross--sectional areas of 151 su~Uy 
dilated lesions were studied in 136 patients during 
balloon Inflation and directly after withdrawal of 
the balloon. To circumvent geometric assumptiortS 
about the shape of the stenosis after PTCA, a 
videodensitometric analysis technique was used for 
the assessment of vascular cross-sectional areas. 
Elastic recoil was defined as the difference between 
balloon cross-sectional area of the largest balloon 
used at: the highest pressure and minimal luminal 
cross-sectional area after PTCA. Mean balloon 
cross-sectional area was 5.2 ± 1.6 mm2 with a 
mean minimal cross-sectional area of 2.8 ± 1.4 
mm2 immediately after inflation. Oversizing of the 
balloon (baD'oon artery ratio > 1) led to more recoil 
(0.8 ± 0.3 vs O.S ± 0.3 mm, p <0.001), suggestive 
of an elastic phenomenon. A d"lffer-ence in recoil of 
the 3 main coronary branches was observed: left 
anterior descending artery 2.7 ± 1.3 mm2, drcum-
flex artery 2.3 ± 1.2 rnrn2 and right coronary ar-
tery 1.9 ± 1.5 mm2 (p <0.025). The difference was 
still statistically significant if adjusted for reference 
area. Thus, nearly SO% of the theoretically aehiev-
abfe Cf'OSSooSedional area (i.e., balloon cross-sec-
tional area} is tost shortly after balloon deflation. 
(Am .J Cardiol 1990;66:1039-1044) 
From the Ca.theteri.zation Laboratory. Thor:ucc:nter. E=us Univer· 
sity. Rotterdrun, The Netherlands. Manuscript ro::ccived January 4, 
1990; revised manuscript received and accepted June 18. 1990. 
Address for reprints: Patrick W. Scrruys. MD, PhD. Catheterizu-
tion Laboratory. Thornxccnter. E=us University, PO Bo:t:: 1738. 
3000 DR Rotterdam. The Netherlands. 
P ercutancous transluminal coronary angioplasty (PTCA) is increasingly being used as an alterna-tive to coronary artery bypass grafting in patients 
with acute and chronically obstructed vessels. 1 ·~ Despite 
many publications on the mechanism of this treatment 
modality, little is Jmown about the elastic behavior of 
the vessel wall during and immediately after angio-
plasty. Castaneda-Zuniga et aJ3 proposed an arterial pa-
ralysis model in which overstretching of the vessel wall 
beyond its limits of elasticity was associated with histo-
pathologic features of smooth muscle cell lysis. Accord-
ing to Sanborn et al4 part of the angioplasty mecha-
nism consists of stretching the vessel wall resulting in a 
fusiform dilatation or localized aneurvsm formation. It 
is, however, a common dinlcal observ;tion that in some 
lesions even the application of an oversized balloon leads 
to a poor angiographic result without a visible intimal 
tear or dissection. This phenomenon may be attributed 
to elastic recoil of the vessel wall after balloon angio-
plasty. Densitometrically assessed cross-sectional areas 
are independent of geometric assumptions on the shape 
of the stenosis and should theoretically be more reliable 
than geometrically derived cross-sectional areas. espe-
cially after the disruptive action of balloon angioplasty 
which is known to cause asymmetric enlargement of the 
lumen.5 This study was undertaken to determine the 
contribution of elastic recoil to the immediate result of 
an angioplasty procedure, with the use of densitometric 
and contour detection analysis techniques. 
METHODS 
Contour detection: The quantitative analysis of the 
stenotic coronary segments was performed with the 
computer-assisted Cardiovascular Angiography Analy-
sis System (CAAS), which has been described in detail 
elsewhere.6•7 To analyze a coronary arterial segment a 
35-mm cine frame was selected. Electronically, a region 
of interest (512 X 512 pixels) encompassing the arterial 
segment to be analyzed was digitized with a high-fideli-
ty videocamera. Contours of the arterial segments were 
detected automatically on the basis of the weighted sum 
of first and second derivative functions applied to the 
diPitin:d brightn...,~ profile. From these contours the 
vessel diameter functions are determined by computing 
the shortest distance between the left and right contour 
positions (the upper curve in Figure 1). Conversion of 
the diameter measurements of the vessels to absolute 
values was achieved by using the contrast catheter as a 
THE AMERICAN JOURNAL OF CARDlOLOGY NOVEMBER 1, 1990 
42 
scaling device. To this end the contours of a user·de-
fined portion of the optimally magnified catheter (opti-
mal magnification factor 2y'2) are detected automati-
cally and corrected for pincushion distortion caused by 
the image intensifiers. In arteries with a focal obstruc-. 
tive lesion and a clearly normal proximal or distal arte-
rial segment, the choice of the reference region is 
straightforward and simple. However, in cases where 
the proximal or distal part of the arterial segment shows 
combinations of stenotic and ectatic areas, the choice 
may become difficult. To circumvent these problems. 
we implemented a method that is independent on a user 
defined reference region. This technique is denoted 
"interpolated reference diameter measurement."S The 
principle of this technlque is the computer estimation of 
the original vessel diameter at the site of obstruction 
(Figure 1). The white areas in the figure are measures 
for the "atherosclerotic plaque" and are defined by the 
actual luminal contours and the reconstructed reference 
contours. The length of the obstruction site is deter· 
mined from the diameter function on the basis of curva· 
ture analysis and expressed in millimeters. Using the 
reconstructed borders of the vessel wall, the computer 
can calculate a symmetry coefficient for the stenosis: a 
symmetrical lesion having a value of 1 and a severe cc· 
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centric lesion having a value of 0. Symmetry is defined 
as the coefficient of the left hand distance between the 
reconstructed and actual vessel contours and the right 
hand distance between reconstructed and actual con-
tours at the site of obstruction. In this equation the larg-
est distance between actual and reconstructed contours 
becomes the denominator. The curvature value at the 
obstruction site. as a measure for coronary bending. is 
computed as the average value of all the individual cur-
vature values along the centerline of the coronary seg-
ment, with the curvature delmed as the fll"St derivative 
of the tangent as it moves along the centerline, which 
for a circle is equal to the reciprocal of the radius. 
Densitometric procedure: Constitution of the rela-
tion between path length of the x-rays through the ar-
tery and the brightness value requires a detailed analy-
sis of the complete x-rayjcinejvideo chain, including 
the film development process,9 For the first part of the 
chain from the x-ray source to the output of the image 
intensifier. Lambert Beer's law is assumed to be valid 
for the x-ray absorption and certain models for the x-
ray source and the image intensifier are applied. Sensi-
tometric transfer functions were assessed from 21 cali-
brated density frames, which are processed photograph-
ically simultaneously with the coronary cine flim. These 
21 density frames arc then exposed homogenously with 
a specially developed sensitometer having the same col-
or temperature as the output screen of the image inten-
sifier. 
The contours of a selected arterial segment are de-
tr!Cted as previously described. On each scanline perpen-
FIGURE 1. Single frame anglograms of a proximal, cin::untflex 
artery (CX-PROX). Contours and densitometrie analysls of the 
severity of the ob5truction {ObW.). The white areas are a 
meawre for the ... atherosclerotie" plaque and are defined by 
tM diff~ between the aetualluminal eontours and the 
"interpolated" reference contoul"5. Superimposed on the 
videoimage are the diameter function curves (upper curve) 
and the densitometrie area function curve (lower curre) to-
gether with the "interpolated reference" curves. A, predilata-
tion (before percutaneous transauminal corona:y angioplasty 
fPRE·PTCAD minimal luminal cross-sectlonal area is 3.5 
mmZ; S. 3.5 mm balloon, filmed at highest inflation pre$$UI"e; 
C., after dilatation (POST ·PTCA), minimal luminal CI"OS!HeC-
tionaJ area is 6.0 mm2. 
dicular to the centerline a profile of brightness values is 
measured. This profile is transformed into an absorption 
proflle by means of the computed transfer functions. 
The background contribution is estimated by an inter-
polative method and subtraction of this background 
yields the net cross-sectional absorption proflle. Integra-
tion of this function results in a measure for the cross-
sectional area at the particular scanline. By repeating 
this procedure for each scanline, the cross--sectional area 
function is obtained. The severity of the obstruction can 
thus be expressed in mmZ, by comparing the minimal 
area value at the obstruction with the reference value 
obtained after an interpolative approach, which is simi-
lar to that described earlier for diameter measurements. 
Validation of this densitometric analysis technique 
was done by analyzing cine fllms of perspex models 
filled with a contrast agent and filmed at 4 kV levels. 
Accuracy was found to be 2.8% and precision 1.8%.10 
The densitometrically determined area stenosis, as 
found by other investigators, correlates well with per-
centage reduction of crOSNectional area measured his-
tologically in postmortem hearts.n.12 
Assessment of elastic recoil: One hundred fifty-one 
successfully dilated segments of 136 patients were ana~ 
lyzed. A successful PTCA was defmed as a visually as-
sessed diameter stenosis after PTCA of <50%. Single 
identical views before and after PTCA, and during 
complete expansion of the largest balloon at highest in~ 
flation pressure were chosen for densitometric analysis. 
Both polyvinyl chloride and polyethylene balloons were 
used for dilatation depending on the choice of the opera-
tor. Inflation pressure and duration of inflation were left 
to the discretion of the operator. Mean balloon cross-
sectional areas were calculated from diameter values, 
assuming a circular cross section at maximal inflation 
pressure. The same x.-ray setting in terms of kilovoltage 
and milliamperes was used during the 3 cine recordings. 
To have the segment to be analyzed as perpendicular to 
the incoming x-rays as possible, a view was chosen with 
the coronary artery appearing least foreshortened. The 
same amount of nitrates, either nitroglycerin, 0.1 to 0.3 
mg, or isosorbide dinitrate, 1 to 3 mg, was given intra-
coronarily before the pre- and postangioplasty cine re-
cordings. This was done to dilate the vessel max.imally 
and thus to control the varying influence of vasomotor 
tone on luminal dimensions. Elastic recoil was then cal-
culated as the difference b(;tween the minimal luminal 
cross-sectional area after PTCA and the mean balloon 
cross-sectional area (mm2). A representative analysis, 
with the detected contours, the diameter function curve 
and the densitometric area function curve superimposed 
on the original video image, is shown in Figure 1 for a 
circumflex lesion. 
RESULTS 
At quantitative analysis 140 (92%) of the dilatations 
were successful using a <50% diameter stenosis after 
PTCA as the success criterion. If in addition a >20% 
improvement in diameter stenosis was required for a 
successful dilatation, 110 (72%) lesions were successful-
ly dilated using quantitative measurements. The densi-
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TABLE I Recoil In 151 Coronary Arterial Narrowings 
BeforePTCA AtterPTCA pValue 
Referel'tee area (mm2) 6.C±2.5 62±2.5 NS 
MLCA(mm2) 1.1±0.9 2.8±1.4 p<O.OOl 
9alloon-CSA(mm2) 52±1.6 
Recoll(mm2) 2.4±1.4 p<O.OOl 
CSA • ~~a~ MLCA • mlnlmollomltlal cro~ctlcMI area; NS • 
dofle""""' not >IJ!:nifocant: PTCA - percutaneous tr~<'l$luml""l <:Ot'Q""'Y angla~:~Sty. 
Recoil• bo~ootl CSA- MLCAalter Pl'CA. 
T AELE II Effect of Balloon OverslZing on the Amount of 
Elastic Recoil 
&llloo,.,.Artery Ratto <1 >1 pValue 
No.ofleslons ., 64 
RelererK:e--diameter (mm) 3.0::1:0.5 2.3±0.4 p<O.OOl 
9alloor>-dlameter (mm) 2.5::1:0.4 2.6±0.4 NS 
Reeoll(mm) 0.6±0.30 0.8±0.3 p<0.001 
3:IIIO<>n-<>"<'r)' ratio • ball0011 dlom<-tor /re!~"'r>ee dlomoter. NS - dll!etenee r.ot 
si€1'"1\eont. 
TABLE Ill Clinical Characteristlcs and Recoil in 136 Patients 
y,. No pValue 
Men (recoil) 112(0.45::1:0.31) 24(0.42±0.23) NS 
Smoking 106 (0.46 ± 0.29) 30 (0.50 ::1: 0.23) NS 
(recoil) 
Hypertenslon 61(0.40±0.28) 75{0.46±0.29) NS 
(recoil) 
Diilbctes type 1 1 135 
(recoil) 
Unstableangltla 23 {0.39 ± 0.27) 113(0.44±0.26) NS 
(recoil) 
RCCQ~ com:ct~d for "'lerOf!Ce ~"'"· 
NS • dlnerenoc not !Jgnlflcant 
tometric analysis of the 151 segments is listed in Table 
I. Mean age of the 136 patients was 56.8 ± 8 years. 
There was no significant chat~ge in "interpolated" refer-
ence area after PTCA: Before PTCA 6.0 ± 2.5 mm2, 
after PTCA 6.2 ± 2.5 mm2 (difference not significant). 
The minimal luminal cross--sectional area increased 
from 1.1 ± 0.9 to 2.8 ± 1.4 mm2 {p <0.001). The mean 
balloon cross-sectional area was 5.2 ± 1.6 mm2. Elastic 
recoil was 2.4 ± 1.4 mm2. Thus, nearly 50% of the theo-
retically achievable cross section (i.e., balloon cross-sec-
tional area) was lost immediately after the last balloon 
deflation. A subset of 16 patients (181esions) were angi-
ographically reexamined 24 hours after PTCA as part 
of a study looking at changes in coronary flow reserve in 
the fli'St 24 hours after balloon dilatation. Minimal lu-
minal cross-sectional area directly after PTCA in this 
group was 2.0 ± 0.8 mm2 and 1.9 ± 0.5 at 24 hours 
(difference not significant). 
BaDoon oversizing and elastic recoil: For each ste-
notic lesion the balloon-artery ratio was calculated. A 
ratio > 1 indicates oversizing of the balloon. The mean 
balloon-artery ratio in this study was 0.95 ± 0.18. This 
indicates a conservative balloon handling, considered to 
give optimal dilatation of the stenotic lesion with mini-
mal residual stenosis and the smallest incidence of coro-
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TABLE IV Anglogr<~phic and Procedural Chor;:~cteristics and Recoil of 151 Lesions 
y~ 
Lesion length>S.2 mm :md <7 mm (recom 50(0.48±0.25) 
Cnlclfled lesion (recoil) 22(0.43±0.29) 
Symmctry<037 (rccol) 51 (0.48± 0.33) 
PIJque oroa <4.5 mm~ (recoil) 50 (0.53 ± 0.33) 
Curvot\Jre <12.5 unit; (recoiO 51 (0.53± 0.34) 
M<JX. infl. pres. <8Jtm (recoiO 49(0.46±0.24) 
lnfiJtion dur<~tlon <220 seconds (re<:oiO 50(0.47±0.30) 
Rocotl corrected tor ">letencc~ro"- S.,., 1":Xtfor~;alp\loo ol cutoff point;. 
Mox. Inti. p...,.~ ~ r"l"l.l>clmolln~obon pres:;ur<: oltt>o botlooo: NS- diH~r<:~ not "'£ntfiCOnt. 
TABLE V Recoil in the Three Mnin CoronJry Arteries 
8;JIIoonCSA(mm') 
MLCAottcrPTCA(mm') 
Rccoll(mm') 
Recoll/r<>ference areJ 
lAD LC Right 
(n=77) {n=34) (n=40) 
5.2± 1.7 5.5± 1.5 4.9±1.4 
2.5±1.3 3.1±1.2 3.0±1.7 
27±1.3 23±12 1.9 ± 1.5 
0.5±0.3 0.4±0.2 0.3±0.3 
AN OVA 
NS 
NS 
p<0.025 
p<O.OS 
ANOVA - ~noty,.o. 01 '"lfl.lnce: CSA- O"OOY..<'~OOol ;>ro;>; LAO - left ontorlor 
d.,....«"11dl11.<; ,,..-y. LC - lett orcumfi~x ;>tto<y, MlCA - m!nl=l lumbol o-=· 
=loMI oreo: NS- dlffN,..,Cc rn>t :;,enJfoc.ont. 
nary dissection. 13,~ 4 Lesions with a ratio >I (ovcrsizing) 
were compared with lesions with a ratio :S:l. The com-
parative data are listed in Table II. No difference was 
found in balloon diameter between the groups. As ex-
pected, reference diameter was higher in the group with 
a ratio ::S: 1. Elastic recoil was more pronounced in the 
second group (0.84 ± 0.29 vs 0.64 ± 0.30 mm, p 
<0.001). Thus, oversizing of the balloon leads to more 
elastic recoil. These results agree with elastic phenome-
na: more stretch leads to more recoil (within li:nits of 
elasticity). 
Clinical characteristics and recoil: Clinical charac-
teristics and risk factors of the 136 patients are listed in 
No pVolue Me on 
101 (0.43± 0.33) NS 6.4±2.4mm 
129(0.45±0.45) NS 
100 (0.41 ±0.30) P"'0.07 0.5±0.3 
101 (0.41 ±0.27) p<O.Ol 6.8±3.9mm< 
100(0.43±0.31) p <0-01 17.7±10.4 
102(0.46±0.35) NS 9.6±2.5otm 
101 (0.44±0.29) NS 309 ± 170 ,;cconds 
Table III. No differences in elastic recoil were observed 
for gender. the presence or absence of risk factors and 
the presence or absence of unstable angina. 
Quantitative .angiographic lesion characteristics 
and recoil: Quantitative data on lesion morphology be-
fore angioplasty are listed in Table IV. To avoid arbi-
trary subdivision of data, cutoff criteria for lesion 
length. symmetry. plaque area and curvature value were 
dcrivOO by dividing the data in 3 groups so that each 
group containOO about one-third of the population. The 
group with the highest amount of recoil was then com· 
pared with the 2 other groups. Lesions with a small 
plaque area and lesions with a shallow curvature 
showed significantly more recoil (Table IV). 
Procedural relat~ variables and re«~il: Table IV 
lis.ts the total inflation duration and maximal balloon 
inflation pressure in relation to elastic recoil. No differ-
ences in clastic :-ecoil were observed. 
Recoil in the three main coronary arteries: The 
amount of rccoi: was calculated in the left anterior de-
scending artery (n == 77), the circumflex artery (n == 
34) and in the right coronary artery (n == 40). Data are 
listed in Table V. The amount of recoil was significantly 
larger in the left anterior descending artery compared 
with the circumflex and right coronary arteries, 2.7, 2.3 
recoil{mm2) .~~~~----,----,----,------------, 
var;oconstriction vasodilation 
6 
4 
2 
~ .·· .- . 
. -~·. ~~-. 
.. ' ·'· . 
...... ·.:- • 1-~ 
.... 
0~-----------r~--~~--+-----------~ 
-3 -2·10 2 3 4 
6. reference area {mm2) 
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RC.URE 2.1n this seatterplot the <fiffe~ 
ence in interpolated reference area before 
and after percutaneous transluminaJ coro-
nary angiOplasty is plotted against the 
.1m011nt of reeoll for each segment. The 
mean diffen:.nce in reference area was 0.2 
± 1.3 mnT! (Yerlical lines in vaph). The< 
v~ are randomly distributed around 
the mean value of 0.2 mnT!, 5llggesting 
that Sl)aSm w.u etrectlvely eliminated. 
and 1.9 mmZ. respectively (p <0.025). When normal-
ized for reference art!a the difference was still statisti-
cally significant. 
DISCUSSION 
Vasoconstriction at the dilatation site is a common 
cause of early luminal narrowing. As has been shown 
elegantly by Ftschell et al 15 this can be rapidly reversed 
by an intracoronary injection of nitrates. Because we 
gave intracoronary nitrates before the pre- and post-
PTCA cine runs, it seems unlikely that the amount of 
recoil observed was caused by vasomotion. In Figure 2 
the difference between the reference area before and af-
ter PTCA is plotted against the amount of recoil for 
each site. The values are randomly distributed around 
the mean value of 0.2 mm2, suggesting the absence of 
vasoconstriction at the post-PTCA film. 
Platelet deposition, and the formation of a nonocclu-
sive mural thrombus despite full heparinization, is not 
an uncommon fmding in postmortem hearts obtained 
from patients who die in the first hours after angio-. 
plasty.16 This has also been confirmed by angioscopy 15 
to 30 minutes after PTCA.17 However, our post-PTCA 
angiograms were recorded within minutes of the last di-
latation. Although we cannot rule out the possibility 
that mural thrombus formation is pady responsible for 
the observed phenomenon, we believe it cannot explain 
the 50% decrease in luminal area found. Subintimal 
hemorrhage is also a cause of severe early luminal nar-
rowing or acute closure. a process which is usually im-
possible to reverse and nearly always results in a failed 
PTCA. In this study only successfully dilated lesions 
were analyzed. 
The mean balloon cross-sectional area was derived 
over the total length of the balloon and compared with 
the minimal luminal cross-sectional area measured im-
mediately after PTCA. In this study. recoil of the part 
of the dilated segment adjacent to this area was not spe-
cifically studied. We assumed a uniform expansion of 
the balloon at maximal inflation pressure.. Theoretically, 
recoil should be assessed using the minimal luminal bal-
loon cross-sectional area. 
The IS lesions restudied 24 hours after PTCA 
showed no difference in minimal luminal cross-sectional 
area with respect to the cross-sectional area directly af-
ter PTCA. This suggests that clastic recoil is an instan-
taneous phenomenon. This finding does not agree with 
the fmdings of Nobuyoshi ct a1,1N who found a signifi-
cant deterioration of minimal luminal diameter 1 day 
after PTCA. However, the small size of this subgroup 
may not be representative of the total population. A 
trend toward more recoil was observed in asymmetric 
lesions. In these lesions the balloon will preferrably 
stretch the nondiseased part of the vessel circumference 
with a subsequent larger clastic recoilY The fact that a 
small plaque area and a low curvature value arc attend-
ed with a significant higher amount of clastic recoil may 
be due to the fact that dissections have been found most 
often in areas containing thick atherosclerolic plaques 
and lesions with a high bending.2o.21 Gross disruption of 
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the vessel wall may prevent the recoil phenomenon. Pro-
cedural variables had no influence on the amount of re-
coiL Longer inflations and higher inflation pressures are 
often used after an initially poor angioplasty result. 
Only a randomized trial can indicate to what extend 
procedural factors influence procedural outcome. 
Jain ct aJZZ found, using an in vivo technique for ob-
taining balloon pressure-volume loops, a pattern consis-
tent with stretching of the arterial wall in 56% of le-
sions. A pressure--volume loop consistent with stretching 
of the vessel was a far more common event than a 
cracking pattern (17%). Stretching within limits of elas-
ticity tmplies its counterpart elastic recoil. More stretch-
ing should lead to more recoil. In our series, oversizing 
of the balloon (i.e., a balloon-artery ratio >1) was asso-
ciated with more recoil, indicative of the elastic phe-
nomenon. Dobrin described pressure radius curves of 
potassium cyanide-poisoned carotid arteries of mongrel 
dogs. At low pressures, the vessel exhibited large 
changes in radius with each step in pressure, whereas at 
high pressure it showed very slight changes in radius. 
The curve described an elastic hysteresis loop, with the 
ascending and descending limb close to each other at all 
pressures, suggesting no active muscle contraction in-
volvement in the retraction proccss.:3 
The differences in elastic recoil observed in the 3 
coronary arteries cannot be easily be explained. Differ-
ences in histologic structure or differences in plaque 
composition in the coronary arteries might be an expla-
nation. To our knowledge these differences have not 
been reported. 
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IN1RODUCTION 
It is a common clinical observation that in some lesions percutaneous transluminal 
coronary balloon angioplasty does not achieve a satisfactory result in the absence of a 
visible tear or dissection. This phenomenon has been investigated using quantitative 
angiography and intravascular ultrasound and has been attributed to elastic recoil of the 
vessel wall that was stretched within its limits of elasticity [1-5]. From pathologic and 
angiographic studies it is known that approximately 70% of atherosclerotic coronary 
lesions are eccentric [6,7]. This implies that part of the vessel circumference is free of 
atherosclerotic plaqne and that this disease free portion will be preferentially stretched 
during balloon angioplasty with little damage to the atherosclerotic plaque [8]. Waller 
suggested that stretching of the plaque free wall segment may result in an initial increase 
in luminal diameter but that gradual relaxation or restitution of tone of this 
overstretched segment reduces the coronary lumen towards its predilatation state in 
hours to weeks after the angioplasty [8]. This study was undertaken to determine whether 
recoil is an instantaneous phenomenon occurring immediately after balloon deflation or 
a phenomenon with a delayed component as assessed 24 hours after a successful 
procedure. 
METIIODS 
Patients. The study population consisted of71 patients that underwent successful elective 
single vessel coronary balloon angioplasty defined as a less than 50% diameter stenosis 
on visual inspection of the post angioplasty angiogram. All patients gave informed 
consent and the study protocol was approved by the institutional review board. 
Angioplasty procedure and 24 hour angiography. Coronary angioplasty was performed 
with a steerable, movable guide wire system via the femoral route. Details of the 
procedure have been described previously [9]. After the procedure the arterial sheaths 
were left in place overnight. The next day (range 17 to 29 hours after angioplasty), a 
repeat angiogram was obtained. 
Three coronary angiograms were obtained in each patient, one just before 
angioplasty, one immediately after angioplasty, and one angiogram at 24 hours follow-up. 
The largest balloon used at its maximal inflation pressure was filmed in all patients in 
a single non~ foreshortened projection. The angiograms were recorded in such a way that 
they were suited for quantitative analysis by the Cardiovascular Angiography Analysis 
System ( CAAS). All necessary details of the procedure were recorded and drawings of 
the segments to be analyzed were made. The exact same angulations of the x-ray 
equipment were repeated for each consecutive angiographic study. To minimize the 
influence of vasomotion on arterial dimensions either 1-3 mg isosorbide dinitrate or 0.1-
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03 mg nitroglycerin was given intracoronary before the pre angioplasty, post angioplasty 
and 24 hour angiograms. For calibration purposes the catheter-tips were cut off for later 
measurement with a microcaliper. To standardize the method of data acqnisition and to 
ensure exact reproducibility of the angiographic studies, measures were taken as 
described previously [1 0,11 ]. All angiograms were processed and analyzed in a central 
core-laboratory. Qualitative morphologic lesion variables were assessed by 2 experienced 
angiographers. Differences were resolved during a third review by consensus. 
Quantitative angiography. All cineangiograms were analyzed using the computer assisted 
cardiovascular angiography analysis system (CAAS) which has been described and 
validated earlier [12-14]. A computer derived reconstruction of the original arterial 
dimension at the site of obstruction (assuming there is no disease present) is used to 
define the interpolated reference diameter. The length of the obstruction is determined 
from the diameter function on the basis of curvature analysis and expressed in 
millimeters. ln addition, this technique allows for the calculation of an eccentricity index 
of the lesion. The index ranges from 0 (severe eccentric) to 1 (perfectly symmetric) The 
area between the reconstructed "non-diseased" vessel contours and the actual contours 
is a measure of the amount of atherosclerotic plaque. 1n case of a total occlusion a value 
of 0 for the minimal lumen diameter and 100% for the percent diameter stenosis was 
substituted. Minimal lumen diameters and reference diameters were taken as the mean 
from matched angiographic projections from the pre-angioplasty, post angioplasty and 
24 hour angiogram. 
Assessment of elastic reeoil. Elastic recoil was calculated as the difference between the 
minimal lumen diameter post-angioplasty and the mean balloon diameter divided by the 
interpolated reference diameter. The latter was done to correct for differences in size 
of the dilated segments. 
RESULTS 
The study group consisted of71 patients, 55 male (77.5%) and 16 female. Mean age was 
58 ± 8 years. The minimal lumen diameter pre angioplasty was 1.01 ± 0.37 mm and 
increased to 1.74 ± 0.32 mm (p< 0.0001, paired t-test) after angioplasty. At 24 hours, the 
average minimal lumen diameter was still 1.74 ± 037 mm. The interpolated reference 
diameter increased significantly from 2.68 ± 0.64 mm pre angioplasty to 2.76 ± 0.60 mm 
post angioplasty and 2.88 ± 0.61 mm at 24 hour follow-up angiography (p<0.005, 
repeated-measures analysis of variance). Mean balloon diameter was 2.72 ± 0.41 mm. 
Figure 1 shows cumulative distribution curves of all individual data. Elastic recoil for the 
entire group was 0.38±0.14. Mean aortic blood pressure was 98.4 :t 17.5 mmHg pre 
angioplasty and 98.3 ± 13.6 mmHg post angioplasty. At 24 hours follow-up angiography 
the mean aortic blood pressure had decreased to 93.0 ± 14.8 mmHg. 
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Lesion and procedural characteristics. 
Table 1 lists several lesion and procedural characteristics and the amount of elastic 
recoil. To avoid arbitrary subdivision of data, cut-off criteria for lesion length, synunetry, 
total inflation time and maximum inflation pressure were derived by dividing the data 
in 3 groups so that each group contained about one third of the population. The group 
with the highest amount of recoil was then compared to the 2 other groups wit an 
unpaired t-test. Lesions dilated with an oversized balloon and eccentric lesions showed 
more elastic recoil, although the latter did not reach a statistically significant level. Total 
inflation time, maximal inflation pressure, visible calcifications, a bend in the dilated 
segment of > 450, lesion length of > 7 mm and vessel type did not influence the amount 
of recoil. 
Figure 2 shows the quantitative angiographic measurements before angioplasty, 
after angioplasty and at 24 hours for eccentric and concentric lesions. Although the 
minimal lumen diameter immediately after angioplasty is lower for eccentric than for 
more concentric lesions, the minimal lumen diameter in both groups does not change in 
the first 24 hours. This suggests that recoil is indeed more pronounced in eccentric 
lesions, but also that recoil is an instantaneous phenomenon without a delayed 
component. 
DISCUSSION 
The presence of immediate recoil after percutaneous transluminal coronary angioplasty 
has now been confirmed by several in vivo studies using quantitative angiography and 
balloon ultrasound inflation catheters (BUIC) [1-5]. As predicted by Waller [8] some 
studies [1-3] showed that recoil was more pronounced in eccentric coronary arteries. In 
these type of stenoses, balloon inflation within the limits of elasticity, may result in 
preferential stretching of the non diseased portion of the vessel circumference. Deflation 
of the balloon will then immediately be followed by elastic recurrence of the vessel wall 
towards its predilatation state. In the present study this was again confirmed. However, 
the predicted slow restitution of tone with gradual recurrence of the lesion in the first 
hours to days after a successful procedure was not found in this study. The minimal 
lumen diameter in the total group as well as in the group with eccentric lesions did not 
change in the first 24 hours after balloon dilatation. As a result of greater immediate 
recoil, the minimal lumen diameter of eccentric lesions was lower in the eccentric lesion 
group at 24 hour group (figure 2). These findings suggests that recoil is an instantaneous 
phenomenon, occurring simultaneously with balloon deflation. Similar fmdings have 
recently been reported by Hanet et al [4]. 
An increase in interpolated reference diameter was observed in the first 24 hours. 
This might be caused by the cumulative effect of vasodilatory drugs administered during 
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Figure 1. Cumulative distributions of minimal lumen diameter (MLD) pre angioplasty, 
mean balloon diameter, MLD post angioplasty, MLD at 24 hours angiography (jat line) 
and interpolated reference diameter (dotted line). for the total group of oatients. 
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Figure 2. Upper panel: Bar graph of mean(=. JSD) minimal lumen diameter (MLD) pre 
angioplasty, post angioplasty and 24 hours angiography, mean balloon diameter and 
interpolated reference diameter pre angioplasty for eccentric lesions (symmetry measure < 
0.25). Lower panel: Bar graph of mean (:!: ISD) minimal lumen diameter (MLD) pre 
angioplasty, post angioplasty and 24 hours angiography, mean balloon diameter and 
interpolated reference diameter pre angioplasty for more concentric lesions (symmetry 
measure ::_0.25). 
Table 1. Relationship between amount of elastic recoil and several procedural and lesional variables 
Balloon artery ratio > 1 
Symmetry < 0.25 
Bend in dilated segment > 45• 
Calcified segment 
Length of stenosis > 7 mm 
LAD dilatation 
RCA dilatation 
LCX dilatation 
Total inflation time < 220 s 
Max. inflation pressure > 8 atm. 
Variable present 
0.46±0.13 (n=41) 
0.41±0.17 (n=23) 
0.35±0.13 (n=20) 
0.51±0.24 (n=6) 
0.38±0.12 (n=25) 
0.40±0.16 (n=35) 
0.33±0.10 (n=21) 
0.40±0.14 (n= 15) 
0.42±0.17 (n=24) 
0.35±0.12 (n=26) 
.. 
Variable absent 
0.28±0.08 (n=30) 
0.35±0.14 (n=45) 
0.39±0.15 (n=51) 
0.37±0.13 (n=66) 
0.37±0.14 (n=43) 
0.37±0.13 (n=47) 
0.39±0.14 (n=45) 
p·value • 
0.0001 
0.08 
0.28 
0.23 
0.95 
0.11 
0.25 
' unpaired Hest, " analysis of variance, p=0.25, LAD = left anterior descending artery, RCA = right coronary artery, LCX = left 
circumflex coronary artery, Max. = maximal 
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the course of the study. All patients received nifedipine 10 mg/2hours for the first 12 
hours after the procedure. Thereafter they received 20 mg of slow release nifedipine 3 
times during the second day after angioplasty. Before repeat coronary angiography all 
patients received an intracoronary dose of nitrates. The effect of the vasodilatory drugs 
is also reflected in a decrease in mean aortic pressure at 24 hours catheterization, while 
aortic pressure did not differ pre angioplasty and immediately post angioplasty. Hanet 
et al. [4] also found an increased reference diameter at 24 hour angiography. 
Subsegmental analysis in their series revealed that the increase was mostly dependent on 
the post-stenotic subsegments. Their explanation for this increase was that the reduction 
in transstenotic gradient and the resulting increase in perfusion pressure distal of the 
obstruction site causes a passive distension of the distal coronary segment. 
Other explanations for early luminal narrowing. 
Vasoconstriction at the dilatation site is a common cause of early luminal narrowing. As 
has been shown elegantly by Fischell and co-workers this can be rapidly reversed by an 
intracoronary injection of nitrates [15]. Since we gave intracoronary nitrates before the 
pre PTCA, post PTCA and 24 hour cine recordings. it seems unlikely that the amount 
of recoil observed was caused by vasomotion. 
Platelet deposition and the formation of a non occlusive mural thrombus despite 
full heparinization, is not an uncommon finding in post mortem hearts obtained from 
patients who die in the first hours after angioplasty [16]. This has also been confirmed 
by angioscopy 15-30 minutes after PTCA [17]. However our post PTCA angiograms were 
made within minutes of the last dilatation. Although we cannot rule out the possibility 
that mural thrombus formation is partly responsible for the observed phenomenon, we 
feel it cannot explain the 40% decrease in luminal diameter found. Furthermore, if mural 
thrombus formation is a substantial contributor to earlier luminal narrowing, this would 
have been picked up at 24 hour angiography. Subintimal hemorrhage is also a cause of 
severe early luminal narrowing or acute closure, a process which is usually impossible to 
reverse and nearly always results in a failed PTCA, In this study only successfully dilated 
lesions were analyzed. 
Deendothelialization of coronary arteries with loss of local endothelial derived 
relaxing factor function is a known cause of local vasoconstriction [18]. However, 
vasoconstriction after coronary balloon angioplasty is not a very common phenomenon 
if vasodilatory drugs are administered during the procedure [15]. Concomitant dilatory 
therapy with organic nitrates, as in the present study, might substitute for the local loss 
of endothelium at the dilatation site. Another explanation might be that damage to the 
arterial media and/or splinting of the vascular muscle by the atherosclerotic plaque, 
prevents the artery from contracting 
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Regional Differences in Elastic Recoil After Percutaneous 
Transluminal Coronary Angioplasty: A Quantitative 
Angiographic Study 
BENNO J. RENSING, MD, WALTER R. HERMANS, MD. BRADLEY H. STRAUSS. MD. 
PATRICK W. SERRUYS. MD, FACC 
Rotterdam, The Netherfands 
The immediate result of percutaneous transluminal coronary 
angioplasty is influenced by both plastic and elastic changes of the 
vessel wall. To cvalu?.tc the amount of ehlstic recoil after coronary 
balloon angioplasty. the minimal luminal cross·Se1:tional area of 
the largest balloon used at highest inflation pressure was com-
pared with the minimal luminal vessel cross-sectional area directly 
after final balloon deflation in 607 lesions (526 patients). Elastic 
re1:oil was defined as the difference between balloon cross-sectional 
area and minimal luminai cross-se<:tional area of the dilated 
coronary segment immediately after balloon withdrawal. A vid-
eodcnsi!omctric analysis technique was used to avoid geometric 
assumptions on stenosis morphology directly after angioplasty, 
Percutaneous transluminal coronary balloon angioplasty re-
mains by far the most applied percutaneous coronary revas-
cu!arization technique (I). Improvements in guide wire and 
balloon catheter design allow us to cross and dilate nearly 
every lesion in the coronary tree. with the exception of some 
chronically occluded lesions. However. the dilation process 
itself has not changed basically since the early duys of 
balloon angioplasty and the mechanism by which luminal 
enlargement is achieved is still the subject of debate (2). 
Apart from plastic changes (dissection. intimal tear). the 
immediate result of a balloon angioplasty is also dependent 
on elastic properties of the vessel wall. We (3) reported 
earlier that elastic recoil after coronary angioplasty ac-
counted for a nearly 50% decrease in lumir.al cross-sectional 
area immediately after balloon deflation. Because the disrup-
tive action of the balloon on the vessel wall causes irregular 
and asymmetric luminal cross sections (4). cross-sectional 
area measurements based on automated edge detection 
techniques are potentially unreliable. Therefore. avidcoden-
sitometric analysis technique. which is theoretically inde-
pendent of geometric assumptions on the shape of the 
From the Catheteri:;:.tion Labor~tory. Thor ... xcenter. ErJ.smu~ Univer-
sity, RonerdJ.m. The Netherlands. Dr. Stmuss i~ a Research Fellow of the 
He:l11 and Stroke Foundation of CanadJ. 
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tory. Thot<lxcenter. El<l~mu~ Vnivc,-.,it}-. P.O. Box 1738.3000 DR Rotterdam. 
The Netherlands. 
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Mean balloon cross-sectional .area was 5.3 ::!:: 1.6 mmz and 
minimal luminal cross-sectional area after angioplasty was 2.8 ::!:: 
1.4 mmz. Reference areas before and after angioplasty did not 
differ (6.0 ::!:: 2.6 and 6.2 ::t 2.6 mm~, respectively). Univariate 
analysis revealed that as~"lt1metric lesions, lesions located in 
less angulated parts of the artery and lesions with a low plaqu~ 
content showed more clastic recoil. Lesions located in distal parts 
of the coronary tree were also associated with more elastic recoil 
probably related to relative balloon oversizln,:: in these dist:d 
lesions. 
(}Am Col/ Cardiol 1991:17:348-SB) 
stenosis. was used. This study was undcnakcn to determine 
the amount and the regional distribution of elastic recoil 
directly after balloon angioplasty with the usc of a quantita-
tive angiographic analysis technique. 
Methods 
Study patients. The study group consisted of526 patients 
(607 lesions) who had undergone successful coronary bal-
loon angioplasty, defined as a <50% diameter stenosis on 
visual inspection of the postangiop!asty angiogram. Patients 
with stable and unstable angina. as described previously (5). 
were included; patients with acute myocardial infarction 
were excluded. The mean age was 56 ::!:: 12 years. 
Coronary angioplasty. This was performed by the femo-
ral route with a steerable. movable guide wire system (5). 
The choice of balloon type (compliant or noncompliant) and 
manufacturer. inflation pressure and inflation duration were 
left to the discretion of the operator. 
Quantitative Coronary Angiography 
Contour detection. All cineangiograms were analyzed 
using the computer-assisted angiographic analysis system 
(CAAS), wh;-;h has previously been described and validated 
in detail (6.7). To describe briefly the important steps. any 
area of size 6.9 x 6.9 mm (512 x 512 pixels) in a selected cine 
frame (overall dimensions 18 x 24 mm) encompassing the 
073~-10971911$3.50 
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desired arterial segment can be digitized with a high resolu-
tion digital camera. Vessel contours are determined auto-
matically based on the weighted sum of first and second 
derivative functions applied to the digitized brightness infor-
mation along scan lines perpendicular to the local centerline 
directions of an arterial segment. A computer-derived esti-
mation of the original arterial dimension at the site of 
obstruction is used to define the interpolated reference 
diameter. The absolute values of the stenosis diameter and 
the reference diameter are measured by the computer using 
the known contrast catheter diameter as a scaling device. All 
contour positions of the catheter and the arterial segment are 
corrected for pincushion distortion introduced by the image 
intensifiers. The area between the actual and reconstructed 
contours at the obstruction site is a measure of the amount of 
"'atherosclerotic plaque" and is expressed in square milli-
meters. The length of the obstruction is determined from the 
diameter function on the basis of curvature analysis and 
expressed in millimeters. 
Using the reconstructed borders of the vessel wall, the 
computer can calculate a symmetry coefficient for the ste-
nosis. Differences in distance between the actual and recon-
structed vessel contours on both sides of the lesion are 
measured. Symmetry is determined by the ratio of these two 
differences. with the largest distance between actual and 
reconstructed contours becoming the denominator. Values 
for symmetry range between 0 for extreme eccentricity to I 
for maximal symmetry (that is, equal distance on both sides 
between reconstructed and actual contours). The curvature 
value at the obstruction site, as a measure for coronary 
bending, is computed as the average value of all the individ-
ual curvature values along the centerline of the coronary 
segment, with the curvature defined by the rate of change of 
the angle through which the tangent to a curve turns in 
moving along the curve and which. for a circle, is equal to 
the reciprocal of the radius. 
Densitometric procedure. Constitution of the relation be-
tween path length of the X-rays through the artery and the 
brightness value requires a detailed analysis of the complete 
X-ray/cine/video chain, including the film development pro-
cess (8). For the first part of the chain from the X-ray source 
to the output of the image intensifier. we use Lambert-Beer's 
law for the X-ray absorption and apply certain models for the 
X-ray source and the image intensifier. From the output of 
the image intensifier up to the brightness values in the digital 
image we use a linear transfer function. Details of this 
technique have been described elsewhere (9). The cross-
sectional area of a vessel is then obtained as follows. The 
contours of a selected arterial segment are detected, as 
described before. A profile of brightness values is measured 
on each scan line perpendicular to the centerline. This profile 
is transformed into an absorption profile by means of a 
logarithmic transfer function. The background contribution 
is estimated by computing the linear regression line through 
the background points directly to the left and right of the 
detected contours. Subtraction of this background portion 
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RCA 
Prox (} A<wtoo 
7 
mid 
"\ dist 
Fi~re 1. Map with the beginning and end points of the coronary 
artery segments. CFX = circumflex artery; D1 and D~ "" first and 
second diagonal branches. respectively: dist == distal; LAD = left 
anterior descending artery: mid "' mid portion: OM "' obtuse 
marginal branch: PL = posterolateral branch: prox "' proximal; 
RCA= right coronary artery. 
yields the net cross-sectional absorption profile. Integration 
of this function gives a measure for the cross-sectional area 
at the particular scan line. By repeating this procedure for 
each scan line, the cross-sectional area function is obtained. 
Calibration of the densitometric area values is accomplished 
by comparing the reference area calculated from the diame-
ter measurements (assuming a circular cross section) with 
thr; corresponding densitometric area value. The complete 
procedure has been evaluated with cine films of perspex 
models of coronary obstructions (8). 
Assessment of elastic recoil. Single identical views before 
and after angioplasty and during complete expansion of the 
largest balloon at highest inflation pressure were chosen for 
densitometric analysis. Mean balloon cross-sectional areas 
were calculated from diameter values. assuming a circular 
cross section at maximal inflation pressure. The same X-ray 
setting in tenns of kilovoltage and milliamperes was used 
during the three cine recordings. Vessel segments were 
analyzed in the least foreshortened projection (that is, per-
pendicular to the incoming X-ray beam). The same amount 
of nitrates-either nitroglycerin. 0.1 to 0.3 mg. or isosorbide 
dinitrate, I to 3 mg-was given by intracoronary injection 
before the pre- and postangioplasty cine recordings. These 
agents were administered to maximally dilate the vessel and. 
hence. to control the vary1ng influence of vasomotor tone on 
luminal dimensions. Elastic recoil was then calculated as the 
difference between the minimal luminal cross-sectional area 
after angioplasty and the mean balloon cross-sectional area 
(mm2). The time between final balloon deflation and the 
postangioplasty cine recordings was usually <I min. To 
compare the amount of recoil in different parts of the 
coronary tree. absolute values were normalized for refer· 
ence area at the obstruction site- The beginning and end 
points of the major coronary segments are shown in Figure 
l. The definitions are slightly modified from those of the 
American Hean Association (10). 
Statistical analysis. The individual quantitative data were 
used to calculate mean values and SD. Univariate analysis of 
variance was performed for the continuous variables. A 
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Table l. Quantitative Angiographic Analysis of 607 Lesions 
in 526 Patients 
Minimalluminn.l cross-sectional area. before 
angioplasty (mm2) 
Mea.n: SD 
1.0 = 0.9 
Minimal luminal cross-sectional area after 
angioplasty (mm2) 
Balloon cross-seetionn.l area (mrn~ 
Reference area before angioplasly (mm~l 
Reference area. :Utcr angioplasty (mm2) 
Elastic recoil (mm2) 
2.8 = 1.4 
5.3 = 1.6 
6.0 = 2.6 
6.2 = 2.6 
2.5 = 1.4 
6.5 = 2.7 
0.5 = 0.3 
7.2 = 4.4 
17.5 = 10.5 
l p<0.0001 
NS 
Lesion length (mm) 
Symmetry value 
Plaque area (mm~ 
Curvature value (U) 
probability value < 0.05 was considered significant. To 
avoid arbitrary subdivision of data. cutoff criteria for con-
tinuous variables were derived by dividing the data into 
three groups so that each group contained about one third of 
the population. The group with the highest amount of recoil 
was then compared with the two other groups (II). This 
method of subdivision is consistent for all variables and thus 
avoids any bias in selection of subgroups that might be 
undertaken to emph::~size a particular point. 
Results 
Angiographic lesion characteristics. The mean minimal 
luminal cross-sectional area predilation ::~nd postdilation and 
the balloon cross-sectional area for the 6071esions arc shown 
in Table 1. The mean minimal luminal cross-section::~! area 
was 1.0 ± 0.9 mm~ before and 2.8 :': 1.4 mm2 after angio-
plasty. The mean balloon cross-sectional area was 5.3 :': 
1.6 mm2• The mean amount of elastic recoil was 2.5::: 1.4 
mm2• These data indicate a nearly 50% loss of maximally 
achievable cross-sectional area directly after balloon defb.-
tion. Reference area before angioplasty was not changed 
significantly by angioplasty. Other quantitative angiographic 
lesion characteristics of the 607 lesions arc shown in Table 1. 
Table 2 shows the grouping of the quantitative data for 
statistical analysis (based on the tertiles), the numbers in 
each group and the amount of recoil relative to vessel size. 
Asymmetric lesions, lesions with a small plaque area and 
Table 2. Qu::mtitative Angiographic Variables and Elastic Recoil 
in 607 Coronary Lesions 
Yo. No 
{recoil/reference) (recoiiJrcfcrcnce) p Value 
Lesion length <5.1 mm 200 (0.49) 407 (0.44) NS 
Symmetry <0.37 205 (0.50) 402 (0.43) p < 0.05 
Plaque me:. <4.7 mm~ 199 (0.55) 408 (0.4!) p < 0.01 
Curvllture <12.5 U 206 (0.51) 401 (0.40) p < 0.01 
Values indicate number of lesions ~nd recoil nonnali~ed for referenu 
diameter (rccoiL'referencc). 
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Table 3. Regional Distribution of Elastic Recoil in 607 
Coronary Lesions 
Recoi!J B:llloonf 
Reference Anory 
N Ratio Ratio 
LAD prox liS 0.43 0.90 
LAD m:d 120 
'-'' 
p < 0.01 0.97 p < 0.01 
LAD dist 
" 
0.61 1.20 
LCx prox 39 0.41 0.80 
LCx mid ,_, 0..11 0.90 
Obtuse mnrgin~l 29 0.47 p < 0.01 0.93 p < 0.01 
Po,tero::l!era1 24 0.54 !.10 
RCA pre.~ 71 0.28 0.78 
I RCA m:d 76 OJS p < 0.01 0.93 p < 0.01 RCA dist 50 0.40 0.98 
dist ~ distal; LAD ~ left Jnterior descending artery; LCx ~ circumflex 
artery; mid "mid portion; prox" proximal; RCA= right coronary artery. 
lesions located in straighter arterial segments (low curvature 
value) were associated with significantly more elastic recoil. 
Regional distribution of elastic recoil. Data on el::tstie 
recoil in the different pans of the coronary tree are summa-
rized in Table 3. Data on diagonal branches and the ramus 
dcscendens posterior in left dominant systems are omitted 
because of the small number of segments dilated in this 
series (5 and 0. respectively). Recoil, nonnalizcd for vessel 
size, increased from proximal to distal pans for all three 
major coron:ll)' brJ.nchcs. This increase in clastic recoil 
corresponds to a significant increase in the balloonl::~nery 
ratio from proxim::~l to distal parts of the coronary arteries. 
Discussion 
Mechanisms of lesion dilation in balloon angiopl~'ty. 
Dotter and Judkins (12) in 1964 envisioned that balloon 
angioplasty worked by remodeling and compression of the 
atheroma because initial pathologic studies revealed little 
intimal destruction and no evidence of dissection. However. 
the vast majority of atherosclerotic plaques in human coro-
nary arteries arc composed of incompressible, dense fi-
brocollagenous tissue and therefore it appears unlikely that 
plaque compression plays a major role in balloon angio-
plasty. However Kaltenbach et al. (13) observed in an in 
vitro model a reduction in weight and thickness of the 
atherosclerotic vcssc:l wall after pressure application. This 
reduction was more pronounced in lipoidotic plaques, sug-
gesting that fluid expression from atherosclerotic tissue 
could play some role in the luminal widening achieved by 
angioplasty (13). According to S::~nbom et al. (14), part of the 
angioplasty mechanism consists of stretching the vessel wall 
with a resulting fusiform dilation or localized aneurysm 
formation. If the lesion is eccentric, then the least diseased 
portion of the vessel wall will stretch (15). 
Castaneda-Zuniga et al. (16) found that angioplasty in-
duced paralysis by overstn::tching the vessel wall beyond its 
limits of elasticity and suggested this to be the cause of 
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Figure 2. Is vasomotion part of the recoil pherlomenon? Scatter plot 
of the difference in reference area after angioplasty from that before 
angioplasty (POST-PRE PTCA) against the amount of recoil for 
each of the 607 lesions (see text for explanation). 
pennanent luminal widening after balloon angioplasty. This 
widening was associated with histopathologic features of 
smooth muscle cell lysis and twisted nuclei. These corrdatcs 
of severe medial damage were not found in human arteries 
examined post mortem after recent dilation (17.18). In in 
vitro models of balloon angioplasty in rabbit iliac artery, 
rabbit aorta and pig carotid artery. only severe ovcrsizing of 
the balloon produced impairment of vasoconstrictor respon-
siveness (19). Because it is becoming clear that oversizing of 
the balloon leads to an increased complication rate (20) and 
that satisfactory initial results can be obtained by conserva-
tive balloon sizing (20.21). deliberate oversizing of the an-
gioplasty balloon is not common in our institution. This is 
reflected by the mean balloon/artery ratio of 0.95 in our 
study. Thus, arterial paralysis must be questioned as an 
explanation for the luminal widening achieved by angio-
plasty in human coronary arteries. The most consistent 
finding after angioplasty is disruption and splitting of the 
neointima and localized intimal dissection (22). 
Mechanisms of early r~1cnosis. Early lesion recurrence 
after balloon ·angioplasty is most likely due to vasoconstric-
tion, intimal flaps. mural thrombus formation or subintimal 
hemorrhage (23-27). Fi:;chell ct a!. (26) showed that vaso-
constriction after balloon angioplasty could be rapidly re-
versed by intracoronary injection of nitrates. Because we 
gave intracoronary nitrates before the pre- and postangio-
plasty cine recordings, it seems unlikely that the amount of 
recoil observed was caused by vasomotion. In Figure 2 the 
difference between the postangioplasty and prcangiopbsty 
reference area is plotted against the amount of recoil for each 
site. The values are randomly distributed around the mean 
value of 0.17 mm~, suggesting the absence of vasoconstric-
tion at the postangioplasty cine recording. 
Despite full heparinization, platelet deposition and the 
formation of a nonocclusive mural thrombus are not uncom-
mon findings in postmortem hearts obtained from patients 
who die in the first hours after angioplasty (27). Such findings 
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have also been confirmed by angioscopy 15 to 30 min after 
angioplasty (28). However, our postangioplasty angiograms 
were made within minutes of the last dilation. Although we 
cannot rule out the possibility that mural thrombus forma-
tion is partly responsible for the observed phenomenon, we 
believe that it cannot explain the observed 50% decrease in 
luminal area. Subintimal hemorrhage is also a cause of 
severe early luminal narrowing or acute closure, a process 
that is usually impossible to reverse and nearly always 
results in failed angioplasty. In this study only successfully 
dilated lesions were analyzed. 
Factors leading to elastic recoil. Eccentric lesions showed 
significantly more elastic recoil. This can be explained by the 
fact that in such lesions, a part of the vessel circumference is 
not diseased. The portion that is not diseased will be 
preferentially stretched by the balloon with subsequently 
more elastic recoil (15). Lesions with a high bending and a 
large bulk of atherosclerotic plaque showed less clastic 
recoil. It is known that dissections arc more common in this 
type of lesion (24.29). The gross disruption of the vessel wall 
and the atherosclerotic plaque as:;ociated with an angie-
graphically visible dissection might release the cicatrizing 
effect of the plaque that had chronically affected the media. 
Release of this force may allow the media to return to its 
more normal outer diameter and thus reduce some of the 
recoil effect. 
Recoil relative to vessel size increases from proximal to 
distal parts ofthc coronary aneries. This phenomenon is due 
to the tendency of balloon ovcrsizing in distal parts of the 
coronary tree (Table 3). If a vessel is stretched within its 
limits of elasticity, it will return toward its rest state along an 
elastic hysteresis loop. More stretch should thus give more 
clastic recoil. It is difficult to discern whether the oversizing 
is based on economic grounds (an extra balloon for a second 
distal site nearly doubles the cost of angioplasty disposable 
equipment) or is due to visual overestimation of smnller 
caliber vessels. In our series. a minority of 40 patients 
underwent multilesion dilation including a proximal and a 
distal segment. ln 31 of these cases. the same balloon was 
used for the proximal and distal stenoses. Mean balloon 
cross-sectional area was 4.7 ~ 1.2 mm~ for the proximal 
stenosis and 4.6 ± 1.2 mm2 for the distal stenosis (p"" NS). 
Reference area was 5.8 ± 2.4 mm~ for the proximal lesions 
and 4.6 ::!: 2.2 mm~ for the distal lesions (p < 0.01). Balloon 
artery ratio was 0.85 ::!: 0.5 for these proximal lesions and 
1.0 ::!: 0.5 for distal lesions (p < 0.0 1). 
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Abstract 
Because many ongoing clinical restenosis prevention trials are using quantitative 
angiography to assess whether a drug is capable of reducing the amount of intimal 
hyperplasia, we determined quantitative angiographic risk factors for angiographic 
luminal narrowing after balloon angioplasty, including stretch and elastic recoil at the 
dilatation site. Quantitative analysis was performed on 666 lesions in 575 patients at 
angioplasty and at 6 months follow-up. Stretch was defined as: balloon diameter - pre-
angioplasty minimal lumen diameter (MLD) I reference diameter and recoil as: balloon 
diameter- post-angioplasty MLD I reference diameter. Multivariate analysis was applied 
to yield independent risk factors for luminal narrowing at follow-up. Predictors of 
absolute change in MLD (mm) were 1) relative gain at angioplasty (gain in mm 
normalized for reference diameter), 2) lesion length. To allow risk stratification, logistic 
regression analysis was applied using the loss in MLD as a binary outcome variable. A 
loss in MLD at follow-up of ::0.72 mm was considered significant. Variables retained 
in the model were: relative gain > 0.3 (rate ratio: 2.9), relative gain 0.2 - 0.3 (rate ratio 
2.1), stenosis length ::6.8 mm (rate ratio: 1.7) and thrombus post angioplasty (rate ratio: 
2.6). Although stretch was significantly related to luminal narrowing at univariate 
analysis, it was not retained in the multivariate models. 
A large gain in lumen diameter at angioplasty, dilation of long lesions, and 
angiographically determined thrombus post angioplasty were found to be accompanied 
with more severe luminal narrowing at follow-up. 
Keywords: 
Angioplasty, Quantitative angiography, Loss in minimal lumen diameter, Restenosis. 
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IN1RODUCTION 
Luminal narrowing following coronary balloon angioplasty still hampers the long term 
vessel patency in a substantial percentage of patients. Several investigators have sought 
predictors of this untoward event [1]. A multitude of patient-, procedural- and lesion 
related variables have been found to predict long term outcome of an angioplasty 
procedure, but since these findings are based on different restenosis criteria and varying 
angiographic follow-up rates, accurate comparison is difficult [2]. 
Conventionally, restenosis is determined by follow-up angiography. Computer 
assisted automated edge detection techniques enhance objectivity and reproducibility and 
reduce the high inter and intra-observer variability inherent to visual interpretation of 
the coronary cineangiogram [3]. Because many ongoing clinical restenosis prevention 
trials are using quantitative angiography to assess whether a pharmacologic agent is 
capable of reducing the amount of intimal hyperplasia (the underlying cause of 
restenosis), it is important to detennine quantitative angiographic risk factors for 
angiographic luminal narrowing after balloon angioplasty. At the moment it is unknown 
which angiographic parameters are associated with an increased risk for luminal 
narrowing. Both over- and underdilating are reported to be associated with an increased 
risk for restenosis. Overdilation might trigger an excessive hyperplastic response because 
of its relation with dissection and deep arterial injury with increased platelet activation 
[4,5]. Stretching of the vessel itself may also be an important stimulus for the 
fibroproliferative vessel reaction by being a detenninant of medial smooth muscle injury 
[6] and by changing the phenotype of the medial smooth muscle cells from contractile 
to syothetic [7]. Elastic recoil after balloon deflation has, at least theoretically [8,9], been 
linked to luminal narrowing at follow-up. Underdilation might leave a significant residual 
stenosis with a possible increased turbulence, platelet activation and restenosis [10]. 
In this study quantitative lesion measurements before angioplasty, after 
angioplasty, and at follow up were obtained and correlated with loss in minimal lumen 
diameter (MLD) at follow-up. To examine the effect of degree of arterial stretching and 
elastic recoil on luminal narrowing at follow-up, balloon diameters were measured. 
Stretch was defined as the difference in mean balloon diameter and MLD pre-
angioplasty [6] and elastic recoil as the difference between mean balloon diameter and 
MLD post-angioplasty [9]. Both stretch and recoil were normalized for reference 
diameter to correct for the influence of vessel size and are therefore dimensionless. 
PATIENTS AND METHODS 
The study population consisted of 697 patients that were originally enrolled in 6 
European centers for the Carport trial [11] (see appendix). In this randomized, double 
blind, placebo controlled trial a novel thromboxane Az receptor antagonist (GR32191B) 
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was investigated for its ability to prevent restenosis after primary coronary angioplasty. 
Follow-up on tbese patients was done on a prospective basis and all patients agreed to 
undergo repeat angiography at 6 montbs. Neitber angiographic, nor clinical benefit of the 
compound could be demonstrated [11], so tbe placebo- and active treatment group could 
be pooled for tbe present study. All patients with botb stable and unstable angina and 
angiographically-proven native coronary artery disease who were scheduled for primary 
angioplasty, were considered for participation in the trial. Specific exclusion criteria are 
given in table I. A screening log was maintained in two centers to assess the relative 
frequencies of these exclusion criteria. 
Table I. Reasons for excluding 1318 of 1614 screened patients in 2 of 6 centers. 
Reason 
Insufficient lead-in time* 
Use of platelet inhibiting 
drugs or non steroid anti inflammatory 
drugs in 7 days preceding the study 
Refusal to participate and/or 
undergo 6 montbs recatbeterization 
Currently taking oral anticoagulant drugs 
Angioplasty for restenosis 
Acute myocardial infarction in 2 weeks 
preceding angioplasty 
Bypass graft dilatation 
History of obstructive airway disease 
History of peptic disease or upper GI bleeding 
Previous participation in tbe trial 
Severe other disease 
Participation in otber trial 
History of intolerance to aspirin 
Under 21 years of age 
Pregnant woman or woman likely to 
become pregnant during study 
Total 
• Urgent referrals outside working hours. 
No 
235 
352 
364 
119 
105 
52 
39 
26 
10 
2 
6 
6 
1 
1 
0 
1318 
(%) 
(18) 
(27) 
(28) 
(9) 
(8) 
(4) 
(3) 
(2) 
(1) 
(02) 
(0.5) 
(0.4) 
(0.1) 
(0.1) 
(0) 
(100) 
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Failure of the angioplasty procedure occurred in 48 patients (6.9% ). Angioplasty 
success was defined as <50% residual stenosis by visual inspection of the post-
angioplasty angiogram and no occurrence of in-hospital complications (death, acute 
myocardial infarction, repeat angioplasty, aorto coronary bypass grafting or recurrence 
of symptoms). 
Five hundred seventy five (88.6%) of the 649 patients with a successful angioplasty 
had a follow-up angiogram suitable for quantitative angiography. Reasons for not 
completing the study were: late death (n =2), contraindication for repeat catheterization 
(n=18), refusal (n=46). Eight follow up angiograms were unsuitable for quantitative 
analysis. 
Angioplasty procedure and follow up angiography. Coronary angioplasty was 
performed with a steerable, movable guide wire system via the femoral route. Standard 
available balloon catheters were used. Choice of balloon type and brand as well as 
inflation duration and inflation pressure were left to the discretion of the aogioplasty 
operator. At the beginning of the angioplasty procedure all patients received 10000 
International Units of intravenous heparin for the first two hours, afterwards 5000 
International Units/hour for as long the procedure continued. All patients received 10 
mg nifedipine every two hours for the first 12 hours after angioplasty. Thereafter they 
received 20 mg slow release nifedipine tablets 3 times during the second day after 
angioplasty. 
Four coronary angiograrns were obtained in each patient, one just before PTCA, 
one during maximal inflation of the largest balloon used, one immediately after 
aogioplasty, aod one angiogram at follow-up. The angiograms were recorded in such a 
way that they were suited for quantitative analysis by the Cardiovascular Angiography 
Analysis System (CAAS). All necessary details of the procedure were recorded and 
drawings of the segments to be analyzed were made. For calibration purposes the 
cathetertips were cut off for later measurement with a microcaliper. To standardize the 
method of data acquisition and to ensure exact reproducibility of the angiographic 
studies, measures were taken as described earlier [2,12]. All angiograrns were processed 
and analyzed in a central core-laboratory (see appendix). 
The follow-up coronary angiogram was performed at 6 months follow-up. If 
symptoms recurred within 6 months, coronary angiography was carried out earlier. If no 
definite restenosis was present aod the follow-up time was less than 4 months, the patient 
was asked to undergo another coronary arteriogram at 6 months. 
Quantitative angiography (figure 1). All cineangiograrns were analyzed using the 
computer assisted cardiovascular angiography analysis system (CAAS) which has been 
described and validated earlier [13,14]. A computer derived reconstruction of the original 
arterial dimension at the site of obstruction (assuming there is no disease present) is 
used to define the interpolated reference diameter. The length of the obstruction is 
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determined from the diameter function on the basis of curvatnre analysis and expressed 
in millimeters. In addition, this technique allows for the calculation of an eccentricity 
index [9] of the lesion. The index ranges from 0 (severe eccentric) to 1 (perfectly 
symmetric). Since the algorithm is not able to measure total occlusions, a value of 0 mm 
was substitnted for the MLD. In these cases the post-angioplasty reference diameter was 
substitnted for the reference diameter pre PTCA. The mean change in MLD from post-
angioplasty angiography to follow-up angiography and from pre-angioplasty to post-
angioplasty was derived from matched angiographic projections. Balloon artery ratio 
was defined as the ratio of the mean balloon diameter measured in a non-foreshortened 
projection and the reference diameter of the dilated segment. Three parameters were 
calculated that reflect the changes occurring during angioplasty (figure 2).; These were 
1) stretch (mean balloon diameter - MLD pre-angioplasty I reference diameter), 2) 
elastic recoil (mean balloon diameter- MLD post-angioplasty I reference diameter) and 
3) relative gain achieved by angioplasty (post angioplasty MLD - pre angioplasty MLD 
I reference diameter). All 3 parameters were normalized for interpolated reference 
diameter to correct for vessel size and are therefore dimensionless. Intracoronary 
thrombus was defined as an intraluminal filling defect visible in all projections or dye 
staining at the site of a total occlusion (inter observer concordance rate for the 
assessment of intracoronary thrombus in the corelab 89% ). 
Significant luminal narrowing. To predict significant luminal narrowing after 
PTCA, we chose a cut-off point above which significant deterioration in MLD is likely. 
We have found a change in MLD of ::0.72 nun to be a reliable indicator of angiographic 
progression of vessel narrowing [2,14]. This value takes into account the limitations of 
coronary angiographic measurements and represents twice the long-term variability for 
repeat measurements of a coronaty obstruction using the CAAS system [14]. This 
variability reflects the long-term random variation in lesion measurements from coronary 
angiograrns made at different catheterization sessions using the CAAS system. The use 
of 1 standard deviation would include 68.3% of the measurement variability, while the 
use of 2 standard deviations (2 x 0.36 ; 0.72 mm) includes 95.5% of the measurement 
variability. Therefore a difference in MLD of more than twice the long-term 
measurement variability can be considered indicative of significant luminal narrowing. 
To compare the criterion of change in MLD with a more conventional criterion of 
restenosis, analyses were also performed with the :': 50%diameter stenosis criterion. 
Data analysis. Data were analyzed using the BMDP statistical sofrware package 
(University of California, Berkeley, California 1990). In a univariate analysis (unpaired 
Stndent's t test) those continuous quantitative angiographic variables that were related 
to a significant loss in MLD were selected. These variables together with elastic recoil 
and balloon artery ratio (known from the literatnre to be related with restenosis) were 
entered in a stepwise multiple linear regression analysis to identify variables with an 
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independent contribution to the prediction of absolute loss in MLD as a continuous 
variable (see appendix). 
a 
INTERPOLATED REFERENCE DIAMETER (RD) 
-----kl~l ~ ·~DETE= 
MLD /CURVATURE ANALYSIS 
EXTENT OF OBSTRUCTION 
DIAMETER FUNCTION 
Figure 1. Graphic representation of the quantitative angiographic measurements. The upper 
panel represents a stenosed arterial segments. The lower panel is the diameter function cun;e. 
MLD ~ minimal lumen diameter. Extent of obstruction ~ Lesion length. Lesion length is 
determined with curvature analysis of the descending and ascending limb of the diameter 
function curve at the site of the MLD. Eccentricity is determined the site of the MLD and 
calculated as ajb. 
To allow risk stratification, logistic regression analysis using indicator variables 
was subsequently applied, with the loss in MLD (using a loss of ;:: 0.72 mm as cut off 
value) and the 50% diameter stenosis criterion as binary outcome variables because the 
logistic regression coefficients are easily related to adjusted rate ratios for the different 
variables. Continuous variables were therefore grouped into three equally sized 
subgroups (tertiles). Three subgroups were selected to enable assessment of trends in the 
incidence of ;::0.72 mm loss and because more subgroups would weaken the strength of 
associations. The incidence of a ;::0.72 mm loss was determined in each subgroup. If a 
trend for a higher incidence was present in each consecutive subgroup, then the subgroup 
with the lowest incidence was chosen as the reference group. If no trend for an 
increasing incidence of ;:: 0.72 mm loss in MLD was present in each consecutive 
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subgroup, the subgroup with the highest incidence was compared with the combined 2 
other subgroups ( = reference group). 
Distortion of relation between different determinants of > 0.72mm loss in MLD 
and the incidence of a loss ;:: 0. 72 mm (confounding) caused by an unequal distributions 
of these determinants among the tertiles was eliminated by multivariate logistic 
regression analysis. Description of the multivariate logistic regression model and the 
methodology to obtain adjusted rate ratios and 95% confidence intervals is given in the 
appendix. 
MLD (mm) 
3 
BALLOON 
2.5 
2 
STRETCH RECOIL 
POST GAIN 
Fignre 2. Graphical representation of the terms used. In this graph the mean absolute values 
of the variables is shown. In the manuscript stretch, recoil and gain were normalized for 
vessel size (reference diameter) to correct for vessel size. pre = pre·angioplasty minimal 
lumen diameter, balloon = balloon mean diameter, post = post angioplasty minimal lumen 
diameter, F-up = follow-up minimal lumen diameter, MLD = minimal lumen diameter. 
RESULTS 
Baseline characteristics of the 575 patients with quantitative angiographic follow-
up are summarized in table II. 
Overall quantitative angiographic findings pre-angioplasty, post·angioplasty and 
at follow up angiography arc presented in table Ill. Reference diameter was not different 
pre-angioplasty, post-angioplasty and at follow up (2.64±0.56 mm, 2.71±0.54 mm and 
2.71 ± 056 mm respectively), suggesting an accurate control of vasomotion during the 
three angiographic studies. 
The incidence of significant luminal narrowing (::': 0.72 mm) was 17.7% (117 of 
666 lesions). The incidence of restenosis according to the 50% diameter stenosis criterion 
was 33% (220 of 666 lesions). 
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Table H. Baseline characteristics 
Number of patients 
Age (years) 
Males/Females 
Time to follow-up angiography (days) 
Number of narrowings dilated 
in Left anterior descending artery 
in Left circumflex artery 
in Rigtht coronary artery 
Prior myocardial infarction 
prior coronary bypass surgery 
prior angioplasty other site 
Univariate analysis 
575 
56:t9 
464/111 (81%)/(19%) 
172:>:41 
666 
321 (48%) 
154 (23%) 
191 (29%) 
221 (38%) 
15 (3%) 
10 (2%) 
With univariate analysis (table IV) the following quantitative angiographic 
variables were associated with a loss in MLD of at least 0.72 mm: pre-angioplasty MLD, 
post-angioplasty MLD, gain in MLD obtained by angioplasty. length of the obstruction, 
and stretch. Thirty six lesions were totally occluded before angioplasty and therefore 
stenosis length and eccentricity coefficient could not be measured. For comparison with 
the traditional restenosis criterion of > 50% diameter stenosis at follow up, values were 
also broken down according to this criterion. The apparent difference in post-angioplasty 
MLD for the 2 criteria and the absence of a difference in relative gain in the :"50% 
diameter stenosis at follow-up group and the > 50% diameter stenosis group is explained 
in the discussion. 
More stretching was accompanied by more recoil. The amount of recoil in the 
tertile with the highest amount of stretch (;:: 0.65) was 0.42 as opposed to 0.25 in the 
combined other 2 tertiles of stretch ( < 0.65)(p < 0.0001, unpaired t test). 
Multiple linear regression analysis. 
The variables significantly related to ;:: 0.72 mm loss in MLD in the univariate 
analysis as well as elastic recoil and balloon artery ratio were entered in the multiple 
linear regression analysis. Only relative gain in MLD at angioplasty and the length of the 
stenosis were retained in the final modeL The amount of stretch induced on the vessel 
wall, although significantly higher in the group of lesions with a ;::0.72 mm loss in MLD 
with univariate analysis, was not retained in the stepwise multiple linear regression 
model. 
Table m. Quantitative angiographic data of 666 lesions 
Mean,SD 
Minimal lumen diameter (mm) 
pre-angioplasty 
post·angioplasty 
follow-up 
Diameter stenosis (%) 
pre-angioplasty 
post -angioplasty 
follow-up 
Difference in Minimal lumen diameter 
post-angioplasty- pre-angioplasty (mm) 
post-angioplasty - follow up (mm) 
relative gain at angioplasty* 
Difference in % diameter stenosis 
post-angioplasty- pre-angioplasty 
post-angioplasty - follow-up 
SD=standard deviation, • see figure 2. 
Logistic regression analysis. 
1.04,037 
1.76,038 
1.48,0.59 
60,13 
34±9 
45,19 
0.75,0.40 
0.28,0.52 
0.28,0.16 
26,14 
ll'= 19 
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Range 
0.00-2.83 
0.85-3.04 
0.00-3.15 
33-100 
6- 76 
4 -100 
The variables retained in the multiple linear regression analysis and 6 variables 
known from the literature to be related to restenosis were entered in the logistic 
regression model. The latter were: vessel dilated [15], total occlusion pre-angioplasty [16], 
angiographically determined thrombus pre angioplasty and post angioplasty, elastic recoil 
and balloon artery ratio. Thrombus pre- and post angioplasty were included because it 
has been reported that thrombotic lesions are longer in length and that total occlusions 
frequently have a thrombotic component. Furthermore it is conceivable that thrombotic 
lesions have a larger relative gain and low elastic recoil. Angiographically a thrombus 
was observed in 32 out of 666 lesions pre angioplasty (5%) and in 16 out of 666 lesions 
post angioplasty (1.6%). Type of trial medication (placebo or active treattnent) was 
forced into the model to rule out any effect on the analysis results. Because dilation of 
totally occluded coronary arteries is known to be associated with a higher restenosis rate 
[16] and it could be argued that in these lesions in general a higher gain at angioplasty 
will be achieved, this determinant was also forced into the model to account for any 
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confounding effect. Totally occluded lesions did not have length measutements, therefore 
the indicator variable for lesion length was set to zero in these cases. 
A relative gain at angioplasty of =:: 03 had an adjusted rate ratio (RR) for 
developing a loss in MLD =::o.72 mm of 2.9. This means that the risk for developing a 
loss of at least 0.72 mm with at least this relative gain is 2.9 times as high as it is for 
lesions with a relative gain <02. The 95% confidence intervals (CI) were 1.9 to 4.5. 
Other variates retained were: relative gain between 0.2 and 0.3 (RR 2.1, (95% CI 1.3 to 
33), lesion length =::6.8mm(RR 1.7, 95% CI 1.2to 23), and thrombus post angioplasty 
(RR 2.6, 95% CI 1.1 to 6.2). Total occlusion pre angioplasty and use of active trial 
medication had no significant independent predictive contribution to a significant loss in 
lumen diameter (RR 1.5, 95% CI 0.8 to 3.0 and RR 1.1, 95% CI 0.7 to 1.5 respectively). 
Stretch, balloon artery ratio, elastic recoil, vessel type and thrombus pre angioplasty were 
not retained in the final logistic regression model. 
To assure that total occlusions did not unduly influence the results, the analysis 
was repeated excluding these lesions. Adjusted rate ratios were similar to those in the 
original analysis (relative gain 0.2-0.3: RR 2.2, 95% CI 1.4 to 3.4, relative gain =::0.3: RR 
3.2, 95% CI 2.0 to 5.1, lesion length =::6.8 mm: RR 1.8, 95% CI 1.2 to 2.6). 
The logistic regression analysis was also performed with the > 50% diameter 
stenosis criterion as dependent variable. Type of trial medication was again forced into 
the model. A lesion length of =:: 6.8 mm (adjusted RR 1.3, 95% CI 1.1 to 1.4) and 
thrombus post-angioplasty (RR 1.8, 95% Cl 1.0 to 3.1) were retained in the final model. 
The use of GR32191B as trial medication had an adjusted rate ratio of 0.98 (95% Cl 0.9 
to 1.1). 
DISCUSSION 
Luminal narrowing after coronary angioplasty is a complex process that is only 
partially understood. Histologic studies of coronary arteries after dilation, obtained by 
either autopsy or atherectomy, have provided direct and indirect evidence that strongly 
support the concept of intimal hyperplasia or proliferation of smooth muscle cells of 
medial or intimal origin as the underlying cause of luminal narrowing after angioplasty 
[5,17]. 
The one factor most strongly associated with luminal narrowing in this study was 
the relative gain in MLD achieved by the angioplasty procedure. This probably best 
reflects the combination of deep arterial injury and reversible stretch imposed on the 
diseased vessel wall. Deep arterial injury and smooth muscle cell stretch are known 
stimuli for smooth muscle cell proliferation. It is now believed that after balloon injury, 
denudation of endothelial cells is followed by platelet adhesion and aggregation with the 
release of growth factors (notably platelet-derived growth factor (PDGF)) and vaso- and 
platelet-active substances. Extensive damage to the endothelial lining of the vessel, which 
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is always present after balloon dilatation, ntight upset the balance between the inhibiting 
effect of endothelial derived heparin sulphates on medial smooth muscle cell growth and 
the ntitogenic and chemotactic effect of PDGF and other growth factors on these cells 
[18]. Not only platelet exposure to the vascular layers but also direct injury to the smooth 
muscle cells is reported to start the proliferative response [19]. So, as suggested by Uu 
eta!. [20], a major factor that deterntines the amount of intimal hyperplasia after balloon 
angioplasty seems to be the extent of permanent mechanical injury inflicted upon the 
vessel wall. Animal experiments with an atherosclerotic rabbits model have shown that 
the combination of balloon oversizing and long inflations caused most damage to the 
vessel wall and was associated with the greatest degree of intimal hyperplasia at follow 
up [21]. Similarly Schwartz eta!. have described an aggressive proliferative response in 
a porcine model as a result of severe stent oversizing [22]. This effect, which they 
attnlmted to penetration of the internal elastic membrane by the stent wires and 
subsequent deep arterial injury, was much less pronounced when the stent was matched 
more closely to the vessel diameter. This has recently also been demonstrated in a 
clinical stent study [23]. Implantation of an oversized stent was attended with a more 
aggressive hyperplastic reaction than when the stent was more closely matched to the 
receiving artery. 
Dilation of totally occluded coronary arteries is known to be attended with a 
higher restenosis rate [16]. However, total occlusions, forced in the logistic regression 
model, did not have a significant independent contribution to the prediction of a loss in 
MLD of at least 0.72 mm, probably due to an unequal distribution of thrombus post-
angioplasty over totally occluded and patent arteries; 6 out of 36 (16.7%) total occlusions 
pre-angioplasty had a thrombus post-angioplasty versus 10 out of 630 (1.5%) patent 
arteries. It could be argued that in total occlusions in general a higher gain at angioplasty 
will be achieved and that this ntight be the explanation for the relation found between 
gain and restenosis. In our population 36 total occlusions were successfully dilated with 
a restenosis rate at follow-up of 333% (12/36) (;::0.72mm criterion). However, if total 
occlusions pre-angioplasty are left out of the analysis, a high relative gain and lesion 
length were still attended with a significant adjusted risk for a loss of at least 0. 72 mm. 
The fact that angiographically deterntined thrombus at the dilatation site pre 
angioplasty was not found to be a risk factor for a significant loss in MLD tends to 
confirm our earlier report that showed no difference in significant luntinal narrowing for 
patients with unstable angina [24]. Angiographically demonstrable intracoronary 
thrombus post angioplasty is the angiographic proof that massive platelet aggregation, 
thrombin activation and fibrin formation has taken place with subsequent release of 
vasoactive substances [25] and growth factors involved in the fibroproliferative restenosis 
process. 
Table IV. Univariate analysis of quantitative parameters and loss in MLD of ~ 0.72mm. 
loss < 0.72 rum loss ~0.72 rum p ~50% DS at f-up > 50% DS at f-up p 
Mean ± 1 SD Mean ± 1 SD Mean ± 1 SD Mean ± 1 SD 
MLD prc-PTCA (mm) • Ul6±0.36 (n•549) 0.94±0.41 (n• 117) 0.0025 1.06±0.40 (n•446) 0.94±0.37 (n•220) <OJXll 
Reference dia. pre-PTCA (rum) 2.64±0.56 (n•549) 2.65±0.56 (n•ll7) NS 2.64±0.54 (n•446) 2.65±0.60 (n•220) NS 
Lesion Length pre-PTCA (mmy 6.08±2.24 (n•524) 6.94±2.39 (n•106) <0.001 6.04±2.20 (n•424) 6.59±2.41 (n•206) <0.01 
Eccentricity 0.38±0.25 (n•524) 0.36±0.23 (n•106) NS 0.37±0.24 (n·424) 0.38±0.25 (n·206) NS 
MLD post-PTCA (mm) • 1.74±0.36 (n•549) 1.89±0.37 (n• 117) <0.0001 1.81±0.36 (n·446) 1.69±0.37 (n•220) <0.001 
MLD f-up (rum) 1.64±0.44 (n·549) 0.72±0.59 (n•l17) <0.0001 1.75±0.40 (n•446) 0.92±0.52 (n•220) <0.0001 
Balloon-artery ratio • 0.98±0.19 (n•490) 1.02±0.24 (n•l05) 0.11 0.99±0.18 (n•3%) 0.99±0.23 (n• 199) NS 
Stretch • 0.58±0.21 (n·490) 0.66±0.26 (n•105) <0.001 0.58±0.21 (n·3%) 0.63±0.25 (n•l99) <0.05 
Recoil • 0.31±0.15 (n•490) 0.30±0.15 (n•105) 0.29 0.30±0.15 (n·3%) 0.33±0.16 (n•199) <0.05 
Gain at angioplasty • 0.27±0.15 (n•549) 0.37±0.18 (n•ll7) <0.0001 0.29±0.16 (n•446) 0.29±0.18 (n•220) NS 
loss in MLD at F-up (rum) 0.10±0.30 (n•549) 1.17±0.42 (n=117) <0.0001 0.07±0.32 (n•446) 0.77±0.58 (n•220) <0.0001 
DS = diameter stenosis P-up = follow up, Gain = (MLD post PTCA- MLD pre PTCA) f reference diameter, MLD = minimal lumen diameter, PTCA =percutaneous 
transluminal coronary angioplasty, Recoil= (balloon diameter- MLD pm PTCA) f reference diameter, Stretch= (Balloon diameter~ MLD pre-PTCA)/reference diameter, 
• subsequently entered in multiple linear regression analysis 
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Furthermore, a recent post mortem study has shown that part of early ( < 1 months) 
restenosis lesions consisted of mural thrombus [5]. 
Longer lesions were found to be associated with a higher relative risk for 
restenosis at follow up. In these lesions more smooth muscle is possibly exposed to injury 
and platelet adhesion, which enhances the risk of restenosis. Several studies have indeed 
shown that long lesions and vessel areas containing thick atherosclerotic plaques are 
related to an increased incidence of dissections and thus more extensive vessel wall 
injury [26,27]. 
Several experimental studies have suggested that dilation of the vessel wall is a 
stimulus for smooth muscle cell proliferation and later intimal hyperplasia [19,21] either 
by stretch or direct injury to smooth muscle cells. In the present study, univariate analysis 
(table IV) showed that a significantly higher amount of stretch was induced on the vessel 
wall in the group with a "': 0.72mm loss in MLD. These findings correlate with the 
observations by Fischel! et al who showed a relationship between the degree of arterial 
stretching and the severity of smooth muscle injury as determined by loss of 
vasoconstrictor responsiveness and histopathological exantination [6], and, as emphasized 
above, more smooth muscle injury has been shown to enhance intimal hyperplasia in a 
more controlled animal model [21]. However after elimination of the unequal 
distribution of stretch over the various determinants of a significant loss in MLD by 
multivariate analysis, stretch was not found to be an independent predictor of luminal 
narrowing. 
Elastic recoil, as measured within minutes after the last dilatation [9] was not 
found to be a determinant of restenosis. This finding is at variance with an other report 
[8], that suggests that recoil might be a factor in luminal narrowing observed at follow-
up. It might be that recoil is not an instantaneous phenomenon but rather exerts its 
effect over a longer period of time and could thus not be picked up by the post-
angioplasty angiogram that was made within minutes after final balloon deflation. 
Limitations. To allow risk stratification for loss in MLD with the use of 
multivariate analysis techniques, a cut-off point had to be chosen that accurately 
describes those lesions that underwent a significant deterioration at follow-up. The 
rationale for the 0.72 mm criterion as a marker for significant luminal narrowing is 
outlined in the methods section. This criterion is not meant to be a restenosis criterion 
in this study, since that implies also some sort of functional measure of lesion severity 
at follow up. The commonly used definition of 50% diameter stenosis at follow-up is 
historically based on the physiological concept of coronary flow reserve introduced by 
Gould and others in 1974 and is taken because it represents the approximate value in 
animals with normal coronary arteries at which blunting of the hyperemic response 
occurs [28]. Although this value may be of some relevance in determining a significant 
stenosis in human atherosclerotic vessels, it tells us nothing about the dynantic behavior 
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of the restenosis process. If the 50% diameter stenosis at follow up is applied, lesions 
with a suboptimal angioplasty result will preferentially be selected (ie have to undergo 
a small loss in lumen diameter to be called restenosed). This is reflected by the lower 
post angioplasty MLD in the >50% diameter stenosis group (table IV) as compared to 
the > 50% diameter stenosis group. The mean percentage diameter stenosis post-
angioplasty in the group with a relative gain < 0.2 was 40% In the group with a relative 
gain between 0.2 and 03 this was 34% and 28% in the group with a gain ::: 03. This 
means that lesions with a small relative gain generally tend to have a poorer post 
angioplasty result and are close to the 50% diameter stenosis cut -off point. Furthermore, 
since the long term variability of diameter stenosis measurements using the CAAS system 
is 6.5% [14], a significant amount of lesions will be defined as restenosed while in fact 
no change has taken place. The mean post-angioplasty percentage diameter stenosis was 
31% for those lesions fulfilling the ;:-:0.72 mm criterion and 37% for the > 50% diameter 
stenosis criterion. Therefore both criteria describe different populations at follow-up and 
if one wants to look at risk factors for change in luminal diameter, the 50% diameter 
stenosis criterion is inappropriate. 
The definition of stretch was essentially the same as used by Fischel! et a!. in a 
series of in vitro experiments with isolated, perfused, non-diseased, whole vessel segments 
of rabbit aortas and dog carotid arteries [6]. In our population of diseased arterial 
segments, stretch was calculated as the difference between mean balloon diameter and· 
MLD pre angioplasty divided by the relaxed reference diameter, because this reflects the 
maximal focal stretch induced on the vessel walL This presumes that no compression or 
extrusion of the atherosclerotic plaque took place during angioplasty. 
The inunediate luminal narrowing after balloon deflation that we attributed to 
elastic recoil could also be caused by spasm or non occlusive mural thrombus formation. 
It has been shown that the administration of intracoronary nitrates after angioplasty 
abolishes possible spasm [19,29]. Furthermore, the mean reference diameter post 
angioplasty was not different from the pre angioplasty value. Our post angioplasty 
angiogram was made within minutes after fmal balloon deflation and although we cannot 
rule out the possibility of mural thrombus to occur in this short time period, we believe 
that it cannot explain the observed immediate 30% reduction in lumen diameter. 
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APPENDIX 
linear regression analysis 
Stepwise multiple linear regression analysis was performed (BMDP statistical 
package, program 2R) to assess the relationship between the variables mentioned in the 
'Patients and methods' section (independent variables = X;) and the loss in minimal 
lumen diameter from post-angioplasty angiogram to follow-up angiogram (dependent 
variable = Y): Y = A + z, B,X. where A is the intercept and B, is the 
,th regression coefficient. The standard 2R criteria of F > 4 for inclusion and F < 3.9 
for elintination were applied. 
Multivariate logistic regression analysis 
Multiple logistic regression analysis was performed with the BMDP statistical 
package (program LR). The linear logistic model relates a probability (P) for the 
outcome event to the value of a baseline characteristic (X) using the linear logistic 
function: P = 1 / 1 + e ·(• + •XJ. The relation between variables retained in the multiple 
linear regression model and restenosis according to the 0.72mm criterion was expressed 
in a multivariate logistic regression model. Also a set of variables reported to be 
predictors of restenosis was selected. All these variables were entered into a model, one 
at a time. The model to describe the risk for developing restenosis was fitted to the data 
of595 lesion dilatations with balloon measurements. The standard LR criteria ofp<0.1 
for inclusion and p>0.15 for elimination were applied. Adjusted rate ratios and 95% 
confidence intervals were obtained according to the method of Miettinen [30] by the 
following formulas, in which the incidence of restenosis was entered for all variates (X,) 
other than the variates for which the adjusted rate ratio was determined; 1 was entered 
for the variate under study (X;) in the numerator an 0 in the denominator: 
. [1 + exp( -(intercept+ z,b,X,+ b;l))r' 
Rate rano = ---------------------
[1 +eip(-(intercept+z,b,X,+ b;0))]"1 
95% confidence interval: rate ratio(l~l.%/(l>i/SE)) 
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Postangioplasty Restenosis Rate Between 
Segments of the Major Coronary Arteries 
Walter R. M. Hermans, MD, Benno J. Rensing, MD, Johannes C. Kelder, MD, 
Pim J. de Feyter, MD, and Patrick W. Serruys, MD 
Conflicting data have been published regarding 
the rate of postangioplasty restenosis observed in 
diverse segments of the coronary tree. However, 
these studies may be criticized for their biased se-
lection of patients, methods of analysis, and defi-
nitions of restenosis. In the present study, 1,353 
patients underwent a successful coronary dilata-
tion of 2:1 site. In all, 1,234 patients (91o/o) had a 
follow-up angiogram after G months, or earlier 
when indicated by symptoms. All films were pro-
cessed and analyzed at the thoraxcenter core lab-
oratory with the coronary angiography analysis 
system (automated contour detection}. Restenosis 
was considered present if the diameter stenosis at 
follow-up was >SO%. No differences in restenosis 
rates were observed between coronary segments 
using this categorical definition. A continuous ap.o 
proach was also used; absolute changes in mini-
mal luminal diameter adjusted for vessel size were 
used in order to allow comparison ~tween vessels 
of different sizes (re[ative loss). No significant dif-
ferences were observed between the Col"onary seg-
ments with this continuous approach. These re-
sults suggest that restenosis is a ubiquitous phe-
nomenon without any predilection for a particular 
site in the coronary b-ee. 
(Am J Cardiol1992;69:194-200) 
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Ever since the introduction of percutaneous translu-minal coronary angioplasty (PTCA) 1 as an alter-native to coronary artery bypass grafting, this 
means of treatment has been plagued by the problem of 
restenosis, which has become an important field of in-
vestigation in interventional cardiology. During the last 
14 years clirilcians have searched extensively for factors 
increasing the risk of restenosis. and many patient-le-
sion-procedure-related factors have been put forward. Z.3 
However, the cause and effect relation of these factors 
can be questioned, because these early studies were. 
in general. retrospective analyses with relatively small 
numbers of patients. In addition. these studies were 
fraught with methodologic problems; angiographic fol-
low-up was incomplete. incidence of restenosis was in-
fluenced by the recurrence of symptoms, and time for 
restudy was not predetermined. Furthermore, the defi-
nition of restenosis varied between the different studies. 
and presence or absence of restenosis was assessed visu-
ally, a method known to be limited by inter- and in-
traobserver variability.4•5 One risk factor for restenosis 
that led to controversy is the site of dilatation. with 
some studies finding a higher incidence of restenosis in 
the proximal left anterior descending coronary artery 
(LAD) as compared with the right or left circumflex 
coronary artery (LC) (Table 1).6-19 Recently, 2 multi-
center restenosis preventior.. trials enrolled > 1.400 pa-
tients who were analyzed at the same angiographic core 
laboratory. In 91% of these patients. follow-up angiog-
raphy was performed, and the same quantitative coro-
nary angiographic method of analysis was used.s.2o The 
present study investigates whether the previously report-
ed differences in restenosis rates in the 3 major coro-
nary arteries could be confirmed in this large study 
group. 
METHODS 
The study population consisted of 1,442 patients 
with significant primary stenoses in native coronary 
arteries who were prospectively enrolled in 2 restenosis 
trials in Europe. Because no angiographic or clinical 
benefit of the 2 tested compounds could be demon-
strated. the control and active treatment groups were 
pooled for the present study. PTCAs and follow-up 
films of all patients with successful dilations were ana-
lyzed at the thoraxcenter core laboratory. Informed 
consent was obtained in all cases before the PTCA pro-
cedure, and all patients were asked to return to the hos-
pital for follow-up angiography. Patients with stable 
and unstable angina pectoris. and those with totally oc-
cluded vessel segments were included in the study. Pa-
JANUARY 15, 1992 
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TABU: I Summary of Restenosis Studies Demonstrating Conflicting Results as to the Site of Dilatation as a Risk Factor for Restenosis 
Anglo Fup Restenosls 
Study Year ?~tJent:; i%1 Definition of Restenosls (%) Coronary Artery Statistical Anatysjs 
Holmes6 ,.., 655 .., NHLSII-IV 33.6 No difference Multivariate 
Kaltrmbach7* 1985 356 
" 
OS Fup <20% OS prt: 12 No Oltference Unlvanate 
Decrease "'-50% of g.Jin 16 
i OS ;:,:30% 17 
Mab&t 1985 63 95 t OS >30% 23 LAO or LC > right Multivariate 
orDS>70% 
01Sclasclo9t 1986 191 
'" 
Decrease ;;,; 50% of g<lln 58 1-VO No difference Umvarlate 
42 2-VD 
lelmgrubcrlO 1986 1.758 57 >50% OS 302 LAD >rlght>LC Multivanate 
Mylerll<: 1987 286 57 >50% OS 41 No d•lferencc MultivarJat(l 
Va]12 1987 181 98 t ~30% OS 29 No dltferenee Mult•varlate 
Vandormael13t 1987 209 62 >50% OS 82 (SympJ LAD > right or LC Multivariate 
30 (NoSymp) Prox >DI:>t 
81acki4~ 1988 
'" 
39 >50% OS 31 Nodlffcronce Multivariate 
d~ Feyter150 1988 179 88 >50% OS 32 LAD >rlghtorLC Multivariate 
Flecki6~ 1988 110 86 LI.MLCA > 1 mm2 (QCAI 58 Nodlfferonce Multivariate 
Qul~lcyl7§ 1989 1i' 83 >50% OS 32 Nodlfferonce Multtvarlate 
Renklnle 1990 278 47•- >50% OS 
-
No difference MultlVarlate 
Rupprechtl9• 1990 676 70 >50% 0S or 29.2 Nodlfferem:e Multivariate 
decrease > 50% of ~am 
Prc--...ent study 1991 1,353 91 >50% OS 31 No diMrence Univariate 
RelatJveloss 0.11 = 0.21 Analysis of vanance 
•Exchl<l<'<l tot.> I occluolono: tmult""'sel ~·~t.ltlon: fmultllaslon dolot>t•on; ~lor re<tenoo•>: junot>ble ""~'""' ~tc~~•ow o! p.~tl""~ wltl> cllnlc.>l ""'"""nee; ·•ong.Ograpl1y + e<erclw 
th.llloum'-CintoeroPhy. 
Anglo Fup- %ot p."<!lent:; wtlh •nvov-•ohlc follow-up; D•ot * ~ool:ll; DS- dl<>motersten<lsls; LAD • left~ntetlor descending: LC * 1<:11 circum~ .. , D.MLCA- c~ngo In mlnlmol 
lum•nolcross-"lCC.IOnal•=: N!-ILBI- National Heort, Luni:, ond BlOOd Institute; pre- below; Prox • prcxlm•I:OCA • qu.:.n!Ot;,o..,eoronaryongiOgraphlc meill<>:l oranarysts; RCA• 
nf:ht coronooy ortery; Symo - symptoms; VD • """"I dl<e•se. 
tients with developing myocardial infarctions and signif-
icant left main disease were excluded from the study. 
PTCA was successful if the final diameter stenosis 
was <50% on visual inspection of the angiogram after 
PTCA. PTCA was considered complete when the guid-
ing catheter was removed from the groin. When recur-
rence of chest pain during the hospital stay led to coro-
nary reintervention, the fllm before reintervention was 
used as the follow-up angiogram. If a follow-up angio-
gram was obtained before 3 months and if no definite 
restenosis had occurred. the patient was asked to under-
go another coronary angiogram at 6 months. 
Figure 1 describes the flow chart of all 1,442 ran-
domized patients. Of the 1,353 patients with successful 
PTCA, 1,234 patients had a follow-up angiogram after 
6 months, or earlier when indicated for symptoms. 
Pereutaneous transDuminal coron.ary angiopma&ty 
pr-ocedure and angiographie analysis: At the beginning 
of the procedure, all patients received a bolus of intrave-
nous heparin (10,000 IU). After 2 hours, an additional 
infusion of heparin (5,000 IU/hour) was administered 
until the end of the procedure. Use of a calcium antago-
nist for 48 hours was permitted. Choice of balloon type, 
inflation duration and pressure was left to the discretion 
of the operator. 
Three angiograms were obtained of each patient (1 
immediately before and 1 immediately after PTCA, 
and I at follow-up). The angiograms were recorded in 
such a way that they were suitable for quantitative 
analysis by the coronary angiography analysis system. 
An example of an analysis is shown in Figure 2. To 
standardize the method of data acquisition and to en-
sure exact reproducibility of angiograms after PTCA 
and at follow-up, measures were taken as described pre-
viously.5..2{1 
All cineangiograms were quantitatively analyzed us-
ing the coronary angiography analysis system that has 
been validated and described in detail previously.S..2{1 
The absolute values of the stenosis diameter as well as 
the reference diameter are measured by computer using 
the known contrast-empty catheter diameter as a seal-
' RANDOMIZED I ! 1442 PATIENTS _I FAILED PTC~ I 
1 
~ru I ____ ,.PATIENTS 
BLE tf PTCA ~I NTS ! .............. PERFORMED 
;suCcESSFUL PTCj " PATIENTS . 
REFUSAL I 8 PATIENTS .I ~'"'" 76 PATIENTS I I CONTRA 
NO QCA ! . INDICATION 
POSSIBLEJ 24 PATIENTS 
11 PATIENTS I WITH Fup ANGlO I 
1234 PATIENTS 
FIGURE 1. Flow ch.t of 1,442 randomized patient:L.In 74 
patienb. ~~ WDIJ umuccessfuf, in 13,. pctr-
eutanuoua trandurnin.lrll coron.ry ancfoplasty (PTCA} WDIJ not 
perlonnoci. and in 2, quantitatJv'O .analy$k (QCA) W115 not ~ 
slbae • .Au&io&a aploic: follow-up (FUp ANGlO) was obtdned In 
1.234 patients ~1%) after successful eof'OMry ~In 
1,353. 
RESTENOSIS IN MAJOR CORONARY ARTERIES 
ing device. For that purpose, the catheter tips were re-
tained for accurate measurement with a micrometer. To 
achieve maximal vasodilation. either nitroglycerin (0.1 
to 0.3 mg) or isosorbide dinitrate ( 1 to 3 mg) was ad-
ministered for each coronary artery involved before and 
after PTCA. and at follow-up angiography. All contour 
positions of the catheter and the arterial segment were 
corrected for pincushion distortion introduced by the 
image intensifiers. Because the algorithm is not able to 
measure total occlusions and lesions with Thrombolysis 
in Myocardial Infarction-! perfusion, a value of 0 mm 
was substituted for the minimal lumlnal diameter and 
100% for the percent diameter stenosis. In these cases, 
the reference diameter after PTCA was substituted for 
the reference diameter before PTCA or at follow-up. 
For each dilated segment, the minimal luminal diame-
ter and diameter stenosis before and after PTCA. and 
91 
at follow-up were taken as the mean value from multi-
ple matched projections.5 
Definition of coronary segments: Austen et al21 di-
vided the coronary tree in 15 different segments (Figure 
3). Because dilatation of the distal vessel segments did 
not occur frequently, it was decided to regroup these 
distal segments. The right coronary artery was divided 
in 4 segments: segment 1 corresponded with the proxi-
mal, segment 2 with the middle. and segments 3 and 4 
were taken together as the distal right coronary artery. 
The LAD was divided in 5 segments; segment 6 corre-
sponded with the proximal LAD, segment 7 with the 
middle LAD, and segments 8. 9 and 10 were taken to-
gether as the distal LAD. The LC was divided in 5 seg-
ments; segment 11 corresponded with the proximal LC, 
segments 13 and 15 were taken together as the middle 
LC, and segments 12 and 14 were taken together as the 
distal LC. 
Definition of restenosis: CATEGORICAL APPROACH; 
Many criteria have been proposed by the National 
Heart, Lung, and Blood Institute to assess restenosis. 
The most frequently used criterion by clinicians is that 
restenosis is present when the diameter stenosis is >50% 
at follow-up angiography.22 This definition was used for 
our data. 
CO:-.!Tl>JUOUS APPROACH: ln addition tO this arbitrary 
categorical approach for restenosis, we wanted to use 
absolute changes in minimal luminal diameter adjusted 
for vessel size, which allows for comparison between 
vessels of different sizes and is a reflection of how the 
lesion behaves during and after PTCA. 
Relative gain depicts the increase in minimal lumi-
nal diameter normalized for the reference diameter dur· 
ing PTCA (minimal luminal diameter [before PTCA-
after PTCA]/reference diameter before PTCA). Rela-
tive Joss depicts the decrease in minimal luminal diame-
ter normalized for the reference diameter (minimallu-
FlGURE Z. Single frame ang!ogrnms of same lesion of the right coronmy artery befor-e dilatation (A), aftff dilatation (B) and at 
follow-up {C). Arteria& boundaries detected by system are $hown on angiogram; upper eune reprezents. diameter function curve. 
Minimal luminal diametec- cbarlges from ll..28 befor-e to 2.58 mm after pen:utaneous tnms&urninal eoronruy angioplasty. At fol:· 
low-up G months later there is a dc<:reas(! of minimai luminal diameter to 1.17 mm. 
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minal diameter [after PTCA -at follow-up]/reference 
diameter before PTCA) (Figure 4). 
Data analysis: Data were analyzed using the bio-
medical-designed program statistical software package 
(University of California Press. Berkeley. California, 
1990). A chi-square test was used to assess differences 
in categorical variables. A 1-way analysis of variance 
was used to assess differences in continuous variables 
among the 3 major coronary arteries and the 9 different 
segments of the coronary tree. A p value <0.05 was 
considered indicative of a significant difference. 
RESULTS 
The mean time to follow-up angiography was 165 ± 
42 days. In 1.234 patients, 1,452 lesions were success-
fully dilated (1.2 lesions/patient). In 74 patients., a to-
tally occluded vessel segment was dilated. In 1,137 pa-
tients. !-vessel dilatation was performed, 93 had 2-ves-
sel dilatation, and 4 had all 3 vessels dilated. The 
majority of stenoses were located in the LAD (684 le-
sions) compared with 414 lesions in the right coronary 
artery and 354 in the LC. 
RESTENOSIS PER VESSEL SEGMENT (N .. 1452) 
~ 
(148) 
28%12 (174) 
.1 0 
' 
13 31%' 
(128) 
4 
5 
~ 
7 35%,' 
{324~ 
8(72),21%. di' 
DIAMETER STENOSIS > SO% AT FUP 
4 
RELATIVE LOSS · 4. MLD/ REF DIAM 
FIGURE 3. Coronary tree dMded in 15 difft:n::nt segments 
with restenollk rate (using >SO% diameter stenosis as criteri-
on) for each segment (A}, and relative los:s per coronary seg-
ment (B) shown in drdcs. ~ brackets are l1l.lmber's. of 
lesioN dilated for that segment. FUP ""follow-up. AMLD/REF 
DIAM "" de<rease ln minimal luminal diametw nonnafaed for 
---
Table II lists the results of the quantitative measure-
ments of the 1,452 lesions. The largest vessel was the 
right coronary artery, w1th an average reference diame-
ter of 2.86 ± 0.55 mm. The LAD and LC had similar 
sizes; the average reference diameters were 2.54 ± 0.53 
mm for the LAD, and 2.55 ± 0.50 mm for the LC (p 
<0.001). In addition. the average increases in minimal 
luminal diameter were 0.82 ± 0.37 rom in the right cor-
onary artery, 0.71 ± 0.36 mm in the LAD, and 0.72 ± 
0.35 rom in the LC. If these values were ''normalized 
for the reference diameter" (relative gain), no signifi-
cant differences were observed among either the 3 ma-
jor coronary arteries (right coronary artery vs LAD vs 
LC; p = 0.44) or the different segments of the coronary 
tree (p = 0.77). During follow-up, the average losses in 
minimal luminal diameter were 0.26 ± 0.55 mm in the 
right coronary artery. 0.30 ± 0.48 mm in the LAD. and 
0.25 ± 0.48 mm in the LC. If these values were normal-
ized for the reference diameter (relative loss), no signifi-
cant differences were observed among the 3 major coro-
nary arteries (right coronary artery vs LAD vs LC: 
p = 0.13) or the different segments of the coronary tree 
(p = 0.19). 
The restenosis rate, and relative gain and loss for the 
3 major coronary arteries and the diverse vessel seg-
ments, using either the categorical or continuous ap-
proach. are listed in Table III. No significant difference 
in either approach was observed. 
DiSCUSSION 
Several investigators have raised the question as to 
whether the dilated vessel constitutes a risk factor for 
the development of restenosis. They have reported con-
flicting results (Table I). The question is becoming even 
more relevant as new interventional techniques (such as 
stenting. athcrectomy. laser photoablation and rotabla-
tion} have been "claimed" to be more effective than 
conventional balloon angioplasty in certain lesion types 
(long lesions and total occlusions), locations or vessels 
(right coronary artery. LAD. LC and bypass graft),23 
RELATfVE GAIN AND RELATIVE LOSS 
l 
u n ,-------; ' ' ' ' 11.0 MM I 
RD MLO PRE MLD POST MLO FUP 
FIGURE 4. See text fw eXplanation of relative gain (RGAIN) 
and rdative lou (RIL.OSS). FUP "'follow-up; MLD"" minliiUII 
luminal d'.ameter; POST "' after; PRE = before; PTCA "' pereu-
tarM!'OUS transluminal eoronary ~ RD = re1erenc» di-
ameter. 
RESTENOSIS IN MAJOR CORONARY ARTERIES 
93 
although these new techniques have not yet succeeded 
in reducing restenosis rates.24·25 Several explanations 
have been put forward to explain the increased risk for 
restenosis in the (proximal) LAD. Mata et a!~; believed 
that a high rate of "continuous success" needs an opti~ 
mal selection of the balloon/artery ratio and optimal 
balloon pressure application. They suggested that ana-
tomic or procedural factors were responsible for reste-
nosis. Leimgruber et al 10 had 3 possible explanations. 
First, because they believed that the proximal LAD is 
TABlE II Baseline Quantitative Anglographic Data per Vessel Segment Dilated 
Coronary PrePTCA RD PostPTCA RD Follow-UP RD Pre PTCAMLD Post PTCA MLD Follow-Up MLD 
Artery 
"· 
Cmml (mmJ (mml (mm) (mm) {mm) 
Totll 1,452 2.63 = 0.54 2.70 = 0.52 2.70 = 0.56 1.02 = 0.38 1.77 = 0.36 1.50 = 0.57 
Roght 
'I' 2.86 = 0.55 2.93 = 0.52 2.97 = 0.58 1.08 ±. 0.41 1.91 ±. 0.37 1.65: 0.65 Proximal !48 2.99 = 0.55 3.05 ±. 0.51 3.07 = 0.55 l.ll ±. 0.45 1.96 .:': 0.39 1.69: 0.63 
Middle m 2.82 .:': 0.50 2.90 .:': 0.50 2.94: 0.59 1.08: 0.41 1.91 .:': 0.34 1.66 .:': 0.65 
Distal 92 2.71 .:': 0.59 2.81 = 0.56 2.85 :': 0.57 1.02 = 0.35 1.83 .:': 0.40 1.57: 0.66 
LAD 
'" 
2.54 = 0.53 2.59 .:': 0.49 2.58 :': 0.53 1.01 .:': 0.36 1.72 = 0.35 1.42 = 0.53 
Proximal 233 2.73 .:': 0.52 2.78 :': 0.48 2.76: 0.53 1.08::: 0.35 1.83 .:': 0.35 1.53: 0.55 
Middle 
'" 
2.48 .:': 0.47 2-52 :': 0.43 2.52 :': 0.47 0.97::: 0.36 1.68 :': 0.32 1.35 .:': 0.51 
Distal 72 2.08 = 0.44 2.14 = 0.44 2.13 = 0.42 0.87 .:': 0.35 1.43 :': 0.29 1.29 = 0.37 
LC 35< 2.55 = 0.50 2-62 = 0.46 2.61 = 0.48 1.01 = 0.36 1.73 = 0.34 1.48 = 0.51 
Proximal 101 2.73 = 0.47 2.75 = 0.43 2.74 = 0.44 1.06 = 0.42 1.82 :': 0.32 1.52 = 0.50 
Middle 125 2.55 = 0.50 2.64 = 0.45 2.61 = 0.50 1.00 = 0.34 1.75 = 0.32 1.52 = 0.53 
Dl~tal 128 2.41 = 0.49 2.50 = 0.46 2.52 = 0.48 0.98 = 0.34 1.63 = 0.34 1.41:: 0.49 
Valut!$ore meano:: •ta!ldard d<:"VIauon 
lAO- lellantonorde:.cendong: LC- lcflc•rcum~e.; MLO- m•nlmallumlnal doamoto~ Poot- oft<>r; Pro- OO!orc; PTCA- pereutanoou• tran•lumonal coronaryanglopla~ty: RO-
rclo"'nco doametor. 
TABlE II! Restenosls Rate per Segment Using the Categorical Definition of >50% OS at Follow-Up, and the Continuous Approach 
with Relative Gain and loss 
OS(%) at Follow-Up >50% 
"· 
'~ 
" 
Relative GJin Relatly,o Loss 
Total 1452 444(31) 1008 (69) 0.29 = 0.16 0.11 = 0.21 
Right 
'1' 123 C30l 239 (70) 0.30 = 0.15 0.10: 0.22 
Proxomal 1'8 45 (30) 103 (70) 0.29 = 0.15 0.10 = 0.21 
Middle m 48 C28J 126 (72) 0.30 = 0.15 0.10 :': 0.22 
Dlst~l 92 30 (33) 62 (67) 0.31 = 0.15 0.11 = 0.26 
LAD 
"' 
224 (33) 457 (67) 0.29.:':0.17 0.12 = 0.20 
Prox1mal 288 95 (33) 193 (67) 0.29:0.17 0.12 = 0.19 
Middle 
'" 
114 (35) 210 (65) 0.29 = 0.17 0.13 = 0.21 
Distal 72 15 C2ll 57 (79) 0.27:0.19 0.07 = 0.15 
LC 354 97 (28) 255 (72) 0.29 = 0.16 0.11 = 0.21 
Proximal 101 33 (331 68 C67J 0.29 = 0.16 0-11 .:': 0.18 
Middle 125 25 (20) 100 (80) 0.30:0.15 0.09 = 0.21 
Distal 128 40(311 ss (69) 0.28 = 0.17 0.09 = 0.21 
p Value (right vs LAD V5 LC) 0.22 OM 0.13 
(9 ~eementsl 0.06 0.77 0.19 
v~rues aro mc.ln~ = stJn<!Ot<l d"''•t·oo 
Abbte\IIO!H)n•"' In Ta~le I. 
TABlE IV Relattve Gain and Loss per Reference Diameter Group 
OS(%) at Follow-Up >50% 
RD(mm) <o. Abwlute Cam (mm) RelatiVe Gain Ab:;.olute Loss (mm) Relative Los~ Yes No BAR 
>4.0mm 18 0.72:: 0.55 0.17 = 0.13 0.13 = 0.46 0.03 = 0.10 6 (33) 12 (67J 0.77 
3.5to4.0 mm 81 0.87 = 0.47 0.24;;!; 0.13 0.10:: 0.50 0.03 .:': 0.13 23 (28) 58 (71) 0.89 
3.0to3.5 mm 222 0.83:: 0.42 0.26 = 0.13 0.33 = 0.54 0.10 = 0.17 71 (32) 151 (68) 0.97 
2.5to3.0 mm 507 0.76 = 0.40 0.28 = 0.15 0.28 = 0.52 0.10 = 0.19 153(30) 354 (70) 1.07 
2.0 to2.5mm 
"' 
0.72 = 0.40 0.32 = 0.17 0.28:: 0.51 0.12 = 0.23 148(33) 306 (67) 1.20 
<2.0mm 170 0.61 = 0.34 0.34 = 0.20 0.27 = 0.46 0.15 = 0.26 44(26) 126(74) 1.39 
Analysis of variance <0.001 <0.001 <0.02 <0.001 NS 
Voiu('"; ~rc means = ~tMdord dNiatoon. 
BAR • bolloon--..rteryrJUO t.oceol the IJolloon ocCOfdonglo m.-.nulocturordl,.d<:-d byt11e rcloroncedLOmoter boloro pe~uton~~ tranolumlnol COfOnoryonf;iopla•ty): DS • doamotor 
~te.-.ool•: NS • r)()t,gnol>e.>nt, ROm rclerencodlometer. 
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most often the largest artery, the 3.0 mm diameter lxll-
loons most frequently used at that time could have been 
undersized for the LAD and oversized for the right cor-
onary artery and LC. This resulted in increased diame-
ter stenosis after PTCA, which seems to be associated 
with a higher risk for restenosis. Second, a dilatation of 
the proximal LAD often involves the origin of the vessel 
and vessel branch points, and this factor also appears to 
be associated with an increased risk of restenosis. Third. 
the proximal LAD is well-recognized to develop "local-
ized stenosis." Whether the same underlying mecha-
nisms may predispose a patient to recurrence of lesions 
after angioplasty is unknown but well-conceivable. 
Because balloon/artery mismatch was not identified 
as a predictor for restcnosis in a group of patients with 
multilesion coronary angioplasty, Vandormael et ai 1J 
suggested that the different anatomic and structural 
features of the proximal segment of the LAD compared 
with those of the proximal segment of the right coro-
nary artery or LC may be responsible for the observa-
tion that dilatation of the proximal LAD is an indepen-
dent risk factor for restenosis. 
According to Califf et al, 3 1 of the methodologic ca-
veats for an increased rate of restenosis in the proximal 
LAD was that an ischemic response to exercise testing 
was more likely to be seen with proximal LAD lesions. 
thereby increasing the chance of preferential detection 
unless angiographic follow-up was complete. Also. a 
larger diameter of this vessel may have increased the 
risk that a satisfactory initial result was not achieved in 
earlier series. especially before the recent development 
of larger balloons to approach large vessels. 
In the present study, no significant difference in the 
restenosis rate was found among the 3 major coronary 
arteries (p = 0.22) or the 9 coronary artery segments 
(p = 0.06) selected for the purpose of analysis. Our re-
sults contradict the earlier observations of Leimgruber 
and Califf and their coworkers that the proximal LAD 
is the largest vessel. In the present study, almost every 
segment of the right coronary artery has a larger diame· 
ter than the proximal LAD. An explanation for this dis-
crepancy may be the differences in patient populations; 
availability of different balloon sizes (with diameters 
<2.0 mm as compared with those in the early days of 
PTCA when only balloon sizes of 3.7 mm were avail-
able) for dilatation may have affected PTCA of the 
proximal LAD. Another argument put forth in the ear-
ly years that there was a mismatch between balloon 
catheters and proximal LAD is no longer valid, because 
in the present study. all patients underwent PTCA be-
tween December 1987 and December 1989 so that in all 
cases matched balloons were available. The differences 
in restenosis rates reported by these investigators are 
probably more related to the biased and incomplete an-
giographic follow-ups of these studies. In contrast, 
the present study has a 91% angiographic follow-up 
rate, and so the biased selection of symptomatic versus 
asymptomatic patients is virtually ruled out. 
Definition of restenosis: The definition of restcnosis 
has been the subject of much debate:' Of the different 
restenosis criteria proposed, >50% di::1meter stenosis 
at follow-up angiography is the most frequently used 
to assess restenosis. because physiologic measurements 
havo;; shown th:lt the threshold for chest pain is near a 
reduction of 50% of the lumen of a nonnal vesselP This 
definition was applied to our data. However, earlier 
studies have shown that the reference diameter can be 
involved in the dilatatiOn process so that the% diameter 
stenosis could underestimate the change in the severity 
of a stenosis after PTCA.26 Furthennore. the 50% di-
ameter stenosis criterion at follow-up reveals nothing 
about the way the lesion has behaved since the PTCA 
procedure. We have previously shown that a change 
~0.72 mm in minimal luminal diameter is an appropri. 
ate method to assess intimal hyperplasia after coronary 
PTCA. 5.:!0.27 However. this criterion was historically as-
sessed in vessels with an average reference diameter of 
3.7 mm.5•20 Therefore, it should be applied to vessels of 
comparable reference diameter; it is unlikely to have a 
decrease ~0.72 mm in coronary segments with a refer-
ence diameter of 2 mm, and a minimal luminal diame-
ter of 1.4 mm. In other words. criteria based on the 
absolute change in minimal luminal diameter are limit-
ed because they make no attempt to relate the extent of 
the rcstenosis process to the size of the vessel. To cir-
cumvent this limitation it was proposed to use the 
change in minimal luminal diameter from after PTCA 
to follow-up, normalized for the reference diameter (rel-
ative loss). This sliding scale criterion that adjusts for 
vessel size allows for regional assessment of the extent 
of the restenosis phenomenon in the entire coronary 
tree. No difference in relative loss among the 3 major 
coronary arteries (p = 0.13) or the coronary segments 
could be observed (p = 0.19). Restenosis should thus be 
viewed as a ubiquitous phenomenon that is inducible to 
the same extent in every segment of the coronary tree. 
It must be emphasized that the relative gain (change in 
minimal luminal diameter from before to after PTCA. 
nonnalized for the reference diameter) and thus the 
stimulus for restenosis28 were similar in every segment 
of the coronary tree. 
Because the subdivision of the American Heart As-
sociation-coronary segments is somewhat arbitrary in 
that vessels of different diameters are grouped together. 
we reanalyzed the data by stratifying the lesions accord-
ing to their reference diameters. Table IV lists the re· 
suits. It appears that the larger the reference diameter is 
before PTCA. the smaller the relative loss is at follow-
up; vice versa, the greatest value of relative loss is ob-
served in the smaller vessels. This may be explained by 
oversizing of the balloon in these vessels. However, if 
the restenosis criterion of >50% diameter stenosis is 
used. then similar rcstenosis rates are found. 
Potential limitation of the study: Our study popula-
tion consisted mainly of patients with I dilatation site; 
1.044 p:nients had I dilatation site. and 190 underwent 
dilatation of ~2 sites. The high incidence of 1 dilatation 
site reflects the fact that the study population included 
in these 2 trials consisted predominantly of patients with 
!-vessel disease. so that our findings may not be extrap-
olated to a population with multivessel disease. Never-
theless, in the subset of 93 patients with multivessel di-
latation. the overall restenosis rate per lesion was also 
31%. However. the relative gain and loss observed in 
RESTENOSIS IN MAJOR CORONARY ARTERIES 
patients with 1- and 2-vessel dilatations differed statisti-
cally: a relative gain of 0.30 ± 0.16 was seen for 1-vess.el 
dilatation versus 0.27 ± 0.16 for 2-vessel dilatation (p 
<0.04), and a relative loss of 0.12 ± 0.21 for 1-vessel 
dilatation versus 0.08 ± 0.20 for 2-vessel ditatation (p 
<0.02). Thus. in the population with 2-vess.el dilatation. 
a reduced gain is associated with a reduced Joss consis-
tent with the concept that PTCA operators are less ag-
gressive in their dilating strategy. 
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Chapter 7 
LUMINAL NARROWING AFll'ER PERCUTANEOUS TRANSLUMINAL CORONARY 
BALLOON ANGIOPLASTY FOLLOWS A NEAR GAUSSIAN DISTRIBUTION. 
A QUANTITATIVE ANGIOGRAPHIC STUDY IN 
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Abstract 
To determine whether significant angiographic narrowing and restenosis after successful 
coronary balloon angioplasty is a specific disease entity occurring in a subset of dilated 
lesions or rather the tail end of a Gaussian distributed phenomenon, we studied 1445 
successfully dilated lesions pre-angioplasty, post-angioplasty and at 6 months follow up. 
The original cohort consisted of 1353 patients of whom 1232 underwent repeat 
angiography with quantitative analysis (follow-up rate 91.1% ). Quantitative angiography 
was carried out off-line in a central core-laboratory with an automated edge detection 
technique. Analyses were performed by analysts not involved with patient care. 
Distributions of minimal lumen diameter pre-angioplasty (1.03±0.37 mm), post 
angioplasty (1.78±0.36 mm), at 6 months follow-up (1.50±057 mm) as well as the 
percentage diameter stenosis at6 months follow-up (44± 19 %) were assessed. Also the 
change in minimal lumen diameter from post angioplasty angiogram to follow-up 
angiogram was determined (0.28±0.52 mm). Seventy lesions progressed towards total 
occlusion at follow-up. All observed distributions approximately followed a normal or 
Gaussian distribution. Therefore restenosis can be viewed as the tail end of an 
approximately Gaussian distributed phenomenon, with some lesions crossing a more or 
less arbitrary cut-off point, rather than a separate disease entity occurring in some lesions 
but not in others. 
Key words: 
-Percutaneous Transluminal Coronary Angioplasty 
-Restenosis 
-Luminal narrowing 
-Distribution 
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INTRODUCTION 
For more than a decade investigators in the field in of coronary balloon angioplasty have 
assumed a Gaussian distribution of continuous (quantitative) angiographic parameters 
used to describe the severity of the coronary lesion before angioplasty, after angioplasty 
and at follow-up angiography. Therefore they used parametric statistical tests for 
comparisons in their studies [1-7]. In a recent study [8] it was reported that the 
percentage diameter stenosis at follow-up angiography follows a bimodal distribution. 
This finding seems to support the clinical observation that the restenosis process is a yes 
or no event occurring in some patients or lesions but not in others. 
In the present study we assessed the distributions of angiographic parameters of 
lesion severity, before angioplasty, after angioplasty, and at 6 months follow up in a large 
population. Quantitative analysis was performed off-line in a central core-laboratory with 
an objective, off-line, automated edge detection technique [9] by analysts not involved 
in the treatment of the patients. 
PATIENTS AND METI!ODS 
The original study cohort consisted of 1427 patients in whom primary coronary 
balloon angioplasty was attempted between December 1987 and June 1990 and agreed 
to undergo a follow-up angiogram at 6 months. All patients signed informed consent and 
the study protocol was approved by the Institutional Review Board. 
The procedure was successful in 1353 patients (primary success rate 94.8% ), 
defined as a less than 50% residual stenosis by visual inspection of the post angioplasty 
angiogram of at least 1 lesion and no occurrence of in-hospital complications (death, 
acute myocardial infarction, bypass grafting, repeat angioplasty or symptom recurrence). 
Patients with stable as well as unstable [10] angina were included. Patients with evolving 
myocardial infarction were excluded. In 2 patients the angioplasty angiogram could not 
be analyzed due to technical deficiencies. A total of 1232 patients (91.1 %) had a follow-
up angiogram suitable for quantitative angiography and this forms the study population. 
Reason,s for not completing the study were: late death (n = 8), contraindication for repeat 
catheterization (n=24), refusal (n=76), while 11 follow-up angiograms were unsuitable 
for quantitative analysis. 
Angioplasty procedure and follow up angiography. Coronary angioplasty was 
performed with a steerable, movable guide wire system via the femoral route. Standard 
available balloon catheters were used. Choice of balloon type and brand as well as 
inflation duration and inflation pressure were left to the discretion of the angioplasty 
operator. At the beginning of the angioplasty procedure all patients received 10000 IU 
of intravenous heparin for the first two hours, afterwards 5000 IU /hour for as long the 
procedure continued. All patients received 10 mg nifedipine every two hours for the first 
12 hours after angioplasty. Thereafter they received 20 mg slow release nifedipine tablets 
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3 times during the second day after angioplasty. 
Three coronary angiograms were obtained in each patient, one just before PTCA, 
one immediately after angioplasty, and an angiogram at follow-up. The angiograms were 
recorded in such a way that they were suited for quantitative analysis by the 
Cardiovascular Angiography Analysis System (CAAS). For calibration purposes the 
cathetertips were cut off for later measurement with a microcaliper. To standardize the 
method of data acquisition and to ensure exact reproducibility of the angiographic 
studies, measures were taken as described previously [3,11,12]. All angiograms were 
processed and analyzed in a central core-laboratory. 
The follow-up coronary angiogram was performed at six months follow-up. If 
symptoms recurred within 6 months, coronary angiography was carried out earlier. If no 
definite restenosis was present and the follow-up time was less than 4 months, the patient 
was asked to undergo another coronary arteriogram at 6 months. 
Quantitative angiography. All cineangiograms were analyzed using the computer 
assisted cardiovascular angiography analysis system (CAAS) which has been described 
and validated earlier [9,13]. In sununary: Any area of size 6.9 x 6.9 mm (512 x 512 pixels) 
in a selected cineframe (overall dimensions 18 x 24 nun) encompassing the desired 
arterial segment is digitized with a high resolution CCD camera. Vessel contours are 
determined automatically baseii on the weighted sum of first and second derivative 
functions applied to the digitized brightness information along scanlines perpendicular 
to the local centerline directions of an arterial segment. A computer derived 
reconstruction of the original arterial dimension at the site of obstruction (assuming 
there is no disease present) is used to define the interpolated reference diameter. The 
absolute values of the stenosis diameter as well as the reference diameter are measured 
by the computer using the known contrast catheter diameter as a scaling device. The 
length of the obstruction is determined from the diameter function on the basis of 
curvature analysis and expressed in millimeters. All contour positions of the catheter and 
the arterial segment are corrected for pincushion distortion introduced by the image 
intensifiers. Since the algorithm is not able to measure total occlusions, a value of 0 mm 
was substituted for the miuimallumen diameter and a value of 100% for the %diameter 
stenosis and % area stenosis. In these cases the post angioplasty reference diameter was 
substituted for the reference diameter pre angioplasty or at follow-up angiography. The 
mean change in miuimallumen diameter from post angioplasty to follow up angiography 
and from pre angioplasty to post angioplasty was derived from matched angiographic 
projections. The percentage area stenosis was calculated using the measured miuimal 
lumen diameter and interpolated reference diameter assuming a circular cross-section 
at the stenosis site. 
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RESULTS 
Baseline characteristics. Table 1 summarizes the baseline characteristics of the 
1232 patients with quantitative angiograpbic follow-up. These patients had 1445 lesions 
successfully dilated (1.17 lesions/patient). Seventy eight totally occluded lesions were 
successfully dilated. At follow-up 70 lesions had progressed to total occlusion. Four 
hundred ninety one patients (39.9%) had a history of myocardial infarction. 
Table 1. Baseline patient and lesion characteristics. 
Patiens 
Lesions 
Male sex 
Age (years) 
Time to follow-up angiography (days) 
Dilated artery 
LAD 
LCX 
RCA 
Extent of coronary artery disease 
1 vessel 
2 vessel 
3 vessel 
1232 
1445 
1002 (81%) 
56;!: 9 
165 ± 42 
681 
352 
412 
755 (61.3%) 
399 (32.4%) 
78 (63%) 
Extent of coronary artery disease was visually assessed, > 50% diameter stenosis was 
considered significant. LAD= left anterior descending artery, LCX =left circumflex artery, 
RCA=right coronary artery. 
Quantitative angiographic findings and distributions. Table 2 summarizes the 
quantitative angiographic data. Reference diameter was not significantly different pre-
angioplasty, post-angioplasty and at follow-up, suggesting that vasomotion was accurately 
controlled during the 3 angiographic studies. Distribution plots of the ntinimal lumen 
diameter data are given in figure 1a to lc. The distribution of the change in ntinimal 
lumen diameter from post angioplasty angiogram to follow up angiogram (loss in 
ntinimalluminal diameter) is depicted as well (figure 1d). A positive change corresponds 
to a decrease in minimalluntinal diameter. If the restenosis criterion of >0.72 rom loss 
in lumen diameter is applied [3], 244lesions (16.9%) were restenosed at follow-up. All 
distributions are more or less bell-shaped and follow the theoretical normal or Gaussian 
distribution for the given mean and standard deviation values if the totally occluded 
lesions are not taken into account (curves superimposed on the distributions). 
Table 2. Quantitative angiographic data of 1445 lesions 
Minimal lumen diameter (mm) 
pre-angioplasty 
post-angioplasty 
follow-up 
Reference diameter (mm) 
pre-angioplasty 
post-angioplasty 
follow-up 
Difference in Minimal Lumen Diameter (mm) 
post-angioplasty · pre-angioplasty 
post angioplasty · follow up 
Diameter stenosis (%) 
pre-angioplasty 
post-angioplasty 
follow-up 
SD;standard deviation 
Mean± 1SD 
1.02±0.38 
1.77±0.36 
1.50±0.57 
2.63±0.54 
2.70±0.52 
2.70±0.56 
0.75±0.41 
028±0.52 
60.5±13.6 
33.6±9.8 
44.2±18.7 
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The distribution of the loss in minimal luminal diameter, excluding lesions that 
were totally occluded at follow-up (bars, figore 1d) is almost identical to the distribution 
including totally occluded lesions at follow up (asterisks, figore 1d) with the latter lesions 
showing a greater loss in minimal lumen diameter. This suggests that lesions progressing 
to total occlusion are not necessarily lesions with a poor or marginal angioplasty result 
and that a different mechanism of luminal narrowing may also be involved. Figure 2 
shows this more clearly. In this normal probability plot of change in minimal lumen 
diameter, slashes denote the expected Gaussian distribution based on the raok of the 
observations and the squares denote the actual observed values. It appears that if the 
lesions that progress to total occlusion are excluded, the observed values closely follow 
the expected Gaussian distribution. 
The distribution of percent diameter stenosis at follow-up was found to be 
unimodal and almost symmetrical and bell-shaped if lesions that progressed towards total 
occlusion were disregarded (figore 3). 
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Figure 1. Histograms of minimal lumen diameter (MLD) measurements of I445 lesions The 
curves superimposed on the histograms represent the theoretical Gaussian distribution curves 
given the mean and standard deviation values of the quantitative angiographic 
measurements, excluding total occlusions. 
Figure I a: histogram of MLD pre angioplasty, 
Figure I b: histogram of MLD post angioplasty, 
Figure I c: histogram of MLD at follow-up angiography, 
Figure Id: histogram of change in MLD from post angioplasty angiogram to follow-up 
angiogram. The asterisks denote the distribution of the change in minimal lumen diameter 
including those lesions that had progressed towards total occlusion. A positive change denotes 
a loss in minimal lumen diameter. The long term variability cut-off points are drawn in the 
histogram (see text for explanation). 
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Figure 2. Normal probability plot of the change in minimal lumen diameter (MLD) from 
post angioplasty angiogram to follow-up angiogram, excluding lesions that had progressed 
towards total occlusion. The slashes depict the theoretical Gaussian distribution. The squares 
are the actually observed values. A change greater than 0 co"esponds to a loss in minimal 
lumen diameter. 
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Figure 3. Histogram of percent diameter stenosis at follow-up angiography of 1445 lesions. 
Mean percent diameter stenosis excluding total occlusions is 41.3 ;: 14.5. Also indicated is 
the mean diameter stenosis pre angioplasty (60.5% ). This limit marks 1.2 standard deviations 
to the right of the 41.3% value, indicating that IL5% of the observations under the curve are 
located to the right of the 60.5% limit. If the 4.8% of totally occluded lesions are added, 
16.3% of all lesions demonstrate restenosis to at least the same severity as the mean stenosis 
severity prior to angioplasty. SD =standard deviation. 
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Disregarding these total occlusions, mean% diameter stenosis at follow-up was 4L3 ::!: 
16.1, The mean 605% diameter stenosis pre-angioplasty marks 1,2 standard deviations 
to the right on the bell shaped curve and thus the area under the curve located to the 
right of the 605% limit comprises 1L5% of all observations. Together with the 4.8% of 
lesions that were totally occluded at follow up 16,3% of all lesions demonstrate restenosis 
to at least the same severity as the mean stenosis severity prior to angioplasty. If the 
>50% diameter stenosis at follow up criterion is applied, 444 lesions (30.7%) were 
restenosed. 
Values of quantitative angiographic measurements. It is apparent from figure 4 
that diameter stenosis measurements of more than 75% were very rarely encountered. 
In fact 90% of all lesions had a diameter stenosis of less than 74% (thin curve in fignre 
4). The corresponding calculated% area stenosis is represented by the fat curve in figure 
4. Ninety percent of all lesions had an area reduction of less than 93% 
%of lesions 
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Figure 4. Cumulative distribution of percent diameter reduction (percent diameter stenosis 
(%DS) thin curve) and of percent area reduction (percent area stenosis (o/oAS), fat curve) 
for 1445/esionspre angioplasty. Ninety percent of all lesions show a% DS of less then 74%, 
which co"esponds to 93% AS. 
Regression in lesion severity at follow-up angiography. Among the 1445 lesions 
analyzed, 429 showed an increase in minimal lumen diameter at follow-up (29.6%) 
(change < 0 mm, fignre ld). The long term variability of minimal lumen diameter 
measurements (i.e. 1 standard deviation of the difference of the means of 2 
measurements of the same lesion at different catheterizations, 90 days apart) was earlier 
found to be 0,36 mm [9]. The mean difference in minimal lumen diameter in that same 
period was found to be 0 mm [9]. This implies that no detectable progression or 
regression occurred over the 90 days period. Therefore the long term variability reflects 
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the long-term random variation in lesion measurements from coronary angiograms made 
at different catheterization sessions using the CAAS system. The use of 1 standard 
deviation would include 68.3% of the variability, while the use of 2 standard deviations 
(2 x 036 ; 0.72 mm) includes 95.5% of the variability. Therefore an increase of more 
than twice the long-term measurement variability (~ 0.72 mm) can be considered 
sigoificant and indicative of regression. If this definition is applied, only 16 lesions 
showed a definite increase in lumen diaroeter (1.1%) over the 6 months follow-up period 
(figore 1d). 
DISCUSSION 
There is increasing evidence that reactive intimal hyperplasia is the underlying 
cause of luntinal narrowing after successful balloon angioplasty. Post mortem studies and 
atherectomy specimen have revealed that medial smooth muscle cell ntigration and 
proliferation with the production of abundant extracellular matrix probably are the key 
factors in the luntinal narrowing process after angioplasty [14-16]. Like most physical and 
biological phenomena this angiographicaly observed natural 'healing' process was found 
to be approximately Gaussian distributed. 
Method of quantitative angiography and distribution of variables of lesion 
severity. In clinical medicine continuously distributed parameters of disease severity pose 
a problem because the decision on when or how to intervene has to be based on a more 
or less arbitrary cut-off point. For coronary stenosis severity, the 50% diameter stenosis 
value has emerged as a cut-off point, because it represents the approximate value in 
animals with normal coronary arteries at which a blunting of the coronary flow reserve 
occurs [17]. In a recently presented study [8] it was reported that the percentage 
diaroeter stenosis of lesions 4 months to 1 year after balloon angioplasty followed a 
bimodal distribution with the nadir between the 2 peaks at 50% diameter stenosis. This 
suggests that after balloon angioplasty 2 types of lesion behavior can occur, a restenosing-
and a non restenosing reaction. If 2 different populations are present from the start, 
then it must be possible to isolate the restenosing patients before angioplasty. However, 
the prediction of restenosis with both invasive and non invasive tools is at most not very 
effective [18,19]. This finding has also far reaching consequences for the statistical 
analysis of angiographic restenosis data. The use of parametric statistical tests ( eg !-test, 
analysis of variance) ntight no longer be appropriate. 
In our population the distribution of percentage diameter stenosis was found to 
be unimodal and almost symmetrical and bell-shaped (figore 3). This discrepancy ntight 
be explained by the fact that quantitative angiography in the study of King et al. was 
carried out on-line in the catheterization laboratory with a non antomated analysis 
technique and before clinical decision making was carried out. In that setting a 
percentage diameter stenosis around 50 is unwanted since it does not add information 
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for the decision making process. Therefore a bias away from the 50% value is likely to 
occur. This type of bias was proposed by King et al. at the 40th annual scientific session 
of the American College of Cardiology as an explanation for the bimodal distribution 
found in their series [8]. In the present study quantitative angiography was carried out 
off-line in a central core laboratory using an objective automated quantitative analysis 
technique with minimal interference of the analysts who were not involved in clinical 
decision making. We therefore believe that the present values have been less biased. 
Values of quantitative angiographic measurements. The leptokurtic distribution 
of the ntinimallumen diameter pre angioplasty with a higber peak than expected (figure 
1a) can be explained by lesion selection. Values around 1 mm correspond with diameter 
stenosis values in the range of 60 to 70%. These are generally the type oflesions selected 
for balloon angioplasty. 
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Figure 5. Theoretical pressure drops calculated with the fluid dynamics equation derived by 
Gould and Kirkeeide [20.21 J at assumed flows of 1.2,3,4 and 5 mljsec respectively. 
Reference diameter was assumed 2. 6 mm and lesion length 6.5 mm. 
Minimal lumen diameters smaller than 0.5 rnm were not encountered. Figure 5 
shows the theoretical pressure drop over a stenosis with a length of 6.5 rmn (mean 
stenosis length in study) and an interpolated reference diameter of 2.6 mm (mean value 
in this study) at assumed flows ranging from 1 mljsecond (rest) to 5 ml/second (maximal 
hyperentic flow). Pressure drops were calculated using the fluid dynantic equation derived 
by Gould and Kirkeeide [20.21]. Luminal diameters less than 0.5 rmn are unrealistic from 
a fluid dynamics point of view since the pressure gradient over the stenosis necessary 
to maintain rest flow will be far beyond the physiological range (figure 5). Lesions that 
are approaching this severity will therefore show a severely reduced flow, become 
unstable and will eventually thrombose and occlude. For the same reason are diameter 
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stenosis measurements of more than 75% very rarely encountered. Only 10% of all 
lesions had a percentage diameter reduction pre angioplasty of more than 74% (figure 
4 ). The highest pre angioplasty % diameter stenosis value encountered in this study 
(excluding total occlusions) was 86%. These at first glance low values of quantitatively 
measured diameter stenosis values correspond however with percentage area reduction 
values of more than 93! (figure 4). Therefore, visual stenosis severity scoring systems that 
allow classification of over 90% diameter reduction do not reflect the actual lesion 
severity and will describe lesions which are physiologically impossible. Furthermore, for 
accurate interpretation of studies using quantitative coronary angiography this 
discrepancy should be kept in mind. 
Lesion progression towards total occlusion. From figure 1d and figure 2 it can be 
inferred that lesion progression towards total occlusion involves not only the near 
normally distributed luminal narrowing process, but that a part of the narrowing in 
lesions progressing towards total occlusion must be ascribed to a different process. Since 
lesions with a minimal lumen diameter of less than 0.5 mm are impossible because of 
the unphysiological high transstenotic pressure necessary to maintain blood flow (figure 
5), it is likely that the last step in lesion progression towards total occlusion is due to 
thrombosis. Delivery and activation of platelets is dependent on shear rate, which is a 
measure of the difference in blood velocity between the center and the periphery of the 
vessel. A tightening stenosis causes progressively higher shear rates to occur which favors 
platelet activation and deposition [22,23]. Animal experiments by Folts eta!. showed that 
platelet aggregation spontaneously occurs in partially obstructed coronary arteries [24]. 
Another explanation might be that a 'silent' thrombotic occlusion occurs early after an 
angiographic successful angioplasty. In the absence of an important collateral circulation 
one would then expect a high amount of myocardial infarctions in patients with a total 
occlusion at follow-up. Sixteen of the 70 totally occluded lesions at follow up were also 
totally occluded before angioplasty and were collaterally circulated. Of the 54 patent 
arteries pre angioplasty only 4 were infarct related during follow-up (enzyme elevation 
to twice normal and/or presence of new Q waves). Visible collateral circulation before 
angioplasty was present in only 8 of these 54 lesions (table 3). A slowly progressing lesion 
on the other hand could allow for a gradual build up of collateral circulation enabling 
a subsequent total occlusion to develop without myocardial necrosis. 
Lesion regression. A definite increase in minimal lumen diameter (regression) was 
observed in 16 patients only (1.1%) (figure 1d). This finding is in concordance with 
earlier reported data [3]. True angiographic regression in the first months after 
angioplasty thus appears to be a rare phenomenon. On the other hand, Rosing eta!. [25] 
descnlled regression of the dilated lesion in 46 patients 3 years after successful 
angioplasty as compared to a 6 months angiogram. This finding can be ascribed to a late 
resorption of the extracellular matrix in the neointima [15]. 
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Conclusion. The process of luminal narrowing after coronary balloon angioplasty 
is approximately normally distributed, with few lesions showing regression, most of the 
lesions showing no change and a considerable amount of the lesions showing progression. 
Restenosis can thus be viewed as the tail end of a near Gaussian distribution, with some 
lesions crossing a more or less arbitrary angiographic cut~off point, rather than a separate 
disease entity that occurs in some lesions but not in others. For comparison of the 
angiographic efficacy of pharmacological agents and new interventional devices, the use 
of change in minimal luminal diameter as end-point rather than restenosis rate is 
therefore recommended. 
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Prevention of Restenosis After Percutaneous 
Transluminal Coronary Angioplasty With 
Thromboxane Az-Receptor Blockade 
A Randomized, Double-Blind, Placebo-Controlled Trial 
Patrick W. Serruys, MD, PhD; Wolfgang Rutsch, MD; Guy R. Heyndrickx, MD; 
Nicolas Danchin, MD; E. Gijs Mast, MD; William Wijns, MD; Ben no J. Rensing, MD; 
Jeroen Vos, MD; and Jeanne Stibbe. MD, PhD, for the Coronary Artery Restenosis 
Prevention on Repeated Thromboxane-Antagonism Study Group (CARPORT) 
Background. GR32191B is a novel thromboxane Arreceptor antagonist with potent antiag-
gregational and antivasoconstrictive properties. We have conducted a randomized, double-
blind, placebo-controlled trial to study its usefulness in restenosis prevention. 
Methods and Results. Patients received either GR32191B (80 mg orally before angioplasty and 
80 mg/day orally for 6 months) or 250 mg i.v. aspirin before angiopiasty and placebo for 6 
months. Coronary angiograms before angiop!asty, after angioplasty, and at 6-month follow-up 
were quantitatively analyzed. Angioplasty was attempted in 697 patients. For efficacy analysis, 
quantitative angiography at follow-up was available in 522 compliant patients (261 in each 
group). Baseline clinical and angiographic parameters did not differ between the two treatment 
groups. The mean difference in coronary diameter between postangioplasty and follow-up 
angiogram (primary end point) was -0.31:!::0.54 mm in the control group and -0.31:!:0.55 mm 
in the GR32191B group. Clin.ical events during 6-month follow-up, analyzed on intention-to-
treat basis, were ranked according to the highest category on a scale ranging from death 
(control, six; GR32191B, four) to nonfatal infarction (control, 22; GR32191B, 18), bypass 
grafting (control, 19; GR32191B, 22) and repeat angioplasty (control, 52; GR32191B, 48). No 
significant difference in ranking was detected. Six months after angioplasty, 75% of patients in 
the GR32191B group and 72% of patients in the control group were symptom free. 
Conclusions. Long-term thromboxane Az-receptor blockade with GR32191B does not prevent 
rcstenosis and does not favorably influence the clinical course after angioplasty. (Circula!ion 
1991;84,1568-1580) 
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Percutaneous transluminal coronary angioplasty (PTCA) is increasingly being used as an alternative to coronary artery bypass graft 
surgery in patients with coronary artery disease. 
From the Thoraxcenter (P.W.S •. BJ.R.), Erasmus University, 
Rotterdam. The Netherlands; K.linikum Charlottenburg (W.R.), 
Berlin, Gennany: Onze Lieve Vrouw Ziekenhuis (G.R.H.), Aalst, 
Belgium; C.H.R.U. de Nancy-Hopitaux de Brabois (N.D.). 
Nancy, France; St. Antonius Ziekcnhuis (E.G.M.). Nieuwegcin. 
The Netherlands; U.C.L St. Luc University Hospital ry./.W.), 
Brussels. Belgium; SOCAR S.A. (J.V.), Givrins, Switzerland; and 
Dijkcigt University Hospital (J.S.), Rotterdam, The Netherlands. 
Although major improvements in angioplasty tech-
niques have resulted in a high initial success rate, the 
late restenosis rate of 20-40% still limits the long-
term benefit of the procedure.I-S For multivessel 
angioplasty, the restenosis percentage is even high-
cr.6 It is well known that restenosis after balloon 
angioplasty is a time-related phenomenon. occurring 
in the first months after balloon angioplasty.s.7 Only 
very rarely does restenosis present itself more than 6 
months after coronary angioplasty8.9; therefore, the 
follow-up period has been limited to the first six 
months after angioplasty in the current trial. 
Supported by Glaxo Group Research Ltd., Greenford, Middle-
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Address for correspondence: P.W. Serruys, MD, PhD, Cathe-
teri~tion Laboratory, Thoraxcenter, P.O. Box 1738, 3000 DR 
Rotterdam, The Netherlands. 
Received March 12. 1991; revision accepted June 11. !991. 
Deendothclialization and vascular disruption at 
the angioplasty site expose vessel wall smooth muscle 
cells and collagen directly to blood. This causes 
platelet adhesion, platelet aggregation, and activa-
tion of the clotring cascade. In addition, platelets may 
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also activate leukocytes to release vasoconstrictor 
lcukotriencs. These effects appear to be thrombox-
ane mediated as inhibition of thromboxane reduces 
leukocyte activation.IO Adhesion and aggregation of 
platelets at the postangioplasty plaque can lead to an 
early occlusion within the first 48 hours after angio-
plasty. Over the long term, platelet- and monocyte-
derived growth factors stimulate smooth muscle cell 
proliferation, leading to the fibroproliferativc reac-
tion of the vessel wall in the first months after balloon 
angioplasty.ll-J3 Apart from the proliferation pro-
cess, organization of mural thrombi may also be the 
cause of restcnosis.H.l!i Early platelet aggregation 
thus appears to play a pivotal role in the occurrence 
of postangioplasty thrombotic occlusion and the rc-
stenosis proccss.J6 
Thromboxane A: {TXA.z) is a potent platelet ag-
gregational agent and vasoconstrictor released from 
activated platelets. Beyond the platelet-activating 
effect, TXA: also appears to have a more direct effect 
on vascular smooth muscle cell proliferation. Using 
primary cultures of smooth muscle from rat aorta, 
Hanasaki ct aJI7 demonstrated a mitogenic effect of 
thromboxane on smooth muscle cells. which occurs 
through binding to its specific receptor and may be 
suppressed by thromboxanc-reeeptor blockade, 17 a 
promising approach to the inhibition of the effects of 
TX.A2•1x TX.A:-receptor blockade prevents the dele-
terious actions of TXA: while sparing the beneficial 
synthesis of prostacyc\in. GR32191B has been shown 
to be a potent and specific TXA2-rcceptor-blocking 
drug that antagonizes the proaggrcgatory, vasocon-
strictor, and bronchoconstrictor actions of TXA:. as 
well as those of agents that act indirectly via TXA:. 
such as collagen and arachidonic acid, and agents 
that directly stimulate the receptor, such as pros-
taglandin H: and the TX.A: mimetic U-46619_lt~.J<J 
Although not affecting platelet adhesion, it potently 
inhibits the aggregation of platelets onto damaged 
blood vessels.1K:o This property, together with the 
ability of the compound to inhibit the platelet-release 
reaction, indicates a potential clinical usc of 
GR32191B in reducing early thrombotic events, late 
intimal hyperplasia, and subsequent restenosis after 
coronary angioplasty. The present multicenter, ran-
domized, double-blind, placebo-controlled trial (Cor-
onary Artery Restcnosis Prevention on Repeated 
Thromboxane-Antagonism ICARPORT]) was car-
ried out to evaluate the role of GR32191B in the 
prevention of late restenosis after PTCA. 
Methods 
All patients with angina and angiographically 
proven coronary artery disease who were scheduled 
for angioplasty were considered for inclusion at one 
of six participating centers (sec "Appendix"). The 
trial was carried out according to the declaration of 
Helsinki, and specific exclusion criteria arc given in 
Table 1. A screening log was maintained in two 
centers. At these two centers. 1.614 patients were 
TAm .. t: L Reasons for Exclusion for 1,318 of 1.614 Screened 
Patient.-. at Two or Six Participating Centers 
Insufficient lead-in time" 
Use o( platelet-inhibiting or nonsteroidal 
anti-inflammatory drugs within 7 days 
preceding the study 
Refusal to participate and/or undergo 
6-month recatheterization 
Currently taking oral antic<Xtgulant drugs 
Angioplasty for restenosis 
Acute myoc:.rdial infarction within 2 
week.~ preceding angioplasty 
Bypass graft dilatution 
History of obstructive airw.Jy disease 
History or peptic disease or upper 
gastrointestinal bleeding 
Previous participation in the trial 
Severe other disease 
Participation in another trial 
History of intolerance to aspirin 
Less th:m 21 years old 
Pregnant woman or woman likely to 
become pregnant during study 
Total 
"Urgent referrals outside working hours. 
Total(%) 
235 18 
352 27 
364 28 
!19 9 
105 
' 
52 4 
39 3 
26 2 
10 
2 0.2 
0.5 
0.4 
0.1 
0.1 
0 
1.318 100 
screened from December 1987 through June 1989, 
and 72% were excluded (Table 1). 
Randomization and Trearment Protocol 
Randomized, double-blind trial medication was 
allocated by telephone after the patient had been 
registered at the central allocation service. Trial 
medication consisted of either GR32191B for 6 
months or control treatment with one dose of aspirin, 
followed by matching placebo. 
One hour before angioplasty. patients allocated to 
GR32191B received 4 tablets of 20 mg GR32191B 
orally and an intravenous injection of a physiological 
salt solution. Patients allocated to control treatment 
received 250 mg i.v. acetylsalicylic acid and 4 placebo 
tablets. In addition to trial medication, all patients 
received a bolus of 10,000 units i.v. heparin at the 
beginning of the procedure. After two hours, 5,000 
units/hr was given for as long as the procedure 
continued. Also, all patients received 10 mg nifedi-
pine every 2 hours for the first 12 hours and 20 mg 
slow-release nifedipine tablets thereafter every 8 
hours up to the second day after angioplasty. 
In those patients in whom angioplasty was suc-
cessful, either 40 mg GR32191B twice daily or 
placebo was started in the evening and continued 
until the end of follow-up. The final dose of trial 
medication was taken 1 hour before the follow-up 
angiogram. In addition, all participants were pro-
vided with paraeetamol in 500 -mg tablets for use as 
analgesic and were asked to avoid acetylsalicylic 
acid or nonsteroidal anti-inflammatory drugs while 
on trial medication. 
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Trial medication and paracetamol were packaged 
and supplied by Glaxo Group Research, which also 
prepared the random plan. Randomization was 
stratified by center. 
Angioplasty Procedure and Follow-up Angiography 
Coronary angioplasty was performed with a steer-
able, movable guide wire system via the femoral 
route. Choice of balloon type and brand as well as 
inflation duration and pressure were left to the 
operator. For the purpose of the study. three coro-
nary angiograms were obtained in each patient- one 
just before angioplasty. one immediately after angio-
plasty, and one at follow-up. Angiograms were re-
corded in such a way that they were suitable for 
quantitative analysis by the coronary angiography 
analysis system (CA..AS). using fixed-table systems 
and 35-mm cinefilm at a minimum speed of 25 
frames/sec. All necessary details of the procedure 
were recorded in the case record form. and drawings 
of the segments to be analyzed were made by the 
investigators. Before the postangioplasty angiogram. 
radiopaque guide wires had to be removed to avoid 
interference with automated edge detection. For 
calibration purposes, catheter tips were cut off and 
sent with the cine:film to the angiographic core labo-
ratory. To standardize the method of data acquisition 
and to ensure exact reproducibility of postangioplasty 
and follow-up angiograms. measures were under-
taken as has been described earlier_5.21Z'- A qualita-
tive assessment of certain lesion characteristics was 
performed (see Table 2). Intracoronary thrombus 
was defined as the presence of a filling defect within 
the lumen, surrounded by contrast material seen in 
multiple projections in the absence of calcium within 
the :filling defect, the persistence of contrast material 
within the lumen, or a visible embolization of intralu-
minal material downstream. Haziness was defined as 
a small radiolucent area within the lumen of the 
vessel disappearing with the passage of contrast 
material (type A dissection according to Dorros et 
a\23). Intimal tear was defined as a filling defect 
within the lumen and dissection as contrast appear-
ing outside the lumen, disappearing or persisting 
with the passage of contrast material (types Band C 
dissections according to Dorros et aFJ). 
Follow-up Evaluation 
After successful angioplasty, defined as at least one 
lesion successfully dilated (i.e., less than 50% diam-
eter stenosis on visual inspection after the proce~ 
dure) as judged by the investigator, patients returned 
to the outpatient clinic after 3 weeks and 3, 6, and 7 
months for an interview, a physical examination, 
laboratory tests, a tablet count, and, except for the 6-
and ?~month visits, a new supply of trial medication. 
Patients with an unsuccessful angioplasty discontin-
ued. trial medication and received the standard med-
ical care. The follow~up clinical status of all patients, 
irrespective of PTCA success, was assessed 6 months 
after the procedure. In one of the participating 
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TAI,lJ..~: 2. Ant:,iogr:tphic Baseline Data of Compliant Patients 
With Quantil:ltlve Angiogr.~phic Follow-up 
Control GR3219JB 
(n=26I) (n=26I) 
" 
% 
" 
% 
Lesions (n) 320 316 
Lesions per patient (n) 1.23 1.21 
Vessels dilated 
LAD 167 52 146 46 
RCA 90 2S 99 31 
LC< 63 20 71 23 
Calcified lesion 19 32 10 
Discrete z.;z 76 239 76 
Asymmetry 133 42 134 42 
Toto:~! occlusion 12 4 10 3 
Tandem lesion 25 8 24 8 
Side branch in stenosis 99 31 7S 25 
Side branch in dilatation 
site 178 56 193 61 
Inflation duration (seconds) 133::!:92 133::!:90 
Maximum infl:J.tion pressure 
(atm) 9::-:2 9:2 
Balloon-to-nrtery ratio J.10::t0.22 1.06::!:0.22 
Thrombus visible nfter 
angiopbsty 12 
Dissection 49 15 46 15 
At balloon site .w 39 
Proximal of balloon I 
Distal of balloon 4 
Intimal tear 37 12 26 
Haziness 45 14 56 18 
LAD. left anterior descending coronary artery, RCA. right 
coronary artery; LCx. left circumflex artery. 
centers (Rotterdam), platelet aggregation tests, using 
ADP and U-46619 (a TXA1 mimetic) as aggregants, 
were carried out to assess pharmacological activity of 
the drug. At 6-month follow-up, 1-4 days before 
angiography, a symptom-limited exercise test was 
performed on a bicycle ergometer according to two 
different protocols. In Berlin, the test was performed 
with the patient in a supine position. starting with a 
work load of 25 W, which increased by 25 W every 2 
minutes. In the other clinics, the test was performed 
with the patient in a sitting position. starting with a 
work load of 20 W, which was increased by 20 W 
every 1 minute. Exercise was continued until anginal 
symptoms, a drop in systolic blood pressure, severe 
arrhythmia, or a ST depression of more than 1 mm 
occurred. A 12-lead electrocardiogram was recorded 
during exercise and recovery. ST changes were mea-
sured 80 msec after the J point. Horizontal or 
downsloping ST segment depression associated with 
anginal symptoms was considered a positive response 
to the stress test. The follow-up coronary angiogram 
was performed at the 6-month visit. If symptoms 
recurred within 6 months. coronary angiography was 
carried out earlier. If no definite restenosis was 
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present and the follow-up time was less than 4 
months, the patient was asked to undergo another 
coronary arteriogram at 6 months. 
Quantitative Angiography 
J\..11 cineangiograms were analyzed using the CAA.S 
system, which has been descnOed in dctaiJ.24--26 A 
computer-derived reconstruction of the original arte-
rial dimension at the site of obstruction (assuming 
there is no disease present) is used to define the 
interpolated reference diameter. The absolute values 
of the stenosis diameter as well as the reference 
diameter arc measured by the computer using the 
known contrast catheter diameter as a scaling device. 
Because the algorithm is not able to measure total 
occlusions, a value of 0 mm was substituted for the 
minimal lumen diameter and 100% for the percent 
diameter stenosis. In these cases, the postangioplasty 
reference diameter was substituted for the reference 
diameter before angioplasty. In contrast, for a totally 
occluded vessel at follow-up angiography, a value was 
not substituted, so that the change in reference diam-
eter from after angioplasty to follow-up was only 
calculated when an actual measurement was available. 
Balloon-to-artery ratio was defined as the ratio of 
the mean balloon diameter measured in a single 
nonforeshortened projection and the reference diam-
eter of the dilated segment in the same projection. 
Assay of GR3219IB and Platelet Aggregation Tests 
Plasma samples of patients allocated to active drug 
treatment were taken before first drug intake and 
approximately 1 hour afterward. These samples were 
analyzed for GR32191B by high-performance liquid 
chromatography with :fluorescence detection after 
solid-phase extraction on an advanced automated 
sample processor. 
For the aggregation tests, blood was drawn from 
the patient by venipuncture. Nine parts of blood were 
mixed with 1 part 0.13 M sodium citrate solution. The 
blood was then centrifuged (15 minutes at 200g at 
room temperature), and the supernatant platelet-
rich plasma (PRP) was carefully removed using a 
plastic Pasteur pipette and transferred to a separate 
plastic tube. The remaining blood was centrifuged for 
10 minutes at 2,000g at room temperature to obtain 
platelet-poor plasma (PPP). PPP was then added to 
PRP to obtain PRP with a platelet count of 200x109 
platelets/!. The PRP was stored at room temperature 
in full, capped tubes (contents, 5 ml) for 30-90 
minutes. Aggregation was performed in a Payton 
twin-channel aggregometer at 37"C with a stirring 
speed of 900 rpm. Maximum and minimum light 
transmission was set up using PPP and PRP, respec-
tively. Samples of 400 ,u.l PRP were incubated in the 
aggregometer for 3 minutes at 37"C, and 40 ,u.l of 
either the TXA2 mimetic U-46619 (final concentra-
tion, 1 ,u.M) or ADP (final concentration, 10 ,u.M) was 
added. Aggregation was allowed to proceed to its 
maximum or a period of 5 minutes was allowed, 
whichever was longer. Aggregation was expressed as 
the peak response and represented in millimeters. 
End Points 
The primary end point of the present study was the 
within-patient change in minimal lumen diameter as 
determined by quantitative angiography after PTCA 
and at follow-up. Post-PTCA values were obtained 
from the last post-PTCA angiogram made before 
withdrawal of the guide catheter. The initial proce-
dure were considered finished when the guide cath-
eter was removed. In case evolution of the clinical 
condition required repeat PTCA (with reinsertion of 
guide catheter), the angiogram made before repeat 
balloon inflations was used to obtain follow-up val-
ues, regardless of the timing of repeat PTCA (hours, 
days, or weeks). Otherwise, the follow-up angiogram 
made according to protocol was used. For each 
dilated segment, the post-PTCA and follow-up min-
imal lumen diameters were taken as the mean values 
from multiple matched projections. Within-patient 
change (i.e., the primary end point) was defined as 
the follow-up minus the post-PTCA value. In case 
more than one segment was dilated (multivessel or 
multisite procedures), the change in minimal luminal 
diameter per patient was calculated as the average of 
the different lesions. Secondary end points were 
clinical events believed to be related to restenosis. 
These were death (regardless of cause), nonfatal 
myocardial infarction (at least two of the following: 
typical pain, electrocardiographic changes suggesting 
acute myocardial infarction, cardiac enzymes more 
than twice the upper limit of normal), coronary artery 
bypass graft surgery (CABG), and repeat angioplasty 
at the same site. Events were classified as "procedur-
al" (i.e., onset of event or decision to perform another 
procedure taken while the guide catheter was still in 
place), ·'early" (i.e., onset within 24 hours of guide 
catheter removal), or "late" (i.e., onset more than 24 
hours after guide catheter removal). Another second-
ary end point was the presence and severity of angina 
pectoris as assessed by the Canadian Cardiovascular 
Society classification at last follow-up. 
Statistical Methods and Analysis 
The minimal sample size was estimated at the 
outset of the study to be 233 patients in each group 
on the assumption of a change of -0.40±0.50 mm in 
mean minimal lumen diameter between postangio-
plasty and follow-up angiogram in the control groupS 
and -0.25±50 mm (i.e., a 30% difference) in the 
active drug group (two-sided test with an a error of 
0.05 and a power of 0.90). 
In the comparison between treatment groups for 
the primary angiographic end point, patients in-
cluded were those who had a successful initial angio-
plasty, had a quantitatively analyzable PTCA angio-
gram, had follow-up angiogram made while on trial 
medication, and were compliant with trial medication 
(had used at least 80% of their trial medication 
during the intervening period and had not discontin-
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TADLE3. Clinical &sdine Dnta of 697 Patients Included in Analysis for Clinical End Points 
Control (n »6) GR32191B (n-351) 
n % n % 
Men (n) 276 80 279 80 
Age (years) 56.9.:!:9.0 56.6:+::9.0 
Ever smoked 259 75 2SO 80 
Current smoker 40 12 57 16 
Diabetes 2S 8 29 8 
History of hypenension Ill 32 120 34 
Lipids (mmol/1) 
Total cholesterol 6.2:+: 1.1 (n:337) 6.2:1.2 (n-"'345) 
LDL cholesterol 4.2:+::1.2 (n=240) 4.1=::1.3 (n"'2Sl) 
HDL cholesterol 1.1:+::0.5 (n=290) 1.2:!:0.5 (n"'297) 
CCS class 
I 37 II '2 12 
II Ill 32 116 33 
Ill 141 'I 140 40 
IV 57 16 52 15 
Pain at rest controlled by intravenous nitrates 
" 
12 
"' 
14 
Duration of angina (months) 2:+::44 24:+::45 
Previous MI 134 39 132 38 
Previous CABG 7 2 12 3 
Previous angioplascy 4 6 2 
Patients on medication 
Nitrates 235 68 225 64 
Calcium antagonists 208 60 222 63 
{3-Blockers 175 51 191 
" Mono therapy 97 2S I <>I 30
Double therapy !51 44 !56 44 
Triple therapy 73 21 74 21 
LDL, low density lipoprotein: HDL, high density lipoprotein; CCS. Canadian Cardiovascular Society angina 
classification: MI. myocardial infarction; CABG, coronary artery bypass graft surgery. 
ued trial medication for more than 3 days). To test 
the null hypothesis that both mean changes in mini-
mallumen diameter are equal, an unpaired t test was 
used and a 95% confidence interval for the effect 
measure was obtained. 
Comparisons for each clinical event were made 
on the basis of intention to treat (i.e., with inclusion 
of all patients who were randomized- defined as 
having taken at least their initial oral dose of trial 
medication- and regardless of angioplasty outcome 
or trial medication compliance). Also, the clinical 
status of each patient at the end of follow-up was 
ranked by assignment to the lowest applicable 
category of the following ordinal scale: 1, death; 2, 
nonfatal myocardial infarction; 3, status after 
CABG; 4, status after repeat PTCA; 5, presence of 
angina pectoris (Canadian Cardiovascular Society 
classification of 1 or higher); and 6, none of the 
above. The percentages of patients in each of these 
categories were compared between treatment 
groups on the basis of intention to treat. For all 
comparisons, the null hypothesis of no difference 
was tested by appropriate statistical tests. 
Results 
A total of 707 patients were randomized. Of these 
patients, 353 were randomized to receive GR32191B, 
and 354 were randomized to the control group. 
Selected demographic, clinical, and angiographic 
characteristics of the two study groups are shown in 
Tables 2 and 3. No baseline differences were ob-
served between the !'No groups. 
Figure 1 shows the patient flow and the reasons 
that subjects could not be evaluated with respect to 
quantitative angiographic restenosis. In 10 patients, 
angioplasty was not performed. One patient, who 
could not be treated because of radiographic equip-
ment failure, was rerandomized 2 weeks later and 
retrospectively excluded as a protocol violator (pre-
vious participation in the trial was an exclusion 
criterion). Angioplasty was successful in 322 of the 
treated patients and 327 of the control group. Angio~ 
plasty was unsuccessful in 29 patients in the treated 
group and 19 in the control group. Thus, 322 treated 
patients and 327 control patients undeiWent success-
ful angioplasty of at least one lesion and were eligible 
for follow-up angiography. Quantitative angiographic 
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FiGURE L Schematic of patient flow in Coronary Artery 
Restenosis Prewntion on Repeated Thromboxane-Amagoni$m 
trial and reasons why no follow-up angiogram and/or quantita-
tive anffwgraphy was obtained. Angio, coronary angiography; 
CABG, coronary aFtery bypass graft surgery; CAAS, coronary 
artery analysis system; DS, dio.mder stenosis; FU, follow-up; 
angioplasf)~ percu.toneous transluminal coronary angioplasty. 
*Patient randomized twice and excluded from triaL 
follow-up as not available in 74 cases (35 treated and 
39 control). In 18 cases, quantitative angiography 
could not be obtained for a variety of reasons: 
peripheral vascular problems (n =3), intercurrent 
noncardiovascular disease rendering repeat catheter~ 
ization not desirable (n=9), one patient moved to 
another country, three patients undenvent CABG 
without preoperative recatheterization, one cinefilm 
was lost, and one film was damaged during process~ 
ing. Finally. 53 patients did not fulfill the compliance 
criteria and were excluded from the quantitative 
angiographic efficacy analysis (Figure 1 ). 
Result of Angiographic Efficacy Arw.lysis 
Table 4 and Figure 2 summarize the quantitative 
angiographic findings of the efficacy analysis. At 
follow~up, the loss of minimal lumen diameter was 
identical in both groups: -0.31 mm (treatment effect, 
0 mm; 95% confidence intervals. -0.09, 0.09). Figure 
100 CUM% 
90 
80 
70 
60 
so 
40 
3 
2 
0 
0.0 0.5 
- CONTROL N•261 
- GA321918 N•261 
MLD (mm) 
LS 2.0 2.5 3.0 
FIGURE 2. Cumulative distribwion curve of minimal lumen 
diameter before percutaneous transluminal coronary angio-
plasty (PTCA),post-PTCA. and at 6-monthfollow-up (F-UP) 
in. both treatment groups. CUM %, cumulative percentage of 
patients; MLD, minimal luminal diameter. 
3 is a cumulative curve of the change in minimal 
lumen diameter observed in both groups. A Joss of 
0.72 mm or mores·17 corresponds to restenosis rates 
of 19% in the control group and 21% in the treated 
group. Therefore, the relative risk for rcstenosis in 
the treated group with respect to the control group is 
1.15 (95% confidence intervals, 0.82, 1.60). 
Results of Bicycle Ergometry 
Of 649 patient who had a successful angioplasty, 
539 underwent exercise testing at follow-up. Reasons 
for not performing the test were death (2 patients), 
unstable angina (45 patients), inability to perform the 
TADLE 4. Quantitative Analysis of 636 Lesions in 522 Patients 
Obstruction diameter (mm) 
Before angioplasty 
After angioplasty 
Follow-up 
Reference diameter (mm) 
Before angiop!asty 
After angioplasty 
Follow-up 
Difference in obstruction diameter (mm) 
After angioplasty minu~ before 
Control 
(n=261) 
0.99:::0.35 
1.77:!::0.34 
1.46:!::0.59 
2.64:!::057 
2.71:!::0.54 
2.72:!::.0.55 
GR3219IB 
(n=261) 
1.06:!::0.39 
1.79:!::0.33 
1.49:::058 
270:!::0.50 
2.76:!::0.48 
2.74:!::0.52 
angiop!asty 0.78:!::0.39 0.73:!::0.38 
Follow-up minus after angioplasty -0.31:!::0.54-0.31:::0.55 
Percentage stenosis(%) 
Before angioplasty 62:13 61:!::12 
After angioplasty 34:!::9 34:!::9 
Follow-up 46:!::19 45:!::19 
Difference in percentage stenosi~ (%) 
After :mgioplasty minus before 
;mgiop!osty -28:14 -26:!::14 
Follow-up minus after <~ngioplast:o 12:20 11:!::19 
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" 
" 
CONTROL (N•261) 
GR 32191B (N•261) 
FIGURE 3. Cumulative distribution curve of change in min-
imal lumen. diameter from after angioplasty to follow-up in 
both treatment groups. CUM %, cumulative percentage of 
patients; MLD, minimallumirwl diameter. 
test (19 patients), refusal (33 patients), and other (11 
patients). Table 5 summari~es resul~ of exercise 
testing in both groups. No dtfference m any param-
eter was observed at submaximal or maximal exer-
cise. ST deviation (depression or elevation) of more 
than 0.1 mV (more than 1 mm) associated with 
anginal symptoms (considered positive) was o~serv<:d 
in 47 patients in the control group and 55 patient!> m 
the GR32191B group. 
Clinical Follow-up 
Table 6 shows the total number of events during 
6-month follow-up as well as the ranking of clinical 
status 6 months after an~oplasty for all 697_patients 
randomized. Adjusted x· test revealed no difference 
in ranking between the two groups. At 6-month 
follow-up, a comparable number of patients in both 
treatment groups were in each Canadian Cardiovas-
cular Society class. Finally, 194 patients (56%) in the 
TABLES. Exercise Test Results 
Control GR32191B 
(n=262) (n=277) 
n % n % 
Position 
Supine 9S 38 no 40 
Sitting 164 62 167 60 
ST deviation >0.1 mV 102 39 117 42 
Anginal symptoms during test 76 32 73 30 
Combination of >0.1 mV segment 
deviation and symptoms 47 18 55 20 
Mnximum work load (W) 142:.41 144:.40 
Expected work load (W) 160:32 161:39 
Elr:ercise time (minutes) 7.8:29 7.8:.3.0 
Systolic blood pressure at peak 
exercise (mm Hg) 193:33 196:31 
Heart rate at peak exercise (min"') 133:24 135:22 
Test perfonned in 539 of 649 patients with successful angioplasty. 
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treated group and 197 (56%) in the control group 
were event and symptom free at 6-month follow-up. 
Results of GR32191B Assay and Platelet 
Aggregation Tests 
In four of the six participating centers, GR32191B 
plasma levels for patients allocated to the _GR32191B 
group were analyzed before first drug mtakc and 
approximately 1 hour after first drug dose. GR32191_B 
was not detected above the limit of quantification m 
the predose samples but was present in the postdosc 
samples at concentrations ranging from 5 to 1,210 
ng/ml, with a mean of 392±241 ng/ml, indicating that 
GR32191B was absorbed into the circulation after the 
oral administration of GR32191B. 
During each follow-up visit of the Rotterdam 
patients, platelet aggregation tests were carried out 
using the TXA~ mimetic U-46619 and ADP as ag-
gregants. During the first three visits (3 weeks, 3 
months, and 6 months after angioplasty). patients 
were on trial medication. The fourth visit (7 months 
after angioplasty) served as a control measurement. 
A total of 162 patients were tested at least one time 
during follow-up (Table 7). Mean ADP aggregation 
during visits 1, 2, and 3, expressed as peak response, 
was 116±12 mm (214 analyses) in the treatment 
group and 125±12 mm (203 analyses) in the control 
group (two-tailed t test, p=0.4). Mean U-46619 ag-
gregation during visits 1. 2, and 3 was 10::!:21 mm (215 
analyses) in the treatment group and 100±35 mm 
(203 analyses) in the control group (two-tailed t test, 
p<0.0001). This significant lowering of U-46619 ag-
gregation in the treated group was observed in all 
except five patients during their 3-month test. These 
five patients showed U-46619 aggregation of more 
than 100 mm. At the 7-month assessment (patients 
off trial medication), mean U-46619 aggregation 
again rose to 80±42 mm (27 analyses) in the treat-
ment group, which is not significantly ~ifferent from 
the value of 99±32 mm (19 analyses) m the control 
group (two-tailed t tcst,p=O.S). 
Bleeding Complications and Tolerability 
Only mild bleeding events occurre~ in the !-Tial. 
In-hospital bleeding events occurred m 18 panents 
(5%) in the control group and 15 patients (4%) in the 
treatment group (hematoma at puncture site of more 
than 5 em, 14 versus 12 patients; prolonged bleeding 
at puncture site. three versus four; hematoma else-
where, one versus none). During follow-up, four 
hematomas were reponed in the control group and 
five in the treatment group. No cerebral bleeding or 
cerebral thrombotic events were encountered during 
the time course of the trial. Generally, the drug was 
well tolerated, and reported side effects were mild 
and evenly distributed in the two treatment groups. 
Total reported side effects were 40 in the control 
group and 44 in the treatment group (epigastric 
discomfort, 19 versus 20 patients; rash. 11 versus 12; 
nausea, six versus three; salivation, none versus two; 
headache, three versus six; fever, one versus one). 
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TADU: 6. Total Number of Events and Rllnking $(::lie 
Total events during 6-month Ranking of clinical Status 6 months 
follow-up :~fter angioplasty 
Control GR3219IB Control GR32191B 
(n=346) (n=351) (n=346) (n=351) 
" 
% 
" 
% 
" 
% 
" 
% 
Death 
'""" 
6 4 
All 6 2 4 6 2 4 
Myocardial infarction 
Procedural 5 5 
Early ll 7 
'""" 
6 
All 22 6 18 5 22 6 18 5 
Bypass graft surgery 
Procedural 3 7 
Early 5 2 
'""" 
18 1S 
All 26 s 27 8 19 6 22 
Repeat angioplasty 
Early 9 6 
'""" 
59 54 
All 68 20 60 17 52 15 49 14 
CCS classification* 
1V 2 0.3 5 2 1 0.3 
1I1 19 6 18 5 11 ll 3 
II 36 11 
" 
14 23 7 30 
26 8 32 9 14 4 19 5 
None 254 75 249 72 194 56 197 56 
CCS, Canadian Cardiovascular Society angina classification. *For 6S7 patients alive at 6-momh follow-up; secondary 
end point. 
Discussion 
Rationale for Selective Thromboxane Blockade in 
Prevention of Restenosis 
At the time of the design of the trial in 1986. it was 
thought that platelet aggregation at the site of endo-
thelial denudation and vascular disruption played a 
pivotal role in the pathogenesis of restenosis. Massive 
platelet deposition and aggregation at the dilatation 
siteD could. on the one hand. lead to organization of 
a mural thrombus28 and, on the other hand, trigger a 
TABU: 7. Platelet ~tion Tests 
fibroproliferative reaction of the vessel wall via the 
release of growth factors and chemotactic agents. 
Balloon angioplasty causes a severe vascular 
trauma that can only be compared with spontaneous 
plaque rupture in unstable anginal syndromes,29 with 
its known deleterious thrombotic consequences. Pre· 
vcntion of thrombotic events by blocking the TXAr 
induced aggregation with aspirin is known to be 
effective in unstable angina30.31 and in the periangio· 
plasty period.32.33 Nevertheless, aspirin may still fall 
Analysis of 
Aggregation agent Visit 1 (3 weeks) Visit 2 (3 months) Visit 3 (6 months) Visit 4 (7 months) variAnce 
ADP active (mm) 116:12 118::!::11 115:14 121:17 NS 
" 
81 72 61 26 
ADP control (mm) 124:13 126:11 127:11 118:11 P""0.03 
" 
81 69 53 19 
U46619 <1ctive (mm) 8:12 7:12 15:34 80::!::42 p<O.OOOl 
" 
81 72 62 27 
U46619 control (mm) 101::!::36 101:34 100::!::37 99:32 NS 
" 
81 69 53 19 
During visits 1. 2. and 3. patients were on trial medication. 
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short as the ideal agent because it is not sufficiently 
specific as an inhibitor of TXA~ production.34 Fur-
thermore, by irreversibly acetylating cyclo-oxygenase 
and preventing the formation of the endoperoxide 
prostaglandin H 2, aspirin can block the production of 
"beneficial'' prostaglandins such as prostacyclin as 
well as the "detrimental'' TXA2• A drug that pre-
served prostacyclin production while inhibiting the 
production or actions of TXA.2 might be expected to 
be superior to aspirin. This could be achieved either 
by a TXA~ synthetase inhibitor or a TXA2-rcceptor-
blocking drug. However, no TXA2 synthetase inhibi-
tor is known to produce a complete blockage of 
TXA2 synthesis. Furthermore, accumulating precur-
sors of TXA2, such as prostaglandin H2, are also 
capable of inducing aggregation via the TXA2-recep-
tors.:IS In contrast, TXA2-receptor blockade will an-
tagonize not only the proaggregatory actions of TXA2 
but also those of agents that act indirectly via TXA2, 
such as collagen, and agents that directly stimulate 
the TXA2-receptor, such as prostaglandin H 2• A role 
for TXA2-receptor blockade after PTCA has been 
suggested by an experimental animal model showing 
reduced intimal hyperplasia after balloon injury of 
rat carotids after treatment with GR32191 (M. Zim-
merman, personal communication). 
GR32191 (in doses of 0.125-1.0 mg/kg p.o) pro-
duced a dose-related antagonism of U-46619-induced 
platelet aggregation ex vlvo, which at the 1-mg/kg dose 
persist'!d for more than 24 hours.36 GR32191B has also 
been demonstrated to produce a long-lasting blockade 
of the TXA.2-receptor on vascular smooth muscle in 
vivo in humans.)(, Chronic dosing (17.5 mg b.i.d.) re-
sulted in progressively increasing antagonism of 
U-46619-induced aggregation such that virtually com-
plete inhibition was achieved over the entire 12-hour 
dosing cycle.37 In healthy volunteers37 as well as in our 
patients, the drug was well tolerated, and bleeding time 
was only slightly prolonged. Finally, GR32191 is en-
tirely devoid of any agonistic actions.3ll 
Trial Design 
The design of CARPORT was based on four 
considerations, each of them having specific conse-
quences. First, it was the underlying assumption that 
TXA:-receptor blockade with GR32191B started be-
fore angioplasty would, at least in theory. affect both 
acute restenosis resulting from platelet aggregation-
induced thrombus formation and chronic restenosis 
resulting from platelet aggregation-induced hyper-
plasia. Second, in view of the fact that patients in 
whom angioplasty did not succeed are not "at risk" 
for restenosis, trial medication was continued only in 
case PTCA was successful. Third, at this stage of the 
development of the therapeutic principle involved, it 
was considered necessary to establish the mechanism 
of action by direct observation of restenosis by angi-
ography. As a consequence, the protocol included 
follow-up angiography regardless of clinical status. 
Within-patient change of minimal lumen diameter, 
as assessed by objective, quantitative measurements 
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of coronary segments filmed in multiple matched 
projections, was chosen as primary end point. Fur-
thermore, the number of patients was planned based 
on what was known about the reproducibility of this 
method rather than on the need to have sufficient 
power for detecting an effect on clinical outcome 
(which would have required a much larger number of 
patients). Fourth, it was considered unethical not to 
give any protection against acute thrombotic events 
during angioplasty to participating patients.32.33 As a 
consequence, one dose of intravenous aspirin was 
given before PTCA to the control group before 
placebo was started. 
Loss in Minimal Luminal Diameter as Primary End 
Poini: A Noncategorical Approach 
The reappearance of angina as a sole criterion of 
restenosis underestimates the angiographic rate of 
restenosis, and the value of recurrent anginal symp-
toms as a marker of restenosis is difficult to assess in 
many studies because the timing and completeness of 
angiographic follow-up often have been determined 
by symptomatic status.3~ 
In the present trial, repeat catheterization with quan-
titative angiography was obtained in 885% of 649 
patients with a successful angioplasty. A majority of 
patients (354 of 522, or 68%) were recatheterized in the 
6-month (±2 weeks) time interval. The remaining 
patients underwent early recatheterization because of 
clinical suspicion for restenosis. Of the 522 compliant 
patients who had angiography at follow-up, 345 were 
angina free and 165 were symptomatic at follow-up. As 
shown in Figure 4B, there was considerable overlap 
between the change in minimal lumen diameter of 
patients with and of those without angina at follow-up 
angiography. This underscores that reappearance of 
angina is a poor proxy to the anatomic substrate at issue 
and confirms the poor predictive value of symptoms 
found in other studies?' which maybe explained by the 
presence of other mechanisms for angina, such as 
incomplete revascularization or progression of disease 
in other vessels. 
Several studies have examined the usefulness of 
ergometry to detect restenosis after angioplasty.39 
These studi~s have generally found that the presence 
of exercise-induced angina, ST segment depression, 
or both is not highly predictive of restenosis whether 
the test is performed early or late after angioplasty.39 
Figure 4B illustrates this for our data in a similar 
fashion as for angina. In view of the above, quanti-
tative coronary angiography has emerged as the most 
reliable method for judging late results. 
In studies evaluating the biology of restenosis, a 
continuous measure of the degree of lumen obstruc-
tion is preferable because any progression of the 
stenosis reflects the process of interest regardless of 
whether an arbitrarily defined threshold of obstruc-
tion is reached. Keeping in mind that an angie-
graphic restenosis study assesses only the anatomic 
component of the restenosis problem, there is no 
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FIGURE 4. Top panel: Cumulative distribution (CUM %) 
curve of change in minimal lumen diameter (MLD) for 
symptomatic and asymptomatic patients at follow-up angif.Jg-
raphy. Bottom panel: Cumulative distribution (CUM %) 
curve of change in minimal lumen diameter (MLD) for 
patients with positive ergometry and negative ergometry at 
follow-up angiography. 
threshold above which a loss of lumen diameter 
would have clinically significant functional or symp-
tomatic consequences. Why, then, would one try to 
define a threshold above which there would be 
"significant" quantitatively determined angiographic 
restenosis? To define the threshold on consideration 
of reproducibility of the measurement in individual 
patients is also questionable. The expected benefit of 
a treatment can be measured with much greater 
precision by using the change in lumen diameter for 
the group. If it is assumed that treatment reduces the 
loss of lumen diameter from 0.4 mm under control 
conditions to 0.25 mm under active medication, 233 
patients per treatment group are required for there 
to be a power of 90%. The above reduction corre-
sponds with restenosis rates (defined as a loss of 
minimal lumen diameter of 0.72 mm or more) of 25% 
and 17.5%, respectively.5,17 This difference, however, 
can be statistically detected only with 620 patients 
per treatment group (power, 90% ). Thus., statisti-
cally, the quantitative outcome determined from 
direct measurements of continuous variables can be 
evaluated with only one third of the number of 
patients required for the categorical outcome. This is 
logical because categorical end points do not take full 
advantage of the available information. 
Possible ExplanaJions for Lack of Effect 
ofGR32191B 
In this trial, TXA2-receptor blockade failed to 
demonstrate prevention of angiographic restenosis 
after angioplasty. Also, there was no apparent effect 
on overall clinical outcome. There are several possi-
ble explanations. 
First, it could be hypothesized that the absence of 
benefit was due to poor absorption. In four partici-
pating clinics, plasma levels of GR32191B before first 
drug dose and 1 hour afterward confirmed an excel-
lent gastrointestinal resorption of the drug in this 
group of patients with coronary artery disease who 
were fasting while awaiting an angioplasty procedure. 
Second, compliance could have been poor. Aggrega· 
tion tests in one participating clinic showed that a 
90% reduction of platelet aggregation via the TXA2 
pathway was achieved in the treated group through-
out the entire study. This indicated that patients were 
taking their medication and that the drug was phar-
macologically active. Third, it might be hypothesized 
that this substantial reduction in the aggregatory 
response of the platelet is still insufficient to prevent 
a substantial release of other factors involved in the 
initiation of the proliferative response.D.40-42 In a 
recently published study, it was shown that GR32191 
had no effect on primary aggregation induced by 
ADP, adrenaline, or platelet aggregating factor.43 In 
the present study, GR32191 was found to inhibit only 
70% of the total platelet deposition on deendothe-
lialized rabbit aorta using min-labeled human plate-
lets from whole blood.43 This was similar to the 
maximum inhibition achieved with p:•ostacyclin and 
aspirin. Because several clinical trials with aspirin 
after balloon angioplasty have failed to prove a 
beneficial effect on rcstenosis,:;z,44-46 it might be 
retrospectively inferred that a similar level of platelet 
inhibition would also fail to alter the restenosis rate. 
Furthermore, the magnitude of TXA1-receptor 
blockade needed after balloon-induced vascular 
damage is nOt known. For example, a substantial 
increase in plasma levels of TXA~ metabolite 11-
dehydro-thromboxane ~ from less than 50 to 174 
pg/ml has been measured in the great cardiac vein 
after angioplasty of the left anterior descending 
coronary artery, despite pretreatment with aspirin.47 
One could question whether TXAz-receptor block-
ade is effective in the face of such an increase, 
although it has been demonstrated that GR32191 can 
achieve a more-than-100-fold displacement to the 
right of the platelet aggregation concentration-effect 
curve for U-46619 in healthy subjects.% 
More recently, it has been advocated that inhibi-
tion of platelet adhesion is a more efficient means to 
prevent subsequent aggregation of platelets.48-5l 
However, it can be argued that complete inhibition of 
adhesion will cause untoward bleeding effects. 
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Finally, the pivotal role of the platelet in the 
initiation of the restenosis process might have been 
overestimated.,52 and antiplatelet therapy as the sole 
modality of treatment may be intrinsically insufficient 
to control the restenosis phenomenon. 
Appendix 
CARPORT Study Group 
Study Chairman 
Patrick W. Serruys, MD. 
Participating Clinics and Investigators 
Thoraxcemer, Rotterdam The Netherlu.nds. P.W. 
Serruys, MD, Principal Investigator; B.J. Rensing, 
MD. H.E. Luijten, MD, PJ. de Feyter, MD. H. 
Suryapranata, MD, M. van den Brand, MD, and 
J.R.T.C. Roelandt, MD. 
Klinikum Charlottenburg. Berlin, Germany. W. 
Rutsch, MD, Principal Investigator; M. Klose, MD. 
C.H.R U de Nancy-Hopilaux de Bra bois, Nancy, 
France. N. Danchin, MD, Principal Investigator; Y. 
Juilliere, MD, A. Hueber, MD, and F. Cherrier, MD. 
Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium. G.R. 
Heyndrickx, MD, Principal Investigator; P.Nellens, 
MD, B. de Bruyne, MD, M. Goethals, MD, and P. 
Goemare, RN. 
SL Antonius Ziekenhuis, Nieuwegcin, The Nether-
lu.nds. E.G. Mast, MD, Principal Investigator; F. 
Jonkrnan, MD, and R.M. Tjon Joe Gin, MD. 
U.C.L. St. Luc University Hospi1a4 Brnssels, Bel-
gium. W. Wijns, MD, Principal Investigator; M. Del-
gadillo, and J. Renkin, MD. 
Data Coordinating and Analysis Center 
SOCAR SA., Givrins, Switzerlu.nd. M. Bokslag, J. 
Vos, MD, and J. Lubsen, MD. 
Data Monitoring and Ethical Commiltee 
University of Southampton, Southampton, UK D.A. 
Wood, MD. 
Klinikum Bogenhausen, Miinchen, Germany. Th. 
Ischinger, MD. 
Chest Hospilal, London, UK R. Balcon. MD. 
Critical Events Committee 
University of Southampton, Southampton, UK D.A. 
Wood, MD. 
Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium. G.R. 
Heyndrickx, MD. 
C.H.RU de Nancy-Hopitaux de Brabois, Nancy, 
France. N. Danchin, MD. 
Quantilative Angiographic Core Laboratory 
Cardialysis/Thoraxcenter, Rotterdam The Nether-
lu.nds. P.W. Serruys, MD, B.J. Rensing, MD, W.R.M. 
Hermans, MD. and J. Pameyer, RN. 
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ta~ Rotterdam, The Netherlu.nds. 1. Stibbc, MD. 
Glaxo Group Research Ltd. 
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Abstract 
To determine which quantitative angiographic parameter best describes functional status 
6 months after coronary balloon angioplasty, we studied 350 patients with single vessel 
coronary artery disease who underwent a single site balloon dilatation. Sensitivity and 
specificity curves for the prediction of anginal status and exercise electrocardiography of 
4 quantitative angiographic variables were constructed. The point of highest diagnostic 
accuracy for the variables was determined at the intersection of the sensitivity and 
specificity curves. Exercise electrocardiography was considered indicative for ischemia 
if horizontal or downsloping ST segment depression of ::: 1 mm occurred. The points of 
highest diagnostic accuracy of the angiographic parameters were similar for both anginal 
status and exercise electrocardiography; 1.45 mm and 1.46 mm for the minimal lumen 
diameter measurements, 45.5% and 46.5% for the % diameter stenosis measurements 
at follow-up, -0.30 mm and -0.32 mm for change in minimal lumen diameter aod -10% 
aod -10% for the change in percent diameter stenosis at follow-up. Angiographic 
parameters reflecting a change in lesion severity at follow-up angiography were only 
slightly less accurate than parameters that describe lesion severity at follow-up. The large 
number of patients studied and the fact that the same optimal values for diagnostic 
accuracy of the various quantitative angiographic variables were obtained for the 
prediction of 2 different markers of ischemia suggests that these values reflect the lesion 
severity or increase in lesion severity in major epicardial vessels at which coronary flow 
reserve is unable to meet myocardial demands. 
Key words: 
-Percutaneous Transluminal Coronary Angioplasty 
-Restenosis 
-Functional Status 
-Quantitative Angiography 
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IN1RODUCDON. 
Soon after the introduction of percutaneous transluminal coronary balloon angioplasty 
the vexing problem of restenosis became apparent. Approximately 30-40% of patients 
will show functional and/or angiographic signs of restenosis in the first months after a 
successful angioplasty procedure. A multitude of angiographic restenosis criteria have 
been developed over the last 12 years [1]. Restenosis criteria currently in use can be 
divided in those that describe the change in lesion severity from the post angioplasty 
situation up to the follow-up angiogram and those that merely describe lesion severity 
at follow-up angiography. An example of the first category is the loss in lumen diameter 
of more than 0.72 mm as proposed by Serruys [2], and an example of the latter category 
is the criterion of > 50% diameter stenosis at follow-up. Criteria that describe a change 
in lumen diameter may ignore the functional significance of the lesion at follow-up, 
especially in large vessels [3], whilst criteria that only describe the situation at follow-up 
will preselect lesions with a suboptimal result after angioplasty and thereby disregard the 
magnitude of the reactive intimal hyperplasia [1]. Recurrence of a flow-limiting stenosis 
can usually be identified by symptoms of chest pain similar to those that occurred before 
angioplasty. In addition to the medical history, exercise electrocardiographic testing is 
generally performed as a non invasive approach to confirm the recurrence of a coronary 
artery obstruction because it is a relatively simple, safe and inexpensive test. To 
determine which quantitative angiographic variable best predicts the functional status of 
the individual patient, we studied the recurrence of anginal complaints and positive 
electrocardiographic exercise testing 6 months after a successful angioplasty of a selected 
patient group with single vessel disease and single site dilatation. The functional 
parameters (recurrence of angina and positive exercise testing) were correlated with 
quantitative angiographic variables of change in lesion severity (change in minimal lumen 
diameter (MLD), change in percent diameter stenosis) and variables that merely describe 
lesion severity at follow-up angiography (MLD and percent diameter stenosis). 
METHODS 
Study population. The original patient group consisted of 697 patients that were 
enrolled in the multicenter CARPORT triaL A list of participating centers and 
investigators has been published previously [4]. Identical angiographic and clinical 
outcomes were observed in both randomization groups, so that the placebo- and active 
treatment group were pooled for the present study [4]. Selection criteria for this trial 
have been published previously [4]. Of the 697 patients, 649 had a successful procedure, 
defined as a less than 50% residual stenosis by visual inspection of the post angioplasty 
angiogram and no occurrence of in-hospital complications (death, acute myocardial 
infarction, bypass grafting, repeat angioplasty or symptom recurrence). Five hundred 
seventy five patients underwent subsequent follow-up angiography that was suitable for 
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quantitative analysis (follow-up rate 88.6% ). Of these 575 patients, 350 had single vessel 
coronary artery disease and underwent a single site dilatation and therefore it was 
presumed that complete revascularization was achieved in this group of patients. All 
patients signed informed consent and the study protocol was approved by the institutional 
review boards of the participating centers. 
A:ngioplasty procedure and follow up angiography. Coronary angioplasty was 
performed with a steerable, movable gnide wire system via the femoral route. Details of 
the procedure have been described previously [4]. 
Three coronary angiograms were obtained in each patient, one just before 
angioplasty, one immediately after angioplasty, and one angiogram at follow-up. The 
angiograms were recorded in such a way that they were suited for quantitative analysis 
by the Cardiovascular Angiography Analysis System (CAAS). All necessary details of the 
procedure were recorded and drawings of the segments to be analyzed were made. For 
calibration purposes the cathetertips were cut off for later measurement with a 
m.icrocaliper. To standardize the method of data acquisition and to ensure exact 
reproducibility of the angiographic studies, measures were taken as described previously 
[4-6]. All angiograms were processed and analyzed in a central core-laboratory. The 
follow-up coronary angiogram was performed at six months follow-up. If symptoms 
recurred within 6 months, coronary angiography was carried out earlier. If no definite 
restenosis was present and the follow-up time was less than 4 months, the patient was 
asked to undergo another coronary arteriogram at 6 months. 
Quantitative angiography. All cineangiograms were analyzed using the computer 
assisted cardiovascular angiography analysis system (CAAS) which has been described 
and validated earlier [7-9]. A computer derived reconstruction of the original arterial 
dimension at the site of obstruction (assuming there is no disease present) is used to 
define the interpolated reference diameter. In case of a total occlusion a value of 0 for 
the minimal lumen diameter and 100% for the percent diameter stenosis was substituted. 
The mean change in minimal lumen diameter from post-angioplasty angiography to 
follow-up angiography and from pre-angioplasty to post-angioplasty was derived from 
matched angiographic projections. 
Follow-up evaluation and bicycle ergometry. One to four days prior to follow-up 
catheterization each patient was seen in the outpatient clinic for an interview, physical 
examination and a symptom limited exercise test. Assessment of anginal complaints and 
test evaluation was documented at the individual centers prior to repeat angiography and 
thus without knowledge of the coronary anatomy. Typical anginal complaints were 
classified according to the Canadian Cardiovascular Society angina classification. The 
exercise test was performed on a bicycle ergometer according to two different protocols. 
In Berlin the test was performed in a supine position, starting with a workload of 25 
watts which increased by 25 watts every 2 minutes. In the other 5 participating clinics the 
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test was performed in a sitting position, slatting with a workload of 20 watts which was 
increased by 20 watts every minute. Exercise was continued until anginal symptoms, a 
drop in systolic blood pressure, severe arrhythmia, or a horizontal or downsloping ST 
segment depression of more than 1 mm developed. A 12 lead ECG was recorded during 
exercise and recovery. ST changes were measured 80 ms after the J point. Horizontal or 
downsloping ST segment depression in any lead of at least 1 mm, as measured with 
calipers, was considered a positive response to the stress-test. 
Of the 350 study patients, 330 performed an exercise test at follow-up. Reasons 
for not performing the exercise test were: unstable angina: 14 patients, orthopedic 
problems: 5 patients and refusal: 1 patient. None of the patients used digitalis or showed 
a bundle branch block on the ECG, rendering the exercise ECG uninterpretable. 
Restenosis criteria. Sensitivity and specificity for anginal status at follow-up and 
exercise testing at different cut-off points of continuous quantitative angiographic 
variables were determined. The angiographic variables were classified as either 
describing the lesion severity at follow-up angiography, '"static variables": percent 
diameter stenosis and minimal lumen diameter, or as describing the change in lesion 
severity at follow-up angiography, '"dynamic variables'": change in percent diameter 
stenosis and change in minimal lumen diameter. In addition, diagnostic accuracy of six 
previously proposed definitions of restenosis was determined; ( 1) an increase in diameter 
stenosis of at least 30% by the time of follow-up angiography (National Heart, Lung and 
Blood Institute criterion 1 [NHLBI 1]), (2) an immediate post-angioplasty diameter 
stenosis of less than 50% increasing to greater than or equal to 70% at follow up 
(NHLBI 2), (3) an increase in stenosis severity to within 10% or less of the predilatation 
diameter stenosis at the time of follow-up angiography (NHLBI 3), ( 4) a loss of at least 
50% of the gain achieved at aogioplasty (NHLBI 4), (5) increase of lesion severity to 
more than 50% diameter stenosis at follow-up, (6) deterioration in minimal lumen 
diameter of at least 0.72 mm from immediately post-angioplasty to follow-up. The latter 
criterion is based on the long-term variability of minimal lumen diameter measurements 
using the CAAS system (036 mm). This variability is 1 standard deviation of the mean 
difference of 2 measurements of the same lesion filmed at 2 catheterization sessions on 
average 90 days apart [7]. This long term variability reflects the long-term random 
variation in lesion measurements from coronary angiograms made at different 
catheterization sessions using the CAAS system [7]. The use of 1 standard deviation 
would include 683% of the variability, while the use of 2 standard deviations (2 x 036 
~ 0.72 mm) includes 95.5% of the variability. 
RESULTS 
Table 1 summarizes the baseline characteristics of the 350 study patients. No 
differences were found in the proportion of patients with recurrent angina and ST 
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depression at exercise with respect to the vessel dilated (Table 2). The occurence of Q 
waves in the area supplied by the dilated artery as an indicator of prior transmural 
infarction (table 2) was low. 
Table 1. Baseline characteristics of the study population. 
No of patients 
Male gender 
Age (years) 
Time to follow-up angiography (days) 
Dilated artery 
LAD 
RCA 
LCX 
History of previous MI 
350 
285 (81.4%) 
56 :!: 9 (range 29-77) 
172:!: 37 
194 (55.4%) 
92 (263%) 
64 (18.3%) 
115 (32.9%) 
Values as mean :!: 1 standard deviation, LAD left anterior descending artery, LCX left 
circumflex artery, MI;myocardial infarction, RCA;right coronary artery. 
Recurrent angina and quantitative angiography. At follow-up 102 of 350 patients 
(29%) had recurrent angina. Percentage correct classification of recurrence of angina 
(sensitivity) and percentage correct classification of absence of angina at follow up 
(specificity) as a function of cut-off points for the different quantitative angiographic 
variables are given in figure 1. The point of intersection of the sensitivity and specificity 
curves represents the cut-off point for which diagnostic accuracy was best. The "static" 
variables minimal lumen diameter at follow-up and percent diameter stenosis at 
follow-up, performed equally well with a sensitivity and specificity slightly above 70% at 
cut-off points of 1.45 mm and 465 % respectively. Parameters that reflect the change in 
lesion severity from directly post angioplasty to follow-up performed only slightly less 
favorable, with a sensitivity and specificity of just below 70% at cut-off points of -030 
mm for the change in minimal lumen diameter and -10 % for the change in percent 
diameter stenosis. In order to compare the diagnostic accuracy of the different variables, 
receiver operator characteristic (ROC) curves were constructed (figure 3). Quantitative 
angiograpbic parameters denoting a change in lesion severity are only slightly less 
accurate than those that denote a static measurement of lesion severity at follow-up. 
Positive exercise test and quantitative angiography. The exercise test result was 
abnormal in 116 patients (35% ). Percentage correct classification for an abnormal test 
(sensitivity) and percentage correct classification for a normal test (specificity) as a 
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Table 2. Ischemia at follow-up and prior Q wave infarction by vessel type. 
Proportion of patients with recurrent angina and 
LAD dilatation 
RCA dilatation 
LCX dilatation 
Proportion of patients with ST 
depression of ::: 1 mm at exercise and 
LAD dilatation 
RCA dilatation 
LCX dilatation 
Proportion of patients with LAD dilatation and 
Q wave in ECG leads V1 to V5 
Q wave in ECG leads II,III,a VF 
Q wave in ECG leads V6,aVL 
Proportion of patients with RCA dilatation and 
Q wave in ECG leads II,III,a VF 
Q wave in ECG leads V1 to V5 
Q wave in ECG leads V6,aVL 
Proponion of patients with LCX dilatation and 
Q wave in ECG leads V6, aVL 
Q wave in ECG leads V1 to V5 
Q wave in ECG leads II,ID,a VF 
28.9% (56 of 194 patients) 
28.3% (26 of 92 patients) 
31.3% (20 of 64 patients) 
37.0% (67 of 181 patients) 
28.7% (25 of 87 patients) 
38.7% (24 of 62 patients) 
10.3% (20 of 194 patients) 
17.0% (33 of 194 patients) 
18.6% (36 of 194 patients) 
3.3% (3 of 92 patients) 
32.6% (30 of 92 patients) 
28.3% (26 of 92 patients) 
20.3% (13 of 64 patients) 
23.4% (15 of 64 patients) 
3.1% (2 of 64 patients) 
p=033* 
p=091* 
LAD=left anterior descending anery, LCX=left circumflex anery, RCA=rigbt coronary 
artery. * Pearson chi-square test 
137 
function of cut-of points for the different quantitative angiographic variables are given 
in figure 2. It is clear that the diaguostic accuracy of exercise testing was lower than for 
anginal status at follow-up. The optimal combination of sensitivity and specificity was 
around 60% for all angiographic variables, with the "static" variables performing slightly 
better than the ''variables of change" (figure 2). However, the cut-off points associated 
with the point of intersection of the sensitivity and specificity curves were similar to those 
obtained with anginal status. This was 45.5 % diameter stenosis at follow-up, 1.46 mrn 
minimal lumen diameter at follow-up, a change of 10% in diameter stenosis and a 
change of 0.32 mm in minimal lumen diameter. ROC curves for the different quantitative 
angiographic variables are shown in figure 4. 
Recurrent angina, positive exercise test and restenosis criteria in current use. 
Table 3 and 4 list the sensitivity, specificity and predictive values for recurrent angina 
and a positive exercise test of different previously proposed restenosis criteria. None of 
the criteria predicted recurrent angina and positive exercise testing with great accuracy. 
In particular a positive exercise test was very hard to predict with all angiographic 
restenosis criteria. Criteria that require a large change (NHLBI 1 and the :': 0.72mm 
criterion), and the NHLBI 2 criterium that requires an extraordinary high diameter 
stenosis at follow-up, had a low sensitivity. In fact the NHLBI 2 criterion is more a pre-
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Figure la and lb. Percentage correct classification of recurrence of angina (sensitivity) and 
percentage correct classification of absence of angina at follow up (specificity) as a function 
of cut-off points for the different quantitative angiographic parameters. The point of 
intersection of the 2 curves denotes the cut-off point with the highest diagnostic accuracy. 
Where appropriate the 50% diameter stenosis and the >0.72mm loss in MLD restenosis 
criteria were drawn in the figure. Fiwe 1 a: curves for minimal lumen diameter at follow-
up. Firure 1 b: curves for percent diameter stenosis at follow-up. MLD = minimal lumen 
diameter, Sens = sensitivity, Spec = Specificity 
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Figure lc and ld. Legend as for figure I a and lb. Fiwe Jc: curves for change in minimal 
lumen diameter at follow-up. Figure I d: curves for change in perceru diameter stenosis at 
follow-up. DS = diameter stenosis, MLD = minimal lumen diameter, Sens = sensitivity, 
Spec = Specificity 
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Figure 2a and 2b. Perceruage correct classification of positive exercise electrocardiography 
(sensitivity) and percentage correct classification of negative exercise electrocardiography 
(specificity) at follow up as a function of cut-off points for the dijfereru quantitative 
angi.ographic parameters. The point of intersection of the 2 curves denotes the cut-off point 
with the highest diagnostic accuracy. Where appropriate the 50% diameter stenosis and the 
>:_O.nmm loss in MLD restenosis criteria were drawn in the figure. Figure 2a: curves for 
minimal lumen diameter at follow-up. Firure 2b: curves for percent diameter stenosis at 
follow-up. MLD = minimal lumen diameter, Sens = sensitivity, Spec = Specificity 
139 
100 100 
90 90 SENS(% 
80 80 
70 70 
SPEC(%) 
60 60 
50 50 
40 40 
30 30 
20 20 
10 c 10 D 
0 0 
-2.5 -2 -~5 -1 -0.5 0 0.5 -80 -60 -40 -20 0 20 
CHANGE IN MLD (mm) CHANGE IN DS (%) 
Figure 2c and 2d. Legend as for figure 2a and 2b. Fir:ure 2c: curves for change in minimal 
lumen diameter at follow-up. Fi~re 2d: curves for change in percent diameter stenosis at 
follow-up. DS = diameter stenosis, MLD = minimal lumen diameter, Sens = sensitivity, 
Spec = Specificity 
Figure 3- Receiver-Operator Characteristic (ROC) curves for comparison of the diagnostic 
accuracy of anginal status at follow-up for minimal lumen diameter at follow-up (solid line), 
percent diameter stenosis at follow-up (normal line), change in minimal lumen diameter 
(dotted line with squares) and change in percent diameter stenosis (dotted line with asterisks). 
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Figure 4. Receiver-Operator Characteristic (ROC) curves for comparison of the diagnostic 
accuracy of exercise electrocardiography for minimal lumen diameter at follow-up (solid 
line), percent diameter stenosis at follow-up (nonnal line), change in minimal lumen 
diameter (dotted line with squares) and change in perceru diameter stenosis (dotted line with 
asterisks). 
dictor of total occlusions since 22 of 26 lesions that fulfilled this criterion were totally 
occluded at follow-up. For the 330 patients that underwent exercise testing, 19 of the 22 
lesions that fulfilled the NHLBI 2 criterium were totally occluded at follow-up. The 
NHLBI 3 and 4 criteria and the :0:50%diameter stenosis criterion performed better. 
The 50% diameter stenosis cut-off point lies close to the optimal cut-off point of 465% 
and is therefore one of the best predictors of recurrent angina or positive exercise 
testing, whereas the NHLBI 1 criterion (change in diameter stenosis :0:30%) and the 
:o:0.72nun criterion are clearly remote from the optimal cut-off points of -10% and -0.32 
mm respectively (figure lc, 1d and figure 2c, 2d). 
Table 3. Diagnostic accuracy of different angiographic restenosis criteria for patients with recurrent angina. 
Criterion 
Characteristic NHLBI 1 NHLBI 2 NHLBIY NHLBI 4* ?:50%DS :::0.72mm 
Prevalence of restcnosis 11.4% (40/350) 7.4% (26/350) 31.2% (109/349) 34.7% (121/349) 31.7% (111/350) 17.7% (62/350) 
Sensitivity 28.4% (29 /102) 20.6% (21/102) 60.8% (62/102) 64.7% (66/102) 63.7% (65/102) 39.2% (40/102) 
Specificity 95.6% (237/248) 98% (243/248) 81% (200/247) 77.7% (192/247) 81.5% (202/248) 91.1% (226/248) 
PVP 72.5% (29/40) 80.8 (21/26) 56.9% (62/109) 54.5% (66/121) 58.6% (65/111) 64.5% (40/62) 
PVN 76.5% (237 /310) 77.3 (243/314) 83.3% (200/240) 84.2% (192/228) 84.5% (?JJ2/239) 78.5% (226/WJ) 
DS"'diameter stenosis; NHLBI 1 to 4 "' National Heart, Lung and Blood Institute restenosis criteria; PVP,predictive value for recurrent angina if criterion is fulfilled, 
PVN"' predictive value for no angina at follow-up if criterion is not fulfilled. * = in 1 patient quantitative analysis was impossible pre-angioplasty, therefore these criteria could not 
be assessed in this patient. 
Table 4. Diagnostic accuracy of different angiographic restenosis criteria for patients with positive bicycle ergometry at follow-up. 
Criterion 
Characteristic NHLBI 1 NHLBI2 NHLBI 3• NHLBI 4• ~50%DS :::o.nmm 
Prevalence of restenosis 11.2% {37/33D) 6.7% {22/33D) 30.7% {101/329) 34.7% {114/329) 31.2% {103/33D) 17% (56/33D) 
Sensitivity 14.7% (17/116) 9.5% (11/116) 37.9% {44/116) 46.5% (54/116) 41.4% (48/116) 26.7% {31/116) 
Specificity 90.7% {194/214) 94.9% {203/214 73.2% {156/213) 71.8% (153/213) 74.3% {159/214) 883% {189/214) 
PVP 45.9% {17/37) 50% {11/22) 43.6% {44/101) 47.4% {54/114) 46.6% ( 48/103) 55.4% {31/56) 
PVN 66.2% {194/293) 65.9% (203/3D8) 68.4% (156/228) 71.2% (153/215) 70% (159/227) 69% (189/274) 
DS =diameter stenosis; NHLBI 1 to 4 = National Hearl, Lung and Blood Institute restenosis criteria; PVP =predictive value for abnormal test if criterion is fulfilled, PVN =predictive 
value for normal test if criterion is not fulfdled. • = in 1 patient quantitative analysis was impossible pre-angioplasty, therefore these criteria could not be assessed in this 
patient. 
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DISCUSSION 
Patient selection and methodological considerations. In this study we 
preferentially studied patients with single vessel disease and with a single lesion which 
was successfully dilated. In these patients only restenosis of this lesion can be held 
responsible for an abnormal ECG response at follow-up exercise testing or recurrent 
angina, whereas in multivessel disease the responsible lesion is not always easy 
identifiable. Moreover coronary angioplasty in multivessel disease will not result in 
complete revascularization in a considerable number of cases [10]. 
With conventional exercise protocols, ECG leads and ECG criteria, exercise 
testing is characterized by a high specificity and a moderate sensitivity [11]. Furthermore, 
its sensitivity increases with the extent of coronary artery disease, which implies a low 
sensitivity in patients with single vessel disease [12-14]. This explains the low predictive 
accuracy found in our population of patients with single vessel disease for the different 
restenosis criteria. These findings are comparable with the findings of Bengtson et a!. 
[15] who found a sensitivity of 32 % and a specificity of 79 % for a positive exercise 
ECG. 
It is known that diagnostic accuracy for restenosis of recurrent angina is better 
than forST segment change [15,16]. From the data of Bengtson eta!. [15] a sensitivity 
for recurrent angina of 59% and a specificity of 73% can be calculated. They applied the 
50% diameter criterion for restenosis. Zaidi et a!. [17] reported a sensitivity of 70% and 
a specificity of 66% for recurrence angina as a test for restenosis. Although the predictive 
accuracy of quantitative angiographic parameters was generally poor in the present study, 
it is remarkable that the points of intersection of the sensitivity and specificity curves 
were similar for 2 different markers of myocardial ischemia. 
Angioplasty of the left anterior descending artery made up 55.4% of all 
procedures iu this study. It might be argued that the large mass of potentially ischemic 
myocardium supplied by this artery in case of severe renarrowing, would render the 
findings of this study only applicable to LAD lesions. However no differences were found 
in the proportion of patients with recurrent angina and ST depression at exercise with 
respect to the vessel dilated (Table 2). Prior myocardial infarction is known to falsely 
increase the accuracy of exercise testing [18]. However the occurence of Q waves in the 
area supplied by the dilated artery (table 2) was low, indicating an only small possible 
influence on our findings. 
Angiographic restenosis and functional status. Restenosis after a successful 
angioplasty procedure is now viewed as a fibroproliferative repair process in response 
to traumatic injury to the vessel wall [19,20]. We recently showed that luminal narrowing 
after angioplasty occurs to a certain extent in all dilated lesions [21] and that 
angiographic restenosis is the tail end of a normally distributed phenomenon. The 
restenosis rate is therefore dependent on the cut-off criterion applied. Generally 2 types 
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of angiograpbic restenosis criteria have been developed: criteria that denote the change 
in stenosis severity at follow-up angiography (e.g. the ;:: 0.72mm change criterion) and 
criteria that assess stenosis severity at follow-up angiography (e.g. the >50% diameter 
stenosis at follow-up criterion). From a functional point of view restenosis can be 
detected by recurrence of angina and by several noninvasive tests. These tests are aimed 
at detecting myocardial ischemia due to a flow limiting stenosis in an epicardial artery 
and give no information on the magnitude of the luminal narrowing process in the 
individual lesion. Angiograpbic restenosis criteria that give a static assessment oflesion 
severity at follow-up have the disadvantage of preselecting lesions with a marginal 
angioplasty result [1 ]. This means that these lesions have to undergo only a small 
deterioration to cross the cut-off point and be classified as "restenosed". Classically the 
50% diameter stenosis criterion is applied to classify lesions or patients as "restenosed" 
at follow-up angiography after angioplasty. This criterion is historically based on the 
physiological concept of coronary flow reserve introduced by Gould and others in 1974 
and is taken because it represents the approximate value in animals with normal 
coronary arteries at which blunting of the hyperemic response occurs [22]. Although the 
50% diameter stenosis criterion is attractive because it links the angiographic appearance 
of a lesion with the clinical situation of the patient, it tells us nothing about the dynamic 
behavior of the restenosis process. Our findings underscore the significance of the 50% 
diameter stenosis criterion because the optimal cut-off point for prediction of functional 
status 6 months after coronary angioplasty was found to be close to this value ( 46.5% 
diameter stenosis). 
Diagnostic accuracy of the absolute stenosis diameter (MLD) at 6 months 
follow-up however, was similar to the diagnostic accuracy of diameter stenosis 
measurements (figure 3 and figure 4) with a point of intersection of the sensitivity and 
specificity curves at 1.4 mm. This indicates that an absolute measure of stenosis severity 
is equally predictive of clinical status after angioplasty as a relative measurement. These 
values correspond well with the findings of Wilson et al. [23]. They found that coronary 
flow reserve dropped below 3.5 (the lower threshold of normal) at a minimal cross 
sectional area of 1.5 mm2 and a percent area stenosis of 75 which corresponds to a 
minimal lumen diameter of 1.4 mm and a percent diameter stenosis of 50% respectively. 
Wijns et al. demonstrated a steep increase in pressure drop over left anterior descending 
artery stenoses once a critical value of minimal cross-sectional area of 2.5 mm2 was 
reached. This corresponds to a minimal lumen diameter of 1.78 mm [24]. The pressure 
measurements were made with a dilatation catheter across the stenosis ( cross~sectional 
area of catheter: 0.64 mm2). If this value is subtracted from the 2.5 mm2 value, a minimal 
lumen diameter value of 1.54 mm emerges, which is close to the 1.45 mm found in the 
present study. 
An approach that more closely reflects the magnitude of the reactive intimal 
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hyperplasia after angioplasty is applying criteria that describe the change in lesion 
severity at follow-up angiography. The major critique on this type of criterion is that they 
might disregard the functional significance of a lesion at follow-up. For instance a lesion 
with a post angioplasty percent diameter stenosis in the range of 0-15% can undergo a 
large deterioration and still not be flow limiting. Our study however, not only shows that 
the static parameters of minimal lumen diameter and percent diameter stenosis perform 
equally well in predicting clinical significance of a lesion 6 months after successful 
coronary angioplasty but also that the parameters of change in lumen diameter and 
change in percent diameter stenosis were only slightly less accurate in predicting the 
clinical significance of the lesions (figure 3 and 4 ). Therefore, parameters of change, 
apart from their usefulness in reflecting the magnitude of the reactive hyperplasia, also 
reflect nearly to the same extent as the "static" parameters, the clinical significance of the 
lesion at follow-up. The optimal cut-off point for the parameters of change was -0.30 mm 
for the change in lumen diameter and -10% for change in percent diameter stenosis with 
nearly equal diagnostic accuracies showing that absolute change in lesion severity (in 
mm) and relative change in lesion severity (in percentage) perform equally well in the 
prediction of recurrent angina or positive exercise ECG, 6 months after coronary 
angioplasty. 
Limitations. First of all more sophisticated invasive and non invasive methods are 
available for the assessment of the functional significance of a coronary stenosis. It is 
known that exercise thallium scintigraphy has a higher diagnostic accuracy than 
electrocardiographic exercise testing [25]. The present data originate from a multicenter 
Trial and therefore it is logistically difficult to standardize the methodology of 
radionuclide exercise tests or flow-reserve measurements in all participating centers. 
Exercise electrocardiographic testing on the other hand is inexpensive, safe and identical 
exercise protocols can be easily implemented in the participating centers. As proposed 
by Popma et aL[26], paired stress tests, (shortly after angioplasty and at 6 months follow 
up) should ideally be obtained, otherwise the interpretation of an ischemic exercise test 
at follow-up may be more difficult, especially in patients with multivessel coronary artery 
disease. Our study population consisted of patients with single vessel disease in whom 
complete revascularization was achieved. The absence of myocardial ischemia at hospital 
discharge after angioplasty. however, was not objectively confirmed by exercise testing. 
The diagnostic accuracy of quantitative angiographic parameters for the prediction of 
recurrent angina and an abnormal ECG response at exercise was not very high. However, 
the absolute values of sensitivity and specificity were not crucial to this study, but rather 
the point of intersection of the sensitivity and specificity curves. Finally all angiograms 
were preceded by an intracoronary dose of nitrates and not all patients were using 
vasodilatory drugs at the time of exercise testing. This might have shifted the points of 
intersection towards a higher minimal lumen diameter and lower percent diameter 
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stenosis. 
Conclusion. The large number of patients studied and the fact that the same 
optimal values for diagnostic accuracy of the various quantitative angiograpbic variables 
were obtained for the prediction of 2 different markers of ischemia (anginal status and 
ST depression at exercise) suggests that these values reflect the lesion severity or 
increase in lesion severity in major epicardial vessels at which coronary flow reserve is 
unable to meet myocardial demands. Relative measurements (percent diameter stenosis) 
and absolute measurements (minimal lumen diameter) were found to be equally 
predictive of ischemia. Since the minimal lumen diameter is the most unambignous 
measurement of lesion severity (independent of an arbitrary "normal" part of the artery), 
this measure can be a more reliable surrogate for clinical outcome than the classic 
percent diameter stenosis measurement in the many restenosis prevention trials with 
drugs and new devices currently underway or in the design phase. 
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Abstract 
Background. The renarrowing process after successful cororuuy balloon angioplasty 
is now believed to be caused by a fibroproliferative vessel wall reaction. The magnitude 
of this process can be assessed by the change in ntinimal lumen diameter (MLD) at 
follow-up angiography. The aim of the present study was to find independent patient 
related, lesion related and procedural related risk factors for this luminal narrowing 
process. A model that accurately predicts the amount of luminal narrowing could be an 
aid in patient or lesion selection for the procedure, it could improve assessment of 
medium term (6 months) prognosis, modification or control oftbe identified risk factors 
could reduce overall restenosis rates and it could assist in the selection of patients at risk 
for a large loss in lumen diameter. This population could then constitute the target 
population for pharmacological intervention studies. 
Methods and results. Quantitative angiography was performed on 666 successfully 
dilated lesions at angioplasty and at 6 months follow up. Multivariate linear regression 
analysis was performed to obtain variables with an independent contribution to the 
prediction of the absolute change in MLD. Diabetes mellitus, duration of angina < 2.3 
months, gain in MLD at angioplasty, pre PTCA MLD, lesion length ::: 6.8 mm and 
thrombus post PTCA were independently predictive of change in MLD. Overall 
prediction of the model was however poor, percentage correct classification for a change 
between -0.1 to -0.3 mm was approximately 10%. 
Conclusion. Re-narrowing after successful PTCA is a process that cannot be 
accurately predicted by simple clinical, morphologic and lesion characteristics. 
Key words: 
PTCA, restenosis, quantitative angiography 
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IN1RODUCTION. 
Luminal narrowing after coronary angioplasty is a complex process that is only 
partially understood. Histologic studies of coronary arteries after dilation, obtained by 
either autopsy or atherectomy, have provided evidence that strongly supports the concept 
of intimal hyperplasia or proliferation of smooth muscle cells of medial or intimal origin 
as the underlying cause of luminal narrowing after angioplasty [1-3]. Pharmacological 
agents aimed at reducing the absolute amount of intimal hyperplasia are currently being 
investigated in many clinical trials. In these trials it is presumed that the clinical outcome 
is related to an anatomical substrate, i.e. the prevention or reduction of reactive intimal 
hyperplasia after angioplasty. 
If restenosis is viewed as an intraluminal growth process after a successful 
angioplasty, risk factors for restenosis should be risk factors for this growth process. The 
angiographically determined change in lumen diameter at follow-up is currently the only 
reliable indicator of the amount of reactive hyperplasia applicable to large study 
populations. 
A model that accurately predicts the amount of luminal narrowing in the 
individual patient would be of value in several ways: First, it could be an aid in patient 
or lesion selection for the procedure because an accumulation of risk factors in the 
individual patient might indicate balloon angioplasty an unattractive means of 
revascularization; secondly, it could improve assessment of medium term (6 months) 
prognosis in the individual patient; third, modification or control of the identified risk 
factors could reduce overall restenosis rates; fourth, the model could assist in the 
selection of patients at risk for a large loss in lumen diameter. This population could 
then constitute the target population for pharmacological intervention studies because 
a larger mean loss in lumen diameter would permit the enrollment of a smaller number 
of patients in a study while maintaining an equal power. Therefore patient related 
factors, lesion related factors and procedural factors were correlated to the quantitative 
angiographic change in lumen diameter from post-angioplasty angiogram to follow-up 
angiogram in the present study. 
METHODS 
Study population- The study population consisted of 697 patients that were 
originally randomized in 6 European centers (see appendix) for the Carport trial [4]. In 
this randomized, double blind, placebo controlled trial a novel thromboxane A:, receptor 
antagonist (GR32191B) was investigated for its ability to prevent restenosis after primary 
coronary angioplasty. Follow-up on these patients was done on a prospective basis and 
all patients agreed to undergo repeat angiography at 6 months. Identical angiographic 
and clinical outcomes were observed [4], so the placebo- and active treatment group 
were pooled for the present study. All patients with both stable and unstable angina and 
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angiograpbically-proven native coronary artery disease who were scheduled for primary 
angioplasty, were considered for inclusion. Exclusion criteria for trial participation and 
their relative frequencies have been published earlier [4]. 
Angioplasty success was defined as a less than 50% residual stenosis by visual 
inspection of the post-angioplasty angiogram and no occurrence of in-hospital 
complications (death, acute myocardial infarction, repeat angioplasty, aono coronary 
bypass grafring or recurrence of symptoms), and was achieved in 649 patients (93.1 %). 
Quantitative angiographic follow-up was available for 575 patients (88.6%) and this 
forms the study population (figure 1). 
697 patients enrolled in CARPORT trial t--" <oil•' eTCA ".o%) 
649 patients eligible for f-up angiography 
1----46 refused re-angiography 
1----18 contraindication lor re-angiography 
t---•2 died 
1----a f-up angiogr11ms unsuitable for QCA 
575 patients with analyzable f-up angio(88.6%) 
Figure 1. Patient flow chart. PTCA =percutaneous transluminal coronary angioplasty, 
QCA =quantitative coronary angiography 
Angioplasty procedure and follow up angiography. Coronary angioplasty was 
performed with a steerable, movable guide wire system via the femoral route. Standard 
available balloon catheters were used. Choice of balloon type and brand as well as 
inflation duration and inflation pressure were left to the discretion of the angioplasty 
operator. At the beginning of the angioplasty procedure all patients received 10000 ru 
of intravenous heparin for the first two hours, afterwards 5000 ru /hour for as long the 
procedure continued. All patients received 10 mg nifedipine every two hours for the first 
12 hours after angioplasty. Thereafter they received 20 mg slow release nifedipine tablets 
3 times during the second day after angioplasty. 
Three coronary angiograms were obtained in each patient, just before angioplasty, 
immediately after angioplasty, and at follow-up. To standardize the method of data 
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acquisition and to ensure exact reproducibility of the angiographic studies, measures were 
taken as descnoed previously [5,6,7]. The angiograms were recorded in such a way that 
they were suited for quantitative analysis by the Coronary Angiography Analysis System 
(CAAS). All necessary details of the procedure were recorded and drawings of the 
segments to be analyzed were made. For calibration purposes the cathetertips were cut 
off for later measurement with a microcaliper. All angiograms were processed and 
analyzed in a central core-laboratory. 
The follow-up coronary angiogram was performed at six months follow-up. If 
symptoms recurred within 6 months, coronary angiography was carried out earlier. If no 
definite restenosis was present and no revascularization procedure was performed and 
the follow-up time was less than 4 months, the patient was asked to undergo another 
coronary arteriogram at 6 months. 
Quantitative angiography (figure 2). All cineangiograms were analyzed using the 
computer assisted angiography analysis system (CAAS) which has been described and 
validated previously [8,9]. A computer derived reconstruction of the original arterial 
dimension at the site of obstruction (assuming there is no disease present) is used to 
define the interpolated reference diameter (figure 2). The area between the actual and 
reconstructed contours at the obstruction site is a measure for the amount of 
atherosclerotic plaque and expressed in mrn'. The length of the obstruction is determined 
from the diameter function on the basis of curvature analysis and expressed in 
millimeters. In addition, this technique allows for the calculation of an eccentricity index 
of the lesion [10]. The index ranges from 0 (severe eccentric) to 1 (perfectly 
symmetrical). Since the analysis system cannot measure total occlusions, a value of 0 mm 
was substituted for the minimal lumen diameter and the post-angioplasty reference 
diameter was substituted for the reference diameter pre PTCA The mean change in 
minimal lumen diameter from post-angioplasty angiography to follow-up angiography and 
from pre-angioplasty to post-angioplasty was derived from matched angiographic 
projections. 
Potential risk factors studied. The loss in minimal lumen diameter was assessed 
for factors reported to be predictive of luminal narrowing after successful PTCA For 
categorical variables the change in lumen diameter from post-angioplasty angiogram to 
follow-up angiogram was determined in each category. Continuous variables were 
grouped into three equally sized subgroups (tertiles) and the change in minimal lumen 
diameter assessed for each tertile. 
Variables potentially predictive for luminal narrowing and eventually restenosis 
were divided in to 3 general categories. Patient related factors are present systemically and 
thereby affect all dilated lesions in a single patient. These include age, gender, diabetes, 
unstable angina (defined as pain at rest requiring treatment with intravenous nitrates), 
extent of atherosclerotic disease (single or multivessel), previous myocardial infarction, 
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Figure 2. Graphic representation of the quantitative angiographic measurements. The upper 
panel represents a stenosed arterial segment. The lower panel is the diameter function curve. 
The length of the analyzed segment is depicted on the X-axis and the vessel diameter on the 
Y-axis. MLD = minimal lumen diameter. Extent of obstruction = Lesion length. Lesion 
length is determined with curvature analysis of the descending and ascending limb of the 
diameter function curve at the site of the MLD. Eccentricity is determined the site of the 
MLD and calculated as ajb. The plaque area is depicted by the hatched part of the upper 
panel drawing. 
previous CABG, previous angioplasty at other site, platelet count, cholesterol level, 
lipoprotein cholesterol levels (HDL,LDL), glucose levels, history of smoking and 
continued smoking after the procedure. Because only 8 patients had type I diabetes, 
diabetes type I and II were pooled. Lesion related factors are characteristics unique to 
each lesion. The following factors were assessed: minimal lumen diameter pre-PTCA and 
post-PTCA, lesion length, eccentricity of the lesion, percentage diameter stenosis pre-
PTCA and post· PTCA, presence of visible collateral circulation to the dilated vessel, 
total occlusion pre-PTCA, plaque area pre·PTCA (figure 2), vessel dilated (either left 
anterior descending artery, circumflex artery or right coronary artery), presence of 
dissection post-angioplasty (defined as filling defect within the lumen, disappearing with 
the passage of contrast material (type A dissection according to Dorros et al [11]) and 
156 
as contrast appearing outside the lumen, disappearing or persisting with the passage of 
contrast material (type Band C dissections according to Dorros eta!.)), relative gain in 
lumen diameter achieved by angioplasty (defined as the difference in obstruction 
diameter before and after angioplasty divided by the interpolated reference diameter 
(vessel size)), presence of thrombus pre and post PTCA (defined as an intraluminal 
filling defect visible in all projections, a visible embolization of intraluminal material 
downstream or dye staining at the site of a total occlusion (inter observer concordance 
rate for the assessment of intracoronary thrombus in the corelab 89% )) and calcification 
of the lesion. Procedure related factors assessed were maximal measured balloon diameter, 
balloon-artery ratio (defined as the ratio of the quantitative angiographic diameter of the 
largest balloon at highest inflation pressure to the reference diameter), maximal inflation 
pressure, number of balloon inflations and total duration of balloon inflation. 
Data analysis. The unit of analysis reported here is the stenotic lesion, not the 
patient. The primary outcome variable was the change in lumen diameter from directly 
post-angioplasty to follow-up angiogram. Data are presented as mean ± 1 standard 
deviation. In univariate analysis continuous variables that were divided into 3 subgroups 
were compared with analysis of variance and for the discrete variables with an unpaired 
Student's t-test. 
To obtain independent predictors for the loss in lumen diameter, variables were 
entered in a stepwise multiple linear regression analysis in which the loss in lumen 
diameter was the dependent variable. Stepwise multiple linear regression analysis was 
performed (BMDP statistical package, program 2R) to assess the relationship between 
the variables mentioned in the 'Methods' section (independent variables = X,) and the 
loss in minimal lumen diameter from post-angioplasty angiogram to follow-up angiogram 
(dependent variable = Y): Y = A + Z; B;X, where A is the intercept and B; is the 
i'h regression coefficient. The standard BMDP 2R criteria ofF > 4 for inclusion and F 
< 3.9 for elimination were applied. 
Continuous variables were entered as such in the multivariate analysis, except 
variables with 2 of 3 tertiles showing approximately the same amount of loss in lumen 
diameter for each tertile. These were entered as discrete variables (lesion length :0:6.8 
mm, cholesterol level :0: 6.5 mmoljl, duration of angina < 23 months and percent 
diameter stenosis pre-angioplasty :0: 56.5). 
To determine how well the regression model performs in predicting restenosis 
according to 2 frequently applied restenosis criteria and to illustrate the discrepancies 
between the 2 criteria, receiver operator characteristic (ROC) curves were constructed 
for each criterion. The criteria applied were: change in lumen diameter :0: 0.72mm at 
follow-np [5,8,12] and the classic criterion of an increase in diameter stenosis from < 
50% post PTCA to :0:50% at follow up. The 0.72 mm value takes into account the 
limitations of coronary angiographic measurements and represents twice the long-term 
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variability for repeat measurements of a coronary obstruction using tbe CAAS system [8]. 
The use of 1 standard deviation would include 68.3% of the measurement variability. 
while tbe use of 2 standard deviations (2 x 0.36 ; 0.72 mm) includes 95.5% of tbe 
measurement variability. The equivalent of the 0.72 mm value for diameter stenosis 
measurements is a change in diameter stenosis of 13%. 
In tbese ROC curves sensitivity (true positive %) at different cut off points of 
predicted change in minimal lumen diameter is graphed as a function of 100% -
specificity (false positive % ). 
RESULTS 
Of 649 patients who had a successful angioplasty, 575 underwent satisfactory 
angiographic follow-up (follow-up rate 88.6%) and formed the study population. Baseline 
characteristics of tbe study population are sununarized in table 1. A total of 666 lesions 
were successfully dilated. Restenosis rate was 32.6% (217 of 6661esions) according to tbe 
>50% diameter stenosis criterion and 17.6% (117 of 666 lesions) if the criterion of ?:: 
0.72 nun loss in lumen diameter was applied. 
UNIVARIATE ANALYSIS 
Patient related variables. Table 2A summarizes the changes in minimal lumen 
diameter for all analyzed patient related variables. Of tbe 18 patient related variables 
ouly 3, unstable angina, diabetes, and angina duration < 2.3 months, showed a 
significantly larger loss in minimal lumen diameter at follow-up. The high loss in lumen 
diameter associated witb tbe presence of tbese variables was probably caused by lesions 
that progressed towards total occlusion at follow-up. Indeed, if totally occluded lesions 
at follow-up (n;42, 6.3%) were excluded from the analysis tben a trend towards a higher 
loss in lumen diameter in tbe presence of one of these factors still existed, although not 
statistically significant: Diabetes: -0.27 ± 0.39 vs -0.20 ± 0.39 mrn, p; 0.18, unstable angina: -
0.20±0.39 mm vs -0.18±0.39 rnrn, p;0.66, duration of angina < 2.3 months -0.24±0.37 
mm vs -0.18±0.40 rnrn, p;0.09. 
Lesion related variables (table 2B). The pre-angioplasty lesion related factors 
associated witb a larger loss at follow-up were: smaller minimal lumen diameter, lesion 
length :;:6.8 rnrn, higher percentage diameter stenosis, larger plaque area, total occlusion 
and collateral circulation to the obstruction site (Table 2B). The post-angioplasty lesion 
related factors associated with a greater loss at follow-up were a larger post-angioplasty 
lumen diameter, lower percentage diameter stenosis post-angioplasty (ie a better 
angioplasty result), a higher relative gain achieved at angioplasty and thrombus post-
angioplasty. Again, if total occlusions at follow-up were disregarded, the presence of total 
occlusions pre-angioplasty, collateral circulation and thrombus post-angioplasty were no 
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longer associated with a significantly higher loss in minimal lumen diameter (total 
occlusion -0.11 ±0.42 mm vs -020± 0.39 mm, p = 025, collateral circulation -0.23±0.41 mm 
vs -0.19 ± 039 mm, p = 0.34, thrombus post-angioplasty -025 ± 0.39 mm vs -0.20 ± 0.39 mm, 
p=0.67). 
Procedure related variables. None of the procedural factors assessed was 
associated with a significantly greater loss in lumen diameter at follow-up (table 2C). 
Table 1. Baseline characteristics 
No of patients 
Lesions 
lesions/patient 
Age (years) 
Male gender (%) 
Follow up time (days) 
Extent disease 
1 vessel 
2 vessel 
3 vessel 
MI.D pre PTCA (mm) 
MI.D post PTCA (mm) 
MLD f_up (mm) 
%DS pre PTCA 
% DS post PTCA 
% DS f-up 
Change in MI.D at f-up (mm) 
575 
666 
1.16 
56±9 (29-79) 
464 (81%) 
172±41 (10-349) 
381 (66.3%) 
156 (27.1%) 
38 (6.6%) 
1.04±0.37 (0-2.83) 
1.76±0.38 (0.85-3.04) 
1.48±059 (0-3.15) 
60± 13 (33-100) 
34±9 (6-65) 
45±19 (4-100) 
-028±052 
%DS = percentage diameter stenosis, f-up =follow-up, LAD= left anterior descending 
artery, LCX=circumflex artery, MLD=minimallumen diameter, RCA=right coronary 
artery. 
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Table 2A. Change in minimal lumen diameter per lesion for patient related variables 
Change in MLD at follow-up P value 
(mm) 
Age (years) 
< 52 (n~211) -026:t051 
52-61 (n~213) -031:t0.52 p~0.54 
>61 (n~242) -0.3l:t 0.57 
Sex 
male (n~533) -0.28:t0.50 p~O.ll 
female(n~ 133) -0.37 :t 0.65 
Diabetes I and TI 
yes (n~56) -0.56:t0.77 p<0.001 
no (n~610) -0.27 :t 0.50 
Unstable angina (pain at rest) 
yes (n~91) -0.42=0.73 p<O.OS 
no (n~575) -0.27= 0.50 
Extent disease 
single vessel (n~401) -0.3l:t 0.55 p~0.45 
multivessel (n~265) -0.28:!:0.52 
Ever smoked 
yes (n~515) -0.28:!:0.54 p~028 
no (n~l51) -0.34:!:0.53 
Still smoking at follow-up 
yes (n~Sl) -0.23 :t 0.46 p~0.22 
no (n~585) -0.34±0.53 
previous MI 
yes (n~253) -0.33 :t 0.60 p~0.13 
no (n~413) -0.27:!:0.50 
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Table 2A continued 
Change in MLD at follow-up P value 
(nun) 
previous CABG 
yes (n=20) -0.22:!:0.42 p=0.45 
no (n=646) -0.30±0.54 
previous PTCA other site 
yes (n=ll) -0.25:!:0.57 p=0.77 
no (n=655) -0.29±0.54 
Duration of angina (months) 
<2.3 (n=210) -0.37:!:0.59 
2.3-8.5 (n=227) -0.26:!:0.50 p=0.06 
>8.5 (n=229) -0.26:!:0.53 
Platelet count (106/ml 
< 168 (n=216) -0.30:!:0.56 
168-175 (n=220) -0.27:!: 0.50 p=0.48 
:::175 (n=222) -0.33:!:0.55 
Total cholesterol (mmol/1) 
<5.7 (n=225) -0.32:!:0.56 
5.7-6.5 (n=217) -0.34:!:0.58 p=0.15 
>6.5 (n=216) -0.26:!:0.47 
HDL cholesterol (mmol/1) 
<0.93 (n=190) -0.32±0.58 
0.93-1.2 (n = 197) -0.26:!:0.49 p=O.SO 
;::1.20 (n=188) -0.31:!:0.54 
LDL cholesterol (mmol/1) 
<3.3 (n=166) -0.36:!:0.59 
3.3-4.6 (n= 169) -0.31:!:0.52 p=O.ll 
>4.6 (n=157) -0.24:!:0.47 
Table 2A continued 
Glucose (mmol/1) 
<4.8 (n=234) 
4.8-5.6 (n=213) 
:::5.6 (n=210) 
Hypertension 
yes (n=223) 
no (n=443) 
AP class at baseline• 
I,TI (n=290) 
ITI,IV (n=376) 
Change in MLD at follow-up 
(mm) 
-026:t0.47 
-0.30 :t 0.54 
-0.35 :t 0.61 
-0.31:!: 0.54 
-0.28 :t 0.54 
-0.27:!:0.49 
-0.32:!: 0.59 
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P value 
p=0.18 
p=0.51 
p=0.25 
CABG=coronary artery bypass grafting, HDL=high density lipoprotein, LDL=low 
density lipoprotein, MI=myocardial infarction, MLD=minimal lumen diameter, • 
Canadian Cardiovascular Society classification. 
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Table 2B. Change in MLD per lesion at follow-up for lesion related variables 
MLD pre PTCA (mm) 
<0.9 (n=219) 
0.9-1.15 (n=216) 
;::1.15 (n=228) 
MLD post PTCA (nun) 
< 1.65 (n=220) 
1.65-1.9 (n=221) 
:::1.90 (n=225) 
Relative gain at PTCA 
<0.2 (n=230) 
0.2-03 (n=209) 
;::o.3 (n=224) 
Length obstruction (mm) 
<5.25 (n=229) 
5.25-6.8 (n = 195) 
;::6.8 (n=203) 
Plaque area (nnn2) 
<4.7 (n=208) 
4.7-7.6 (n=212) 
> 7.6 (n =207) 
Eccentricity 
<0.2 (n=210) 
0.2-0.45 (n=205) 
;::0.45 (n=212) 
% diameter stenosis pre-PTCA 
<56.5 (n=244) 
56.5-64.5(n=210) 
;::64.5 (n=209) 
Change in MLD at follow-up 
(mm) 
-037±0.58 
-031±0.51 
-0.22±0.51 
-0.16±0.48 
-0.33±0.50 
-039±0.55 
-0.13±0.45 
-0.33±0.49 
-0.46±0.58 
-0.23±0.46 
-0.24±0.51 
-038±055 
-0.21 ±0.45 
-0.29±0.53 
-0.34±0.53 
-0.31±0.52 
-0.26±0.50 
-0.27±0.50 
-0.20±0.48 
-035±054 
-0.35±0.58 
% diameter stenosis post-PTCA 
<29.5 (n=217) -0.40± 0.57 
29.5-38 (n =225) -0.32±0.53 
>38 (n=224) -0.17±0.49 
P value 
p<0.02 
p<0.001 
<0.001 
p<0.01 
p<0.03 
p=0.42 
p<0.001 
p<0.001 
Table 2B continued 
Change in MLD at follow-up 
(nun) 
Vessel size (nun) (reference diameter) 
<2.4 (n=240) 
2.4-2.85 (n=214) 
:':2.85 (n=212) 
Patency pre-PTCA 
total occlusion (n=36) 
patent (n=630) 
Collateral circulation to obstruction site 
yes (n=122) 
no (n=544) 
Thrombus pre PTCA 
yes (n=32) 
no (n=634) 
Thrombus post PTCA 
yes (n=16) 
no (n=650) 
Vessel dilated 
LAD (n=321) 
LCX (n=154) 
RCA (n=191) 
Calcified lesion 
yes (n=233) 
no (n=433) 
Tandem lesion 
yes (n=25) 
no (n=641) 
Dissection post PTCA 
yes (n=l25) 
no (n=541) 
Branch in stenosis 
yes (n=194) 
no (n=472) 
-030;:053 
-030ot051 
-0.28;:0.57 
-0.54ot0.87 
-0.28ot0.50 
-039ot0.64 
-0.25 ot0.49 
-032ot0.51 
-0.29ot0.52 
-0.71;:0.90 
-0.28;:0.52 
-0.27ot0.46 
-0.28ot0.55 
-0.34;: 0.63 
-0.29;:0.50 
-03H056 
-0.2h039 
-0.29ot0.54 
-032ot0.59 
-0.29ot0.52 
-03lot0.49 
-0.29;:0.56 
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P value 
p=0.91 
p<O.Ol 
p<O.OS 
p=0.65 
p<O.Ol 
p=0.36 
p=0.61 
p=0.82 
p=0.60 
p=0.69 
LAD= left anterior descending artery, LCX =circumflex artery, MLD =minimal lumen 
diameter, RCA=right coronary artery, PTCA=percutaneous transluminal coronary 
angioplasty 
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Table 2C. Change in MLD per lesion at follow-up for procedure related variables 
Change in MLD at follow-up 
(nun) 
Maximal balloon diameter (mm) 
<235 (n=189) 
2.35-2.7 (n=214) 
?:_2.7 (n=192) 
Balloon artery ratio 
<0.9 (n=201) 
0.9-1.05 (n=201) 
> 1.05 (n = 193) 
No. of inflations 
1 (n=178) 
2-4 (n=254) 
>4 (n=234) 
Maximal inflation pressure (atm) 
<8 (n=261) 
8-10 (n=264) 
>10 (n=141) 
Total inflation duration (sec) 
<220 (n=202) 
220-470 (n=230) 
>470 (n=224) 
MLD =minimal lumen diameter 
-0.26±0.50 
-030±0.50 
-035±0.55 
-0.27±0.55 
-0.29±0.53 
-0.36±0.54 
-0.29±0.47 
-0.30±0.51 
-0.35±0.57 
-0.31±0.58 
-0.30±0.52 
-0.24±0.50 
-0.30±0.54 
-0.28±0.52 
-0.27± 0.48 
P value 
p=O.ll 
p=0.17 
p=0.55 
p=0.43 
p=0.69 
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MULTIPLE LINEAR REGRESSION ANALYSIS 
The stepwise multiple linear regression analysis showed 2 pre-angioplasty 
angiographic characteristics as predictive of luminal narrowing at follow-up, namely 
length of the stenosis and the minimal lumen diameter pre-angioplasty (table 3). Only 
2 clinical variables and 2 one post-angioplasty variable, namely diabetes, duration of 
angina, the relative gain in lumen diameter achieved at angioplasty, and thrombus post 
angioplasty were found to be independently predictive for luminal narrowing following 
balloon angioplasty. 
To rule out any influence of the investigational drug on our findings, the use of 
either the thromboxane A2 receptor blocker GR32191 or placebo was forced into model. 
Trial medication had only a very small, statistically unsignificant, contribution to the fit 
of the model (table 4). 
In an attempt to assess how well the model predicted the amount of luminal 
narrowing at follow-up, the percentage of correct classified lesions was calculated for 5 
intervals of predicted change in lumen diameter (table 4). Correct prediction by the 
model was poor, particularly in the range of predicted change from -0.1 to -0.4 mm. In 
fact only 10% oflesions in the middle 3 categories were correctly classified by the model. 
On the other hand lesions showing no change or regression and lesions showing large 
progression were more predictable. The information content of the model according to 
the ROC curves (figure 3) was optimal for the '1oss of :::0.72 mm" restenosis criterion. 
For the ">50% diameter stenosis" criterion the curve was very close to the line of "no 
prognostic value". If in addition to >50% diameter stenosis at follow-up also a loss of 
at least 13% in percent diameter stenosis ( = twice the long term variability for diameter 
stenosis measurements, using the our analysis system) was required for a lesion to be 
classified as restenosis, a shift of the ROC curve to the left upper corner was apparent. 
These findings underscore the poor predictability of luminal narrowing and restenosis 
after balloon angioplasty and explain the differences between the restenosis criteria. 
DISCUSSION 
During 15 years of percutaneous transluminal coronary balloon angioplasty an 
abundance of clinical and experimental studies have been carried out in an attempt to 
elucidate factors that can predict the "Achilles heel" of coronary angioplasty, namely 
progressive luminal narrowing after a successful procedure. Although many clinical, 
procedural and lesion related factors have been linked to a higher angiographic 
restenosis rate, results of these studies are sometimes conflicting. As pointed out by Beatt 
et a! [13], most of the discrepancies can be attributed to 1) patient selection, 2) the 
method of analysis and 3) the definition of angiographic restenosis employed. 
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Table 3. Multivariate linear regression model for the prediction of change in MLD 
Model coefficient SE of coefficient F to remove 
Intercept 0.40 
Relative gain at PTCA -136 0.18 57.5 
MLDprePTCA -0.19 O.o7 6.7 
Lesion length ;:: 6.8mm -0.19 0.04 19.7 
Diabetes -034 0.07 20.7 
Duration of angina 
<23 months -0.11 0.04 62 
Thrombus post angioplasty -031 0.14 5.2 
Allocation to GR32191B 0.03 0.04 0.5 
MLD =minimal lumen diameter, PTCA =percutaneous trans luminal coronaryangioplasty. 
SE =standard error. 
Table 4. Percentages of correct classification 
Interval of predicted 
change in MLD 
<-0.4 mm 
-0.3 to -0.4 mm 
-0.2 to -03 mm 
-0.1 to -0.2 mm 
>-0.1 mm 
Percentage correct 
classification * 
98/197 
9/116 
13/123 
12/106 
72/121 
(49.7%) 
(7.8%) 
(10.5%) 
(113%) 
(59.5%) 
MLD = minimal lumen diameter • = total amount of lesions is 663, because gain could 
not be calculated for 3 lesions that were located distal to a total occlusion pre PTCA and 
therefore the minimal lumen diameter is unknown. 
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Patient selection. To obtain objective, unbiased results, all patients should be 
recatheterized after a predetermined follow-up period regardless of their symptomatic 
status. Failure to perform angiographic follow-up in a majority of patients will introduce 
bias in the assessment of the true change in minimal lumen diameter at follow-up. The 
restenosis rate according to a more or less arbitrary cut-off point will be biased towards 
higher values if symptomatic patients or patients with unfavorable anatomy post-
angioplasty are preferentially recatheterized. In this study 88.6% of all patients with a 
successful angioplasty had a follow-up angiogram performed within a predetermined time 
frame of 6 months. 
Method of analysis. A well validated quantitative angiographic analysis system 
should be employed. Computer assisted automated edge detection techniques enhance 
objectivity and reproducibility and reduce the high inter- and intra-observer variability 
inherent to visual interpretation of the coronary angiogram [14,15]. The quantitative 
analysis system we applied for the analysis of the angiograms meets these requirements 
[13]. 
Restenosis criteria. The third factor influencing the restenosis rates is the 
restenosis criterion. The most frequently applied criterion in the literature is the > 50% 
diameter stenosis at follow-up criterion. This criterion is historically based on the 
physiological concept of coronary flow reserve introduced by Gould and others in 1974 
and is taken because it represents the approximate value in animals with normal 
coronary arteries at which blunting of the hyperemic response occurs [16]. Although 
this criterion may be of some relevance in determining a clinically significant stenosis in 
human atherosclerotic vessels, it is a static measurement of lesion severity and tells us 
nothing about the dynamic behavior of the restenosis process. If the "50% diameter 
stenosis at follow up" criterion is applied, lesions with a suboptimal angioplasty result will 
preferentially be selected (ie have to undergo a small loss in lumen diameter to be 
classified as restenosed). Bourassa et a!. [17] have recognized this shortcoming and thus 
considered lesions with ?::50% diameter stenosis at follow-up that did not show a change 
of at least 10% at follow-up as not "restenosed". 
The predictive accuracy of the multivariate model for restenosis according to the 
50% diameter stenosis criterion was very poor (figure 3). If in addition a change in 
percent diameter stenosis of at least 13% (twice the long term variability for percent 
diameter stenosis measurements) was required, then predictive accuracy of the model 
improved markedly, since lesions with a suboptimal angioplasty result did no longer 
unduly influence the restenosis rate. This requirement shifts the ROC curve to the left 
upper corner. A criterion that better reflects the dynamic behavior of the lesion after 
PTCA is the :::0.72 mm loss in lumen diameter criterion as proposed hy our group 
[5,8,12]. This criterion is not meant to be a restenosis criterion strictu sensu, since that 
implies also some sort of functional measure of lesion severity at follow up, but rather 
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an indicator of significant intraluminal growth as monitored angiographically. 
Predictive factors for luminal narrowing after balloon angioplasty. 
If restenosis is viewed as an intraluminal growth process after a successful 
angioplasty, risk factors for restenosis should be risk factors for this growth process. 
Therefore we determined risk factors for the absolute amount of quantitative 
angiographic luminal narrowing, rather than for the crossing of a more or less arbitrary 
cut-off point (eg 50% diameter stenosis or loss ;::0.72mm). 
True positives (%) 
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Figure 3. Receiver operator characteristic curves (ROC cwves) for comparison of restenosis 
criteria at different cut off points of predicted change in lumen diameter. The diagonal line 
is the line of identity or line of "no prognostic value': ROC curves on the line of identity have 
no prognostic value, those in the left upper comer are most informative. Solid curve: 0. n 
mm criterium, normal auve: 50% diameter stenosis criterium with a change in diameter 
stenosis at follow-up of at least 13%, dotted curve: 50% diameter stenosis criterion. 
A distinction should be made between lesions that progress towards total 
occlusion and lesions that remain patent at follow-up, since it is likely that part of the 
luminal narrowing observed in former lesions is caused by thrombosis and not only by 
the fibroproliferative process. The larger luminal narrowing in lesions in patients with 
diabetes, unstable angina, in totally occluded lesions, lesions with visible collateral 
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circulation and lesions with a visible thrombus post-angioplasty was largely detennined 
by a higher incidence of total occlusions at follow-up. 
Patient related factors. Diabetes, unstable angina and duration of angina shorter 
than 2.3 months were associated with more luminal narrowing at follow-up. lf total 
occlusions at follow-up were disregarded, none of these variables showed significantly 
more narrowing. In multivariate analysis however, diabetes was independently predictive 
of luminal narrowing. 
The assumption that risk factors for restenosis are similar to risk factors for 
atherosclerosis was not confirmed in the present study. Only diabetes was found to be 
independently related to the amount of luminal narrowing at follow-up. This finding has 
also been recognized by others [18-25].ln a recent study by Bourassa et al [17] using the 
same quantitative angiographic analysis system, diabetes was however not found to be 
predictive of restenosis. Other classic risk factors for atherosclerosis such as male gender, 
systemic hypertension, high cholesterol level and continued smoking after the PTCA, 
were not found to be related to luminal narrowing in the present study. The controversy 
regarding these risk factors is considerable, with many studies being positive for one or 
more patient related factors and many studies being negative [26,27]. 
Lesion related factors. Pre-angioplasty variables. In univariate analysis 5 pre-
angioplasty variables were associated with more luminal narrowing at follow-up: minimal 
lumen diameter pre-angioplasty, percent diameter stenosis pre-angioplasty, length of 
stenosis, total occlusion pre~angioplasty, and collateral circulation to dilatation site. A 
relation between stenosis severity and restenosis rate has been shown previously 
[17,19,20,28]. It is conceivable that more severe lesions undergo more severe vessel wall 
damage during the procedure, a known trigger for the hyperplastic reaction [29-31]. In 
our multivariate analysis the pre-angioplasty minimal lumen diameter was found to 
be an independent determinant of subsequent loss in lumen diameter. In longer lesions 
more smooth muscle is possibly exposed to injury and platelet adhesion, which probably 
enhances the intimal hyperplastic reaction. 
A relation between stenosis length and restenosis has also been described by 
others [17,32,33]. Total occlusion pre-angioplasty is a well knowo factor connected with 
total occlusion at follow-up [34,35] and thus a large loss in lumen diameter at follow-
up. Because total occlusion pre-angioplasty is part of the continuous variables minimal 
lumen diameter and diameter stenosis pre PTCA, total occlusion pre-angioplasty was not 
found to be an independent predictor of loss in lumen diameter. 
Collateral circulation to the dilatation site will be more abundant in case of a 
severe stenosis or total occlusion. Since the severity of the lesion (minimal lumen 
diameter) pre-angioplasty was found to be an independent detenninant for the absolute 
loss in lumen diameter at follow-up, the presence of collaterals was not retained in the 
model. 
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No differences in luminal narrowing was observed for the 3 coronary arteries. 
Others [23,28,37-39] have reported a higher incidence of restenosis for the left anterior 
descending artery, a finding recently challenged by Hermans et al [40]. 
Post-angioplasty variables. Relative gain achieved at PTCA was both in univariate 
and multivariate analysis the strongest predictor (largest F to remove in final model) of 
luminal narrowing at follow-up. This variable probably best reflects the amount of 
damage inflicted upon the vessel wall by the angioplasty balloon. It is conceivable that 
more damage to the vessel wall with more deep arterial injury will result in a more 
aggressive repair process [1,29-31]. Other post-angioplasty variables that were related to 
more luminal narrowing at follow-up in univariate analysis were: higher minimal lumen 
diameter post-angioplasty, diameter stenosis post-angioplasty < 29.5% and visible 
thrombus post-angioplasty. Thus a better post-angioplasty result leads to more luminal 
narrowing or intimal hyperplasia at follow-up. Others have reported that a poorer post-
aogioplasty result was predictive of restenosis [17,20,22,28,36,41]. In general they applied 
the 50% diameter stenosis cut off point and, as discussed above, lesions with a poor post-
aogioplasty result will exceed this cut-off point with only minimal additional 
deterioration. 
Because lesions with a low percent diameter stenosis and a large lumen diameter 
post- aogioplasty were also the lesions that underwent a high relative gain at angioplasty 
aod since tltis variable was the strongest independent predictor of the absolute amount 
of luminal narrowing at follow-up, percent diameter stenosis post-aogioplasty and lumen 
diameter post-angioplasty were not retained in the multivariate analysis. 
Thrombus post-angioplasty was retained in the multivariate modeL Five of 16 
lesions (31%) with a visible thrombus post-angioplasty were totally occluded at follow-
up and therefore showed a greater overall loss in lumen diameter. 
We did not find an association between coronary dissection immediately post-
angioplasty and subsequent luminal renarrowing. Conflicting data have been reported 
concerning dissection and restenosis [21,22,42,43]. It is however clear that severe 
dissections are associated with a higher acute complication [44] aod restenosis rate, the 
latter probably due to a poorer angioplasty result in combination with the 50% diameter 
stenosis criterion. 
Proeednre related variables. Balloon oversizing (balloon-artery ratio > 1.05) was 
not related to more luminal narrowing at follow-up. Some investigators found a positive 
effect of balloon oversizing on restenosis [28,41] others have not [17,45], however in a 
prospective randomized study, Roubin et al found a higher incidence of acute 
complications in case of oversizing but no difference in restenosis rate [44]. 
Limitations. Although this study suggests several factors that may be deterntinants 
of luminal narrowing after coronary balloon angioplasty it does not address the actual 
mechanism of restenosis. Vasomotion at follow-up angiography cannot be ruled out as 
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a possible cause of the observed luminal renarrowing in individual lesions, although 
intracoronary nitrates in appropriate doses were administered before each angiography. 
Mean reference diameter was not different before PTCA, after PTCA and at follow-up 
2.64:!:056 nun, 2.70±0.53 mm and 2.70±0.56 mm respectively, suggestive of accurate 
control of vasomotion. Due to the relatively small sample sizes of some variables, B error 
cannot be ruled out in this study. Furthermore, in performing multiple statistical 
comparisons, there is a risk that some of them may reach significance by chance alone. 
The multivariate model was developed and tested in the same population. Generally a 
model will be less accurate if assessment of fit is carried out in a different population. 
However, the poor fit of the model even if tested in the same population underscores the 
poor predictability of the restenosis process. 
Conclusion. Prediction of luminal narrowing with baseline clinical and quantitative 
angiographic was shown to be poor. Only 6 variables, namely minimal lumen diameter 
pre-angioplasty, relative gain at angioplasty, lesion length, diabetes, duration of angina 
and thrombus post-angioplasty were found to be independent determinants of the 
hyperplastic intimal reaction after balloon angioplasty. Control of these factors alone, if 
at all possible, will probably not result in a reduction of the amount of luminal narrowing 
and restenosis. Furthermore, since (elective) angioplasty is still a procedure performed 
to alleviate symptoms it seems not feasible to deny diabetics, patients with recent onset 
angina or patients with a severe lesion a balloon angioplasty procedure. Restenosis is 
obviously a process that cannot be predicted by simple clinical and morphologic patient 
or lesion characteristics. Therefore additional biochemical or histochemical factors [46] 
of importance in the restenosis process should be investigated and where possible tackled 
with appropriate pharmacological intervention. 
The variable most strongly associated with the amount of luminal narrowing at 
follow-up was the relative gain at angioplasty. It must be noted that lesions with a large 
gain at PTCA not only can but also will undergo a larger loss in lumen diameter at 
follow-up. Because drugs currently under development to prevent restenosis after balloon 
angioplasty are designed to reduce the absolute amount of intimal hyperplasia, the 
highest possible benefit of a new drug treatment might be expected in lesions with the 
characteristics retained in the present multivariate model. 
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Summary 
Percutaneous transluminal coronary angioplasty has gained worldwide acceptance as a 
safe and effective alternative to coronary bypass grafting for the treatment of coronary 
artery disease [1]. Improvements in angioplasty hardware and x-ray equipment and 
increased operator experience have made it possible that by now approximately half of 
all coronary revascularization procedures are carried out with this technique in the 
Uuited States. Also in the Netherlands this figure will be reached soon. 
The major shortcoming of coronary balloon angioplasty is the recurrence of the 
stenosis at the site of balloon damage. Depending on the definition used 20 to 40% of 
all treated patients experience angiographic or clinical recurrence within the first months 
after a successful balloon angioplasty procedure [2]. Reinstatement of pharmacological 
therapy, a repeat angioplasty or surgical intervention are often necessary to alleviate 
symptoms or objective signs of myocardial ischemia. Apart from the psychological 
disadvantage of temporary revascularization and re-intervention(s) for a considerable 
group of patients, balloon angioplasty will also loose its financial advantage over surgical 
treatment if lasting revascularization can only be achieved after several procedures. 
The cause of restenosis is largely unknown but is probably an exaggerated repair 
to injury process after severe barotrauma inflicted upon the vessel wall by the angioplasty 
balloon. A very complex process in which platelets, fibrin, thrombus, vasoactive 
substances, growth factors and smooth muscle cells are involved is likely responsible for 
this luminal narrowing after a successful coronary balloon angioplasty. 
Many new coronary interventional devices and pharmacological agents have been 
developed and clinically tested over the last decade to tackle this "Achilles Heel" of 
coronary angioplasty. None of these new techniques or pharmacological treatments has 
so far consistently shown to be superior to balloon angioplasty or placebo medical 
treatment after balloon angioplasty [3,4]. 
The central topic of this thesis is early (immediate and up to 24 hours) and late 
(6 months) luminal narrowing after percutaneous transluminal coronary balloon 
angioplasty as assessed by quantitative angiography. 
Most of the data on which the studies described in this thesis are based, originate 
from a randomized, double blind, placebo-controlled, multicenter european restenosis 
prevention trial, the CARPORT trial (Coronary Artery Restenosis Prevention On 
Repeated Thromboxane-antagonism trial). In this trial the novel thromboxane A2 
receptor antagonist GR32191B was clinically tested against placebo for its usefulness in 
restenosis prevention. Objective quantitative angiography was performed pre-angioplasty, 
post-angioplasty and at 6 month follow up angiography, to assess the angiographic 
efficacy of the drug. All quantitative analyses were performed in a central core-laboratory 
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at Cardialysis in Rotterdam with the extensively validated Cardiovascular Angiography 
Analysis System (CAAS) [5]. Neither angiographic, nor clinical benefit of the compound 
could be demonstrated. The results of this trial are described in detail in chapter 8. 
In the introductory chapter the requisites for accurate quantitative angiography 
in general and especially quantitative angiography for long term follow-up studies are 
described. The latter requires a high degree of standardization in acquisition and analysis 
of the coronary cineangiograms. This asks for a highly cooperative attitude of all 
angioplasty operators, technicians and nurses in the participating clinics. Nevertheless, 
all participants in Berlin, Nancy, Aalst (B), Brussels, Nieuwegein and Rotterdam 
succeeded in following the rigid protocol in almost all cases. Only 8 follow-up films were 
not made according to the protocol and could therefore not be analyzed [chapter 8]. 
Standardization of film analysis cao, in our opinion, only be achieved if the analysis takes 
place in a central core-laboratory with strict guidelines for the analysts in order to 
minimize their influence on the automated edge detection process. Furthermore, central 
storage and reference facilities of the baseline quantitative data is of paramount 
importance for correct analysis of the follow-up angiograms. Over the last 3.5 years a 
professional quantitative angiographic core-laboratory has been set up at the 
Thoraxcenter / Cardialysis in Rotterdam that meets the logistic and technical requirements 
to accurately analyze and process the large amounts of cineangiograms produced in the 
frame of restenosis prevention trials, atherosclerosis progression-regression studies and 
studies with new interventional devices. 
In chapter 2 to 4 the role of elastic recoil of the vessel after balloon angioplasty 
is studied. Diameters of the largest angioplasty balloon at its maximal inflation pressure 
were therefore measured with the CAAS system. In chapter 2 the amount of elastic 
recoil, defined as the difference in cross-sectional area of the balloon (mean 53 mm2) 
and the post angioplasty cross-sectional area (mean 2.8 mm2), was found to be 
approximately 2.5 mm2, implying that almost 50% of the theoretical achievable cross-
sectional area (i.e. the balloon cross-sectional area) is lost shortly after balloon deflation. 
The amount of recoil was more pronounced in eccentric lesions, this can be explained 
by the fact that in such lesions part of the vessel circumference is not diseased. This 
pottion will be preferentially stretched by the balloon [6] with subsequently more elastic 
recoil. 
Waller [7] suggested that recoil could follow a more protracted course, especially 
in eccentric lesions. In his view, overstretching of the plaque-free wall may result in an 
initial increase in luminal diameter, but gradual relaxation or restitution of tone of this 
overstretched segment reduces the coronary lumen towards its predilatation state in 
hours to weeks after the angioplasty. In chapter 3 we investigated whether recoil 
progresses in the frrst 24 hours after balloon angioplasty. In 71 patients with single vessel 
dilatation, a follow-up angiogram was made 1 day after the procedure. No difference in 
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minimal lumen diameter (MLD) at 1 day follow-up angiography was observed. It was 
therefore concluded that recoil is most likely an instantaneous phenomenon with no 
delayed component. 
In chapter 4 it is described that the amount of recoil increases towards distal parts 
of the vessels. This increase was caused by oversizing of the balloon in distal, smaller, 
vessel segments. 
In chapter 5 angiographic risk factors, including stretch and recoil, for luminal 
narrowing 6 months after a successful procedure were investigated. To obtain 
independent predictors of a significant loss in MLD (loss ;:: 0.72 mm), a multivariate 
logistic regression analysis was applied to 595 lesions with balloon measurements. The 
relative gain in MLD at angioplasty, defined as the difference in post angioplasty MLD 
and pre angioplasty MLD normalized for vessel size, was the most powerful predictor 
of a significant loss in lumen diameter at follow-up angiography. Relative risk for a 
relative gain > 0.3 was 2.9. This means that the risk for developing a loss of at least 0. 72 
mm with at least this relative gain is 2.9 times as high as it is for lesions with a relative 
gain of < 02. Other independent predictors were a relative gain between 0.2 and 03 
(relative risk 2.1), a lesion length ;::6.8 mm (relative risk 1.7) and visible thrombus post 
angioplasty (relative risk 2.6). Stretch of the vessel wall was significantly related to 
luroinal narrowing at univariate analysis but was not retained in the multivariate model. 
We concluded, since it is known that the amount of deep arterial injury is related to the 
restenosis process [8,9], that relative gain at angioplasty probably best reflects the amount 
of arterial injury inflicted upon the vessel wall at angioplasty. 
Several investigators have sought predictors of restenosis [10]. A multitude of 
patient-, procedural- and lesion related variables have been found to predict long term 
outcome of an angioplasty procedure. But since these findings are based on different 
restenosis criteria and varying angiographic follow-up rates accurate comparison is 
difficult. One risk factor that has been the subject of controversy in the literature is the 
site of dilatation, with according to some, a higher risk of restenosis observed in the 
proximal left anterior descending (!.AD) coronary artery as compared to lesion in the 
right coronary artery and circumflex artery. In chapter 6 this was investigated in 1234 
patients (follow-up rate 91%) and we found neither a higher restenosis rate according 
to the classical 50% diameter stenosis criterion nor a greater loss in lumen diameter at 
follow-up angiography for proximal !.AD dilatations. An explanation for the higher 
restenosis rates after !.AD dilatation found by others might be the incomplete 
angiographic follow-up rate in their studies. An ischemic response to exercise is more 
likely to be seen with proximal !.AD lesions, thereby increasing the chance of 
preferential detection unless angiographic follow-up is complete. 
In chapter 7 the distributions of several quantitative angiographic parameters that 
reflect the restenosis phenomenon were determined. Both percentage diameter stenosis 
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at follow-up angiography and change in lumen diameter at follow-up angiography 
approximately followed a Gaussian or normal distribution. Therefore restenosis can be 
viewed as the tail end of a normally distributed phenomenon, with some lesions crossing 
a more or less arbitrary cut-off point, rather than a separate disease entity occurring in 
some lesions but not in others. 
In chapter 8 the clinical and angiographic results of the Carport trial are 
extensively discussed. 
In chapter 9, we investigated which quantitative angiographic parameter best 
predicts the functional status of patients 6 months after successful coronary balloon 
angioplasty. Accuracy of several quantitative angiographic parameters for the prediction 
of 2 different markers of myocardial ischemia, anginal status and ST depression of at 
least 1 mm at exercise electrocardiography, was determined. The cut-off points at which 
anginal status and exercise electrocardiography result were best predicted was 1.45 mm 
for the MW at follow-up, 465% for the percent diameter stenosis at follow up, -030 
mm for the change in MW at follow-up and -10% for the change in percent diameter 
stenosis. Furthermore, parameters that depict a change in lesion severity at follow-up, 
were only slightly less accurate for the prediction of anginal status and exercise 
electrocardiographic result than parameters that merely describe lesion severity at follow 
up (MW and percent diameter stenosis). 
In chapter 10, an attempt was made to predict the absolute change in lumen 
diameter at follow-up angiography with simple, independent, clinical, lesion related and 
procedure related variables collected in the CARPORT trial. Therefore a multiple linear 
regression analysis was applied to 6661esions with the change in minima! lumen diameter 
from post angioplasty angiogram to follow-up angiogram as dependent variable. It is now 
believed that the restenosis process is caused by a fibroproliferative vessel wall reaction 
after balloon trauma. The magnitude of this process can reliably be reflected by the 
change in minimal lumen diameter at follow-up angiography. Several variables with an 
independent contribution to the prediction of change in Mill were found. These were 
relative gain at angioplasty, obstruction diameter pre angioplasty, lesion length ;::6.8 mm, 
diabetes, duration of angina < 2.3 months and visible thrombus post angioplasty. 
However, correct prediction by the multivariate model was poor and modification or 
control of the risk factors will probably not influence the magnitude of the 
fibroproliferative reaction. 
Restenosis is obviously a process that cannot be predicted by simple clinical, 
morphologic or procedural characteristics. Therefore, additional biochemical, histologic 
and cytologic factors of importance in the restenosis process should be investigated and 
where possible tackled with appropriate pharmacological intervention. 
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Sam en vatting 
Percutane transluminale coronaria angioplastiek (PTCA, dotteren) is nu wereldwijd 
geaccepteerd als een veilig alternatief voor bypass cbirurgie bij de behandeling van 
obstructief coronaria lijden [1]. Verbeterde rontgentechnieken, betere angioplastie 
materialen en toegenomen ervaring met de procedure zelf hebben bet mogelijk gemaakt 
dat op dit moment de belft van alle revascularisatie procedures in de verenigde staten 
ntiddels ball on dilatatie wordt verricbt. In Nederland zal dit op korte terntijn ook bet 
geval zijn. 
Ondanks bet boge primaire succespercentage van PTCA, zijn de resultaten op 
ntiddellange terntijn minder gunstig. Afhaokelijke van de gebruikte definitie ontstaat bij 
20 tot 40% van de patienten in de eerste maanden na een geslaagde procedure een 
nieuwe vemauwing (re-stenosering) op de plaats van de ballondilatatie [2]. De 
consequentie hiervan is dat patienten vaak opnieuw mediscbe bebandeling behoeven, 
betzij met geneesntiddelen hetzij met een PTCA of bypass operatie. Een aanzienlijke 
groep patienten zal dus pas definitief geholpen zijn na meerdere ingrepen aan hun 
kranslagaders. Hierdoor zal de goedkopere PTCA behandeling in deze groep patienten 
bet financiele voordeel op de bypass cbirurgie verliezen, nog afgezien van bet psychische 
trauma van slecbts tijdelijke klachtenvermindering. 
De oorzaak van restenosering is nog grotendeels onbekend maar berust 
waarschijnlijk op een overdreven wondgenezing na de locale beschadiging van het 
bloedvat door de dilatatie ballon. Bloedplaatjes, stollingseiwitten, thrombus,groeifactoren 
en gladde spiercellen lijken betrokken bij dit zeer ingewikkelde proces. 
In een paging het restenose percentage te verlagen zijn de laatste jaren een aantal 
nieuwe methodieken ontwikkeld om vernauwingen in kranslagvaten op te heffen. Lasers, 
stents en apparaten die de atherosclerotische plaque wegsnijden zijn kliniscb onderzocht 
maar zijn tot dusver niet succesvol gebleken. Ook is een heel scala van geneesmiddelen 
getest die op theoretische gronden de restenose vornting zouden kunnen voorkomen of 
afremmen. Oak op dit vlak is geen enkele vooruitgang geboekt [3,4]. 
Het centrale thema in dit proefscbrift is vroege (tot 24 uur na de procedure) en 
late (tot 6 maanden na de procedure) bloedvatsvernauwing na een PTCA, zoals gemeten 
met behulp van een objectieve quantitatieve angiografiscbe analyse techniek [5]. 
De meeste gegevens waarop de in dit proefscbrift bescbreven studies zijn 
gebaseerd zijn afkomstig van de CARPORT studie (Coronary Artery Restenosis 
Prevention On Repeated Thromboxane-antagonism). In deze studie werd met bebulp van 
quaotitatieve angiografie onderzocbt of de nieuwe thromboxane Az receptor antagonist 
GR32191B minder bloedvatsvernauwing geeft in de eerste 6 maanden na een PTCA dan 
placebo bebandeling. Zowel klinisch als angiografiscb bood GR32191B geen voordeel 
boven placebo bebandeling. De resultaten van deze studie worden uitgebreid besproken 
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in hoofdstuk 8. 
In hoofdstuk 1 worden de benodigdheden voor nauwkeurige quantitatieve 
angiografische analyse van met name lange termijns follow-up studies beschreven. Dit 
vereist een hoge mate van standaardisatie bij zowel bet maken van de coronair 
angiogrammen als bij de latere analyse. Dit vraagt een zeer co6peratieve instelling van 
alle betrokken cardiologen, technici en verplegend personeel in de deeinemende 
klinieken omdat het studie protocol vaak afwijkt van de plaatselijke gewoontes. 
Niettentin slaagden de deelnemers in de klinieken in Aalst (B), Berlijn, Brussel, 
Nieuwegein en Rotterdam er in om in praktisch alle gevallen bet rigide protocol te 
volgen. Slecbts 8 follow-up fihns waren niet volgens bet protocol vervaardigd [hoofdstuk 
8]. Naar onze mening kan standaardisatie van de film analyse slecbts bereikt worden als 
alle analyses worden uitgevoerd door een centraal analyse laboratorium met strikte 
aanwijzingen voor de analisten, waardoor de menselijke en dus subjectieve invloed op 
het automatiscbe analyse proces gentinimaliseerd wordt. Bovendien zijn centrale opslag 
en referentie faciliteiten van de quantitatieve gegevens van de PTCA films onontbeerlijk 
voor goede analyses van de vervolg films, die pas ruim een half jaar na de PTCA film 
kunnen worden geanalyseerd. Gedurende de laatste 3,5 jaar is er in Rotterdam een 
professioneel laboratorium voor quantitatieve analyse van coronair angiogrammen 
opgezet dat voldoet aan de logistieke en technische eisen nodig voor de accurate 
verwerking en analyse van de grate hoeveelheid films die gemaakt worden in bet kader 
van lange termijns angiografiscbe studies. 
In de hoofdstukken 2 t/m 4 wordt de rol van het elastisch terugveren (elastic 
recoil) na ballon deflatie besproken. 
In hoofdstuk 2 werden de diameters van de in opgeblazen toestand gefilmde 
dilatatie ballonnen gemeten met behulp van quantitatieve angiografie. Elastic recoil werd 
gedefinieerd als bet verschil in doorsnede oppervlakte van de ballon (gentiddeld 5.3 
mm2) en de doorsnede oppervlakte van bet bloedvat na de dilatatie (gentiddeld 2.8 
mm2). Dit betekent dat bijna 50% van de theoretisch haalbare bloedvatverwijding ( dit 
is de doorsnede oppervlakte van de opgeblazen ballon) direct na bet leegzuigen van de 
ballon verloren gaat. Er werd meer elastic recoil gevonden in bloedvaten waarbij de 
vemauwing aan een zijde van bet vat gelocaliseerd was ( excentriscbe vemauwingen). In 
dit type vemauwingen is een dee! van de bloedvatwand niet aangedaan door de taaie 
atherosclerotische plaque en dit dee! zal dus bij voorkeur opgerekt worden door de 
ballon [6]. Dit meer elastiscbe dee! zal dan ook meer recoil vertonen. 
Waller [7] suggereerde dat elastic recoil in met name excentrische vemauwingen 
een meer verlengd verloop zou kunnen hebben. Overrekking van bet plaque vrije dee! 
van de bloedvatsomtrek zou naar zijn mening in eerste instantie resulteren in een 
toename van de luntinale afmeting, maar langzame relaxatie en berstel van vaattonus 
zouden tot restenose in de eerste 24 uur na de dilatatie kunnen leiden. In hoofdstuk 3 
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werd onderzocht of recoil inderdaad een meer verlengd verloop kent. Bij 71 patienten 
werd 1 dag na de PTCA opnieuw een angiogram vervaardigd. Er werd geen verschil in 
minllnale luminale diameter (MLD) gevonden na 1 dag vergeleken met de MLD direct 
na de procedure. Recoil lijkt dus een fenomeen dat ogenblikkelijk optreed zonder 
vertragings component. 
In hoofdstuk 4 wordt beschreven dat elastic recoil toeneemt naarmate een meer 
distaal dee! van een kransslagvat gedilateerd wordt Deze toename kan echter verklaard 
worden doordat voor dilataties van de kleinere distale vaatgedeelten een relatief grotere 
ballon gebruikt werd dan voor de grotere proximale vaatgedeelten. 
In hoofdstuk 5 werden angiografische risicofactoren onderzocht voor het optreden 
van vaatvernauwing 6 maanden na de PTCA. Om onafhankelijke voorspellers van een 
significante afname in MLD te verkrijgen, werd een multivariate logistische regressie 
analyse toegepast op 595 lesies waarbij ook de ballon diameter gemeten was. De 
toename in MLD bereikt met de ballon dilatatie, gedefinieerd als bet verschil in MLD 
na de dilatatie en de MLD v66r de dilatatie was de sterkste onafhankelijke voorspeller 
voor een later significant verlies. Andere onafhankelijke voorspellers waren lange 
vernauwingen (!anger dan 6.8 mm), en een zichtbare thrombus op het angiogram na de 
dilatatie. Het is bekend dat bescbadigingen dieper in de wand van het bloedvat 
gerelateerd is aan een meer uitgesproken restenose reactie [8,9]. De toename in MLD 
door de ballon dilatatie zou dus een soor index kunnen zijn voor de uitgebreidbeid en 
diepte van de vaatwandbeschadiging. 
Sinds bet begin van de PTCA is er gezocht naar voorspellers van restenose [10]. 
Een veelvoud aan factoren is bescbreven. Maar omdat de bevindingen veelal gebaseerd 
zijn op verschillende restenose criteria, uiteenlopende tijdstipen van hercatheterisatie en 
wisselende percentages patienten met een vervolg angiogram, is vergelijking van deze 
bevindingen moeilijk. Een risicofactor waarover in de literatuur controverse bestaat is 
de plaats van de dilatatie. Sommigen menen dat een boger risico op restenose bestaat 
na dilatatie van het proximale gedeelte van de ramus interventricularis anterior (LAD) 
van de linker kransslagader in vergelijking met dilataties uitgevoerd in de recbter 
kransslagader of de ramus circumflexus van de linker kransslagader. In hoofdstuk 6 
onderzochten we dit bij 1234 patienten (vervolg catheterisatie percentage 91%) en er 
werd noch een boger restenose percentage gconstateerd volgens bet klassieke 50% 
diameter stenose criterium nocb een groter verlies in MLD bij vervolg angiografie 6 
maanden na dilatatie van een proximale LAD lesie. 
In boofdstuk 7 werden van verscheidene quantitatieve angiografische parameters 
die bet restenose proces weergeven de verdelingen onderzocbt. Zowel bet percentage 
vemauwing bij vervolg angiografie als bet verschil in MLD van het post dilatatie 
angiogram en bet 6 maanden vervolg angiogram waren normaal verdeeld. Hieruit wordt 
geconcludeerd dat restenose gezien kan worden als de staart van een normaai verdeeld 
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fenomeen, waarbij sommige Jesies een meer ofminder arbitrair afknotpunt overschrijden, 
en niet als een aparte reactie die optreed in sommige lesies en niet in andere. 
In hoofdstuk 8 worden de klinische en angiografische resultaten van de 
CARPORT studie uitgebreid besproken. 
In hoofdstuk 9 wordt beschreven welke quantitatieve angiografische parameter het 
best overeenkomen met de klinische status van patienten 6 maanden na een geslaagde 
eenvats ballon dilatatie. De waarden van de quantitatieve angiografische parameters 
waarop de aan- of afwezigheid van angina pectoris en de aan- of afwezigheid van een 
positief inspannings electrocardiogram het best werden voorspeld werd vastgesteld met 
behulp van sensitiviteit en specificiteit curves. Voor de MLD op 6 maanden was dit 1.45 
mm, voor het percentage diameter vemauwing op 6 maanden was dit 46%. Voor de 
verandering in MLD van post angioplastie angiogram tot het 6 maanden vervolg 
angiogram was het afknotpunt -0.30 mm en voor de verandering in percentage diameter 
vemauwing was dit -10%. Bovendien waren de parameters die de verandering in ernst 
van de lesie, en dus bet restenose proces, weergeven slecbts weinig minder nauwkeurig 
bij de voorspelling van de functionele status dan de parameters die de ernst van de lesie 
bij vervolg angiogram weergeven. 
In hoofdstuk 10 hebben we geprobeerd de absolute verandering in MLD van het 
angiogram direct na de PTCA tot het vervolg angiogram te voorspellen met behulp van 
eenvoudige klinische, angiografische en procedurele variabelen. Hiertoe werd een 
multipele liniaire regressie analyse toegepast op 666 gedilateerde kranslagvaten uit de 
CARPORT studie. Verschillende onafhankelijke voorspellers van het restenose proces 
werden geidentificeerd: relatieve winst in bloedvatafmetingen verkregen door PTCA, de 
ernst van de obstructie v66r de dilatatie, een vemauwing Ianger dan 6.8 mm, diabetes 
mellitus, een kortere duur van angineuze klachten v66rdat PTCA verricht werd en 
zichtbare thrombus op het angiogram direct na de dilatatie. Als met deze gegevens 
echter geprobeerd wordt de individuele verandering in MLD te voorspellen blijkt dit een 
zeer matig resultaat op te leveren. Restenose is dus zeer moeilijk te voorspellen met 
behulp van deze eenvoudige klinische, angiografische en procedurele factoren. 
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